Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
1 
 Abbreviated Title:  LMB-100 + Abrx in PDA 
CC Protocol #: 16C0128 L 
Version Date: December 11, 2018 
NCT #:  [STUDY_ID_REMOVED]  
 
Title: A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in 
Combination with Nab-Paclitaxel in Participants  with Previously Trea ted Metastatic and/ or 
Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors  
NCI Principal Investigator: Christine Alewine, M.D., Ph.D. Laboratory of Molecular Biology (LMB), CCR, NCI Building 37, Room 5116
 
9000 Rockville Pike  
Phone: 240-760-6146 
Email: Christine.alewine@nih.gov 
 
Investigational Agents:     
Drug Name: LMB-100 (formerly RO6927005) Mesothelin Expression Testing 
IND Number: 123332 NSR device 
Sponsor/Holder: Center for Cancer Research, NCI, 
NIH Center for Cancer Research 
Manufacturer: F. Hoffman-La Roche Ltd NCI Laboratory of Pathology 
 Commercial Agents NAB Paclitaxel will be obtained from commercial sources by the NIH CC pharmacy.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
2 
 PRÉCIS  
Background: 
x Pancreatic cancer is the fourth most common cause of cancer death in the United States, 
claiming more than 40,000 lives each year. 
x Incidence nearly equals mortality with just 6%  of participants living five years beyond their 
diagnosis. Most patients are diagnosed at an a dvanced stage, but even patients with early 
stage disease have a long term survival of less than 20%. 
x Mesothelin is specifically a marker of adenoc arcinoma in the human disease and is not 
expressed in preceding pre-malignant stages of tumor development  
x Expression of mesothelin in pancreatic ductal adenocarcinoma (PDA) has been examined 
in several published studies and ranges from 86 to 100% 
x Recombinant immunotoxins (RITs) are antibod y-based therapeutics that carry a toxin 
payload.  RITs that target mesothelin contain  a genetically engineered variant of 
Pseudomonas exotoxin A (PE) in which the nati ve cell-binding domain of PE is replaced 
by the mesothelin-binding antibody fragment. SS1P was the first mesothelin-targeted RIT 
tested in patients.  
x LMB-100 contains a newly engineered PE fragment that has improved activity against most pancreatic cancer cell lines in vitro, and is also much less toxic than SS1P in pre-clinical 
models. The new PE contains modificati ons specifically designed to reduce 
immunogenicity of the molecule. 
x Pre-administration of paclitaxel with SS1P wa s demonstrated to increase the amount of 
immunotoxin internalized by tumor cells and to reduce levels of shed mesothelin in the 
intra-tumoral environment so that more immunotoxin could bind tumor cells. The effect is even more pronounced with NAB-paclitax el in a pancreatic cancer model. 
x Initial clinical testing of LMB-100 was performed by Roche in a multi-center international first in human trial ([STUDY_ID_REMOVED]). The agent wa s well tolerated and appeared to have 
decreased immunogenicity compared to SS1P based on preliminary results. 
x In initial and subsequent clinical testing, LMB- 100 was found to have half-life of ~60 mins.  
This is shorter then that measured for previous RITs used in the clinical setting. 
Primary Objectives: 
¾ Arm A1 (Phase I, short infusion): 
x To determine the maximum tolerated dose of short infusion LMB-100 in combination nab-
paclitaxel chemotherapy in particip ants with advanced pancreatic cancer   
¾ Arm B1 (Continuous infusion single agent lead-in): 
x To determine the maximum tolerated dose of LMB-100 given in a continuous infusion 
format over 24 - 96 hours to patients with advanced solid tumors that express mesothelin 
¾ Arm B2 (Continuous infusion combination therapy): 
x Establish a tolerated dose of LMB-100 given by continuous infusion in combination with 
nab-paclitaxel chemotherapy in particip ants with advanced pancreatic cancer   
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
3 
 ¾ Arm A2 (Phase II, short infusion): 
x To determine the objective response rate (PR+CR)  according to RECIST 1.1 criteria of short 
infusion LMB-100 in combination with nab-paclitaxel chemotherapy in participants with 
advanced pancreatic cancer 
Eligibility: 
x Age ≥ 18 years  
x Histologically confirmed recurrent, metas tatic and/or advanced pancreatic ductal 
adenocarcinoma (Except for Arm B1 [Single Agent Lead-in]) 
x For Arm B1 (Single Agent Lead-in), ONLY : Histologically confirmed solid tumor 
malignancy for which no curative therapy exists with at least 25% of tumor cells expressing 
mesothelin as determined by NCI Laboratory of Pathology. Determination can be made 
using archival tumor tissue or fresh biopsy. 
x Treatment must include at least one prior chemotherapy regimen 
x No nab-paclitaxel or paclitaxel  treatment in the last four months (Except for Arm B1 [Single 
Agent Lead-in]) 
x Adequate organ function 
x Participants with HIV, active HBV or HCV infections are eligible only for the Arm B1 
(Single Agent Lead-in) 
Design: 
x This study is a Phase I/II open label study to  assess the safety and efficacy of LMB-100 in 
combination with the standard of care agent nab-paclitaxel in participants metastatic and/or 
locally advanced pancre atic ductal adenocarcinoma 
x Subjects will be treated for up to 2 or 3 cycles depending on arm. 
x In Arm A1 (Phase I, short infusion) of the stud y, up to 3 dose levels will be evaluated. LMB-
100 will be administered on days 1, 3 and 5 of a 21-day cycle and nab-paclitaxel will be 
administered on days 1 and 8 
x In Arm A2 (Phase II, short infusion), if explore d, up to 20 evaluable participants (including 
those treated at 65 mcg/kg, will be enrolled. Arm A2 will not be explored if 65 mcg/kg is 
not deemed safe in Arm A1 
x In Arm B1 (Continuous infusion, single Agent Lead-in), escalating doses of single agent 
LMB-100 will be administered.  The study drug will be given as a continuous infusion for the 1, 2, 3, or 4 days of a 21-day cycle. 
x Arm B2 (Continuous infusion, combination therap y) will be initiated after completion of 
both Arm A1 and Arm B1 Single Agent Lead-in.  It will test a single dose level of LMB-100 based on data from the Lead-in given in combination with nab-paclitaxel.  LMB-100 
will be given as a continuous infusion for  24 hours on Day 1 of a 14-day cycle. Nab-
paclitaxel will also be given on Day 1. 
x The Arm A2 (Phase II, short infusion) portion of the study, if explored, will be conducted 
in a Simon Minimax two stage phase II desig n.  The first stage will enroll 13 evaluable 
participants, including the six participants treated at 65 mcg/kg. If 1 or more has a response, 
then accrual would continue until a total of 20 evaluable participants have been enrolled.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
4 
 TABLE OF CONTENTS  
PRÉCIS ........................................................................................................................ ....................2  
TABLE OF CONTENTS .................................................................................................................4  
1 INTRODUCTION .................................................................................................................. 9 
1.1 Study Objectives .............................................................................................................. .9 
1.1.1  Primary Objective: ......................................................................................................9  
1.1.2  Secondary Objectives: ................................................................................................9  
1.1.3  Exploratory Objectives: ..............................................................................................9  
1.2 Background and Rationale ..............................................................................................10  
1.2.1  Background on Disease.............................................................................................10  
1.2.2  Mesothelin (MSLN) as a therapeutic target ..............................................................10  
1.2.3  Recombinant Immunotoxins (RITs) .........................................................................13  
1.2.4  LMB-100...................................................................................................................15  
1.2.5  Pharmacokinetics of LMB-100 and modeling of continuous infusion .....................24  
1.2.6  Rationale for treating pancreatic canc er patients with LMB-100 and NAB-
paclitaxel combination ..............................................................................................25  
1.2.7  Rationale for assessing continuous infusion of LMB-100 ........................................25  
1.2.8  Rationale for the initial dose and sche dule and subsequent dose escalation of 
continuous infusion LMB-100 ..................................................................................27  
1.2.9  Rationale for use of mesothelin testing (NSR device) ..............................................28  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT .......................................................29  
2.1 Eligibility Criteria .......................................................................................................... .29 
2.1.1  Inclusion Criteria ......................................................................................................29  
2.1.2  Exclusion Criteria .....................................................................................................31  
2.2 Screening Evaluation ......................................................................................................31  
2.3 Registration Procedures ..................................................................................................32  
2.3.1  Arm B1, Single Agent Lead in Cohort Subjects with Diseases other than 
Epithelioid Mesothelioma or Pancreatic Adenocarcinoma Only ..............................32  
2.3.2  All other subjects ......................................................................................................33  
2.3.3  Treatment Assignment  Procedures ..........................................................................33  
3 STUDY IMPLEMENTATION ............................................................................................34  
3.1 Study Design .................................................................................................................. .34 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
5 
 3.1.1  Study Schema for short infusion LMB-100 w ith nab-paclitaxel (Arm A1 (Phase 
I))............................................................................................................................ ...35  
3.1.2  Study Schema for continuous infusion LMB-100 (Arm B1 [Single Agent Lead-
in]) .......................................................................................................................... ...36  
3.1.3  Study Schema for continuous infusion LMB-100 with nab-paclitaxel (Arm B2) ....36  
3.1.4  Study Schema for Phase II ........................................................................................37  
3.1.5  Dose Limiting Toxicity .............................................................................................37  
3.1.6  Dose Escalation .........................................................................................................38  
3.2 Drug Administration .......................................................................................................42  
3.2.1  LMB-100...................................................................................................................42  
3.2.2  Nab-Paclitaxel ...........................................................................................................46  
3.2.3  Co-administration of Nab-paclitaxel and LMB-100 .................................................46  
3.3 Dose Modifications .........................................................................................................46  
3.3.1  LMB-100...................................................................................................................47  
3.3.2  Nab-paclitaxel ...........................................................................................................50  
3.4 Study Calendars ..............................................................................................................5 1 
3.4.1  Calendar for patient receiving short infusion LMB-100 (Arms A1 and A2) ...........51  
3.4.2  Calendars subjects in Arm B1 (single agent continuous infusion LMB-100) ..........54  
3.4.3  Calendar for Subjects in Arm B2 (LMB-100 24-hour continuous infusion 
combination therapy) ................................................................................................60  
3.5 Criteria for Removal from Protocol Therapy and Off Study Criteria .............................63  
3.5.1  Criteria for removal from protocol therapy ..............................................................63  
3.5.2  Off-Study Criteria .....................................................................................................63  
4 CONCOMITANT MEDICATIONS/MEASURES ..............................................................63  
4.1.1  Permitted Therapy .....................................................................................................63  
4.1.2  Prohibited Therapy....................................................................................................63  
5 BIOSPECIMEN COLLECTION ..........................................................................................64  
5.1 Correlative Studies for Research /Pharmacokinetic Studies ............................................64  
5.1.1  LMB-100 Pharmacokinetic Assessments .................................................................64  
5.1.2  Nab-Paclitaxel Pharmacokinetic Assessments .........................................................65  
5.1.3  Pharmacogenetic Studies ..........................................................................................66  
5.1.4  Assessment of anti-drug antibodies (ADAs) ............................................................66  
5.1.5  Retrospective Analysis of Mesothelin Expression in tumor tissue ...........................67  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
6 
 5.1.6  Cytokines for identification of mechani sm for PE-mediated capillary leak 
syndrome ...................................................................................................................67  
5.1.7  Circulating endothelial cells (CEP and CEC) for identification of mechanism for 
PE-mediated capillary leak syndrome ......................................................................68  
5.1.8  Immune subset analysis ............................................................................................68  
5.1.9  Peripheral blood immune gene expression ...............................................................69  
5.1.10  Circulating tumor cells ..............................................................................................70  
5.1.11  Treatment Effect on Tumor Microenvironment .......................................................70  
5.1.12  Serum Megakaryocyte Potentiating Factor (MPF) level ..........................................70  
5.2 Sample Collection schedule ............................................................................................72  
5.2.1  Sample Collection for Patients receiving short infusion LMB-100 (Arms A1 and A2) ........................................................................................................................... .72
 
5.2.2  Sample Collection for Patients receiving continuous infusion of LMB-100 (Arms B1 and B2) ................................................................................................................74
 
5.3 Sample Storage, Tracking  and Disposition .....................................................................80  
5.3.1  Clinical Pharmacology Program ...............................................................................80  
5.3.2  Leidos Biomedical, Inc. Lab .....................................................................................80  
5.3.3  Laboratory of Jane Trepel .........................................................................................81  
5.3.4  Protocol Completion/Sample Destruction ................................................................81  
5.4 Samples for Genetic Analysis .........................................................................................82  
6 DATA COLLECTION AND EVALUATION .....................................................................82  
6.1 Data Collection ...............................................................................................................82  
6.2 Data Sharing Plans ..........................................................................................................83  
6.2.1  Human Data Sharing Plan .........................................................................................83  
6.2.2  Genomic Data Sharing Plan ......................................................................................83  
6.3 Response Criteria ............................................................................................................83  
6.3.1  Definitions.................................................................................................................84  
6.3.2  All Diseases except pleural mesothelioma ...............................................................84  
6.3.3  Pleural Mesothelioma ...............................................................................................89  
6.3.4  Duration of Response ................................................................................................91  
6.3.5  Progression-Free Survival .........................................................................................91  
6.3.6  Objective Response Rate ..........................................................................................91  
6.3.7  Disease Control Rate.................................................................................................91  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
7 
 6.4 Toxicity Criteria ..............................................................................................................91  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN .......................................................................................................................... ..........91  
7.1 Definitions.................................................................................................................... ...91  
7.1.1  Adverse Event ...........................................................................................................91  
7.1.2  Suspected adverse reaction .......................................................................................92  
7.1.3  Unexpected adverse reaction ....................................................................................92  
7.1.4  Serious.......................................................................................................................9 2 
7.1.5  Serious Adverse Event ..............................................................................................92  
7.1.6  Disability ...................................................................................................................9 2 
7.1.7  Life-threatening adverse drug experience .................................................................92  
7.1.8  Protocol Deviation (NIH Definition) ........................................................................93  
7.1.9  Non-compliance (NIH Definition) ............................................................................93  
7.1.10  Unanticipated Problem..............................................................................................93  
7.2 NIH Intramural IRB and Clinical Director (CD) Reporting ...........................................93  
7.2.1  NIH Intramural IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths.................................................................................................93
 
7.2.2  NIH Intramural IRB Requirements for PI  Reporting at Continuing Review ...........93  
7.2.3  NIH Intramural IRB Reporting of IND Safety Reports ............................................94  
7.3 IND Sponsor Reporting Criteria .....................................................................................94  
7.3.1  Reporting Pregnancy .................................................................................................94  
7.4 Data and Safety Monitoring Plan ....................................................................................95  
7.4.1  Principal Investigator/Research Team ......................................................................95  
7.4.2  Sponsor Monitoring Plan ..........................................................................................95  
7.4.3  Safety Monitoring Committee ..................................................................................96  
8 STATISTICAL CONSIDERATIONS..................................................................................96  
8.1 Primary endpoints ...........................................................................................................96  
8.1.1  Part A ........................................................................................................................96  
8.1.2  Part B: .......................................................................................................................97  
8.2 Determination of Sample Size ........................................................................................98  
9 HUMAN SUBJECTS PROTECTIONS ...............................................................................98  
9.1 Rationale For Subject Selection ......................................................................................98  
9.2 Participation of Children .................................................................................................99  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
8 
 9.3 Participation of Subjects Unable to Give Consent ..........................................................99  
9.4 Evaluation of Benefits and Risks/Discomforts ...............................................................99  
9.4.1  Risks from Study Drugs ............................................................................................99  
9.4.2  Risks of study procedures .......................................................................................100  
9.5 Risks/Benefits Analysis ................................................................................................100  
9.6 Consent and Assent Process and Documentation .........................................................100  
9.6.1  Consent procedure for non-English speaking patients............................................101  
9.6.2  Telephone consent procedure .................................................................................101  
10 PHARMACEUTICAL INFORMATION ...........................................................................101  
10.1  LMB-100 (IND # 123332) ............................................................................................102  
10.1.1  Source .....................................................................................................................102  
10.1.2  Toxicity ...................................................................................................................102  
10.1.3  Formulation and preparation ...................................................................................103  
10.1.4  Stability and Storage ...............................................................................................104  
10.1.5  Administration procedures ......................................................................................104  
10.1.6  Incompatibilities .....................................................................................................104  
10.2  Nab-paclitaxel ...............................................................................................................105  
10.2.1  Source .....................................................................................................................105  
10.2.2  Toxicity ...................................................................................................................105  
10.2.3  Formulation and preparation ...................................................................................106  
10.2.4  Stability and Storage ...............................................................................................107  
10.2.5  Administration procedures ......................................................................................108  
10.2.6  Incompatibilities .....................................................................................................108  
11 REFERENCES ...................................................................................................................1 09 
12 APPENDICES .................................................................................................................... 114 
12.1  Appendix A – Performance Status Criteria ..................................................................114  
12.2  Appendix B – Cockcroft-Gault Formula for Calculation of Creatinine Clearance ......115  
12.3  Appendix C: Sample Chemotherapy Notes ..................................................................116  
12.3.1  For Part A ................................................................................................................116  
12.3.2  For Arm B1 .............................................................................................................117  
12.3.3  For Arm B2 .............................................................................................................118  
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
9 
 1 INTRODUCTION 
1.1 STUDY OBJECTIVES  
1.1.1 Primary Objective: 
1.1.1.1 Arm A1 (Phase I, short infusion): 
x To determine the maximum tolerated dose (MTD) of short infusion LMB-100 when given 
in combination with nab-paclitaxel to partic ipants with advanced pancreatic cancer  
1.1.1.2 Arm B1 (Continuous infusion single agent lead-in: 
x To determine the maximum tolerated dose of LMB-100 given in a continuous infusion 
format over 24 - 96 hours to patients with advanced solid tumors that express mesothelin 
1.1.1.3 Arm B2 (Continuous infusion combination therapy): 
x Establish a tolerated dose of LMB-100 given by continuous infusion in combination with 
nab-paclitaxel chemotherapy in particip ants with advanced pancreatic cancer 
1.1.1.4 Arm A2 (Phase II short infusion): 
x To determine the objective response rate (PR+ CR) according to RECIST 1.1 criteria of short 
infusion LMB-100 in combination with nab-paclitaxel chemotherapy in participants with advanced pancreatic cancer 
1.1.2 Secondary Objectives: 
1.1.2.1 All Phases 
x To determine the safety and tolerability  of LMB-100 or the combination with nab-
paclitaxel in participants with advanced pancreatic cancer   
x To assess additional measures of efficacy including: 
x  change in the CA 19-9 serum marker w ith treatment (or other appropriate tumor 
marker for Arm B1 [Single Agent Lead-in]) 
x objective response rate (ORR) in Arms A1, B1 and B2  
x disease control rate at 4 months (as defined in section 6.3.7)  
x progression free survival  
x overall survival  
x To define the pharmacokinetics of LMB-100 in the absence and presence of participant 
LMB-100 anti-drug antibodies (ADAs)  
1.1.3 Exploratory Objectives: 
Both phases 
x To identify a threshold titer of particip ant LMB-100 ADAs that predicts inadequate 
drug exposure 
x To examine the relationship between MSLN expression and response to treatment 
x To identify the mechanism for Pseudomonas endotoxin-mediated capillary leak 
syndrome 
x To examine the effect of immunotoxin tr eatment on the microenvironment in the Part 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
10 
 B portion of the study 
x To determine the effect of LMB-100 on the pharmacokinetics of nab-paclitaxel 
x To correlate plasma concentrations of nab- paclitaxel to clinical response, toxicity, 
pharmacogenetic analyses a nd pharmacodynamic endpoints 
x To assess the genotype of the most relevant drug metabolizing enzymes and transporters 
(DMET) 
1.2 BACKGROUND AND RATIONALE  
1.2.1 Background on Disease  
Pancreatic cancer is the fourth most common cause  of cancer death in the United States, claiming 
more than 40,000 lives each year. Incidence nearly e quals mortality with just 6% of patients living 
five years beyond their diagnosis. Most patients are diagnosed at an advanced stage, but even 
patients with early stage disease have  a long term survival of less than 20%.[1] Combination 
chemotherapy with FOLFIRINOX provides the grea test survival advantage for patients who have 
advanced disease, but the median overall survival (OS) for this regimen does not reach one year 
and most pancreatic cancer patients are not fit enough to tolerate it.[2] Gemcitabine with NAB-
paclitaxel is an alternative regimen and exte nds median overall survival to 8.5 months from 6.7 
months with gemcitabine alone.  The response rate (RR) to this regimen in the first-line is 23% 
with less than 1% of patients achieving a complete response (CR).[3] Prospective and retrospective 
cohort studies have estimated a 17% RR to this regimen when given in second-line to good 
performance status patients following FOLFIRINOX.[4, 5] Single agent gemcitabine remains the 
recommended treatment for patients with poor perf ormance status. Erlotinib is the only targeted 
therapy with efficacy against this disease and extends median OS by approximately 10 days when 
added to gemcitabine at the expense of significant toxicity.[6] Median survival of patients able to 
receive second line therapy is approximately 3-6 months.[7] New paradigms for the effective 
treatment of pancreatic cancer are sorely needed.   
1.2.2 Mesothelin (MSLN) as a therapeutic target 
MSLN is a cell surface glycoprotein that is a differentiation antigen for  mesothelial cells; 
expression in normal tissues is confined to the pleura, pericardium and peritoneum. The normal 
function of MSLN is unknown. MSLN is expressed by a wide variety of solid tumors ( Table 1) 
Expression of MSLN in PDAC has been reported in several published studies and ranges from 86 
to 100%.[8-10] Please see Table 2 below for a summary of this expression. MSLN is also expressed 
in tumors from genetically engineered mouse models (GEMMs) of PDAC, including the KPC 
model.[11]  MSLN is specifically a marker of adeno carcinoma in the human disease and is not 
expressed in preceding pre-malignant stages of tumor development.[12] Increased MSLN 
expression in early stage PDAC participants who undergo surgical resection confers decreased 
survival.[13] MSLN expression is also associated with more aggressive disease in 
cholangiocarcinoma, lung, ovarian and breast cancers.[14-17 ] In pancreatic cancer cell lines, 
overexpression of MSLN increases proliferation, mo tility and invasion and decreases survival of 
mice bearing tumors grown from these cells.[18] These properties make MSLN an attractive target 
for anti-neoplastic therapies, and more than fi ve anti-MSLN agents are currently undergoing 
clinical testing.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
11 
  
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
12 
 Table 1. Prevalence of MSLN expression by tumor type[19] 
 
Table 2. Pancreatic ductal adenocarcinoma (5B2 antibody)[10] 
 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
13 
 1.2.3 Recombinant Immunotoxins (RITs)  
1.2.3.1 Mechanism and structure of RITs 
RITs are antibody-based therapeutics that carry a 
toxin payload.  RITs that target MSLN contain a genetically engineered variant of Pseudomonas exotoxin A (PE) in which the native cell-binding domain of PE is replaced by a MSLN-binding antibody fragment. In this way, the RIT binds specifically to MSLN on the cell surface and gets internalized through endocytic processes. In the cytosol, PE catalyzes an irreversible, inactivating modification of eukaryotic Elongation Factor-2 
(eEF-2). This prevents the elongation step of protein 
synthesis, halting production of new cellular proteins, a stressor that triggers apoptosis. This mechanism of action results in cytotoxicity to both proliferating and non-dividing cells, therefore proper targeting is critical to the safety profile.
[20]   
 Tumor-targeted bacterial toxins that inhibit the protein synthesis of cancer cells have previously 
shown signs of preclinical and clinical efficacy . For instance, SS1P, a classical immunotoxin 
format molecule derived from mouse anti-mesothelin antibody SS1 and a 38 kDa PE toxin fragment (PE38) is one example. Besides SS1P, the most clinically advanced PE-based immunotoxins are moxetumomab pasudotox, a CD22 -targeted fusion protein in development by 
Astra Zeneca/ Medimmune, and LM B2, a CD25-targeted PE fusion protein developed by the 
National Cancer Institute (NCI). Both agents have shown encouraging signs of efficacy in different 
hematological malignancies and are currently in Phas e II and III clinical trials. Denileukin difitox 
is the only immunotoxin approved by the US Food and Drug Administration (FDA); a fusion 
protein of diphtheria toxin with interleukin-2 that is  clinically used for intravenous treatment of 
cutaneous T cell lymphoma.  
1.2.3.2 Rationale for the development of LMB-100 
The clinical use of SS1P, and of immunotoxins in general, has been hampered mainly by two key 
issues: firstly their high immunogenicity and se condly that they cause vascular leak syndrome 
(VLS) as a common severe side effect that is clinically difficult to manage.  LMB-100 (see Figure 
1 for structure) is a next ge neration PE-fusion protein that has been protein-engineered to 
maximally reduce its immunogenicity and its propensity to induce VLS by:  
1. Using a fully humanized Fab fragment derived from the anti-mesothelin antibody SS1 for tumor targeting 
2. Substituting the bulk of domain II (residues 251 –273 and 284 –394 of native PE) by an 
extended furin cleavable linker whose sequence is devoid of any T cell neoepitopes 
3. Deimmunizing domain III of PE, which has the catalytic activity for ADP-ribosylation by introducing 7 point mutations that silence B- and T-cell epitopes 
 
Figure 1: RIT Structure 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
14 
 Classical PE-based immunotoxins, such as SS1P, contain a 38 kD fragment of the exotoxin 
encompassing the so called translocation domain II and the catalytic domain III. Omission of the domain II from LMB-100 has not only removed a highly immunogenic 14 kD portion of PE that contains the main T-cell epitopes,
[21] but has also resulted in reduced incidence of VLS.[22] 
1.2.3.3 Nonclinical summary of previous generation MSLN-targeted RIT SS1P 
The SS1P molecule is composed of the V L from SS1, an affinity-matured derivative of an anti-
MSLN monoclonal antibody , disulfide bonded to a fusion of V H of SS1 with PE38. Compared to 
wild type toxin, the PE38 fragment lacks the cell-binding domain I (residues 1 –252) as well as the 
toxin portion encompassing positions 365 380. 
Viability of tumor cell lines expressing mesotheli n is potently reduced by treatment with SS1P, 
resulting in half-maximal inhibitory concentration values (IC50) in the single digit ng/mL range 
(equivalent to ~10 pM) or even lower for some tumor cell lines, while mes othelin-negative cancer 
cells are insensitive to SS1P even at 100 ng/mL.[23, 24] 
Using primary tumor cells from ascites or pleural effusion from nine mesothelioma patients, Zhang 
et al.[25] found that in most cases mesothelin expression was lost upon in vitro culture. However, 
for the few samples that retained mesothelin positivity, the mesothelin level on the cell surface, 
which ranged from 600 200,000 sites/cell, correlated with SS1P sensitivity. 
In mice, SS1P had severe off-target toxic effects on the liver, limiting the maximum tolerated dose 
(MTD) in a 3 uper week QOD schedule to d0.5 mg/kg.[22] Using MTDs and the 3 uper week 
QOD regimen, SS1P was shown to have significant monotherapy efficacy in xenograft models of 
the NCI-H226 cell line (derived from pleu ral effusions of a mesothelioma patient).[26] 
Monotherapy anti-tumor efficacy of SS1P has also been shown in xenografts of the stably 
transfected A431 K5 cell line,[27] that expresses very high levels of mesothelin on the cell surface 
(25 million molecules per cell). In the same st udy, synergistic antitumor activity was found for 
the combination of SS1P with paclitaxel in vivo but not in vitro. The underlying mechanism has 
subsequently been claimed to be related to  improved tumor penetration and intratumoral 
distribution of SS1P associated with a paclitaxel -mediated reduction of shedding of mesothelin 
from the tumor cells.[28, 29] 
When given to BALB/c mice as IV bolus injections (100 μL/mouse) at doses of 0.125 or 0.4 
mg/kg, SS1P has been reported to have a serum half-life of about 26 minutes, reaching a maximum 
serum concentration of 3.4 P g/mL at 30 minutes post-injection. The mean residence time has been 
reported as 0.64 minutes and the area under the plasma concentration curve as 0.36 minutes 
mg/mL.[30] 
Toxicology studies of SS1P were conducted in cynomolgus monkeys with different doses and 
schedules, including a 1 mg/kg 3 uper week QOD schedule. Decreased appetite and physical 
activity was observed in animals treated with the 1 mg/kg dose level of SS1P. Necropsy studies of 
SS1P-treated cynomolgus monkeys showed dose-de pendent, microscopic i nflammation of serosal 
membranes, suggesting that pleuritis a nd/or pericarditis could be dose limiting.[31] 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
15 
 1.2.3.4 Clinical Summary of previous generation MSLN-targeted RIT SS1P 
SS1P has been tested in a clinical setting by the NCI in the United States.[31] The related adverse 
events (AEs) included pleuritic pain, VLS, hypo albuminemia, weight gain, fatigue, fever, and 
edema. In an initial Phase I trial, a cohort of 17 patients received SS1P QOD u 6 doses. The MTD 
was 18 Pg/kg and the dose-limiting toxicities (DLTs) included Grade 3 urticaria (1 patient) and 
Grade 3 VLS (2 patients). To allow further SS1P dose escalation, another 17 patients were treated 
on a QOD u3 doses schedule with the MTD reaching 45 μg/kg. The DLT observed was Grade 3 
pleuritis (2 of 2 patients treated at 60 Pg/kg and 1 of 9 patients treated at 45 μg/kg). A second trial 
evaluated the safety and PK profile of SS1P given as continuous infusion for 10 days.[31] The MTD 
in this study was 25 μg/kg/day u10 doses, where 1 of 6 patients had a DLT due to reversible VLS. 
The most common adverse events  were edema (71%), hypoalbuminemia (62%), fatigue, (62%), 
weight gain/VLS (54%), nausea  (46%), fever (46%), hypotensi on (38%), and allergy/rash (33%).  
The clinical efficacy of SS1P in humans has been li mited to date, with 4 minor responses out of 
33 evaluable patients in the initial IV bolus monotherapy trial[31] and 1 partial response out of 24 
patients in the continuous infusion trial.[31] This is most likely due to the immunogenicity of the 
compound, which led to the development of neutralizi ng ADAs in the vast majority of the patients 
after 1 cycle of therapy in both the IV bolus and the continuous infusion trials. This hypothesis is 
supported by an exploratory trial currently ongoing by the NCI in which patients are pretreated 
with an immunosuppressive chemotherapy regi men (pentostatin and cyclophosphamide) for 14 
days prior to administration of SS1P. In this tria l, 3 out of 10 patients achieved a partial response 
and another 3 patients achieved  durable disease stabilization.[31, 32] One of the three patients 
achieving a partial response did so after receiv ing just two cycles of SS1P before developing 
neutralizing anti-SS1P antibodies and coming off treatment. In addition, a recent Phase1b study 
was published where SS1P was given with pemetrexed and cisp latin in advanced malignant pleural 
mesothelioma (MPM). SS1P was shown to be safe and well tolerated and exhibited significant 
antitumor activity in patients with unre sectable, advanced pleural mesothelioma.[33] 
Based on the safety profile described previously  for SS1P when given as single agent or in 
combination, the potential risks of treatment with  LMB-100 were expected to include VLS, 
hypoalbuminemia, edema, pleuritis, infusion-relat ed reactions, and immunogenicity. Precautions 
for diagnosis, monitoring, prevention, and treatment of adverse events will be provided in the Phase I studies. 
1.2.4 LMB-100 
1.2.4.1 Nonclinical Studies of LMB-100  
1.2.4.1.1 Nonclinical Pharmacology  
In vitro LMB-100 inhibited viability of a variet y of mesothelin-positive cancer cell lines at 
effective concentrations typically around 14 pM (~1 ng/mL). The cytotoxic potency of LMB-100 
varied between 0.35 ng/mL in primary mesothelioma cells (RH21) and 15.7 ng/mL in an adenosquamous lung carcinoma cell line (H596 ). Binding studies showed that while the Fab 
fragment did not bind to mouse or rat mesothelin, th e binding affinities to cynomolgus and human 
mesothelin were identical. In agreement with this, LMB-100 induced apoptosis in mesothelin-positive primary cynomolgus pericardial cells and si gnificantly impaired viability of HEK293 cells 
transfected with human mesothelin, but not of ra t mesothelin transfected or untransfected HEK293 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
16 
 cells. In addition, control experiments showed that free PE24 was 100 1000 fold less potent on 
mesothelin-positive target cell lines, confirming low cytotoxic potential of PE24 lacking a 
targeting moiety. 
Animal studies demonstrated that a single cycle of LMB-100 treatment given at an optimal dose 
of approximately 2 mg/kg, 3 uper week, every other day (QOD) achieved tumor regressions in 
subcutaneous xenografts of adenosquamous lung carcinoma (H596) in severe combined 
immunodeficient (SCID) beige mi ce. Three consecutive treatmen t cycles, given with 1 week 
breaks in between, led to massive shrinkage of large tumors with an average initial volume of 600 
mm3. Tumor regressions in monotherapy were al so achieved when treating subcutaneous 
xenografts of mesothelioma (NCI-H226), gastric (M KN-28), and triple negative breast (HCC70) 
cancer cell lines in athymic nude mice. Highly sy nergistic antitumor efficacy was observed in 
combination therapy with paclitaxel when tr eating subcutaneous xenografts of the recombinant 
high mesothelin expressing A431H9 cell line or the pancreatic cancer ce ll line KLM1. These 
results support evidence that LMB-100 may provide clinical benefit to participants with cancer. 
1.2.4.1.2 Combination of taxane with LMB-100  
A favorable in vivo interaction between paclitaxel and SS1P was first described by the Pastan lab 
nearly ten years ago[27] Pre-administration of paclitaxel was demonstrated to increase the amount 
of immunotoxin internalized by tumor cells and to reduce levels of shed MSLN in the intra-tumoral 
environment so that more immunotoxin could 
bind tumor cells.[28] Consistent with this 
mechanism, no synergy was observed in vitro.  A similar effect has been observed with LMB-100.
[34, 35] The effect is even more pronounced 
with NAB-paclitaxel in a pancreatic cancer model, 
where all combination treated mice develop complete regressions of their tumors ( Figure 2 ). 
Strikingly, the tumors never regrew in most of the animals. Similar results have been seen with in A431 cells stably overexpressing MSLN and also in tumors grown from primary mesothelioma cells. Research in our laboratory has demonstrated 
that this synergistic interaction can also be 
observed in vitro suggesting that a direct 
mechanism accounts for at least part of the effect (data not shown, manuscript in preparation).  The 
exact mechanism remains under investigation. 
These data support testing of this combination in the clinic as it may have clinical benefit for pancreatic cancer patients.  
Figure 2 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
17 
 1.2.4.1.3 Pharmacokinetics in Animals  
The pharmacokinetics (PK) of LMB-100 were tested in cynomolgus monkeys following single IV 
administration at doses ranging from 0.03 mg/k g to 0.3 mg/kg. Two different enzyme-linked 
immunosorbent based formats were used for anal yzing plasma levels of LMB-100; free and total 
drug assay (where the total drug assay was the sum of free LMB-100 and LMB-100 complexed with binding molecules). LMB-100 showed a rela tively rapid plasma clearance and a volume of 
distribution at steady-state similar to the plasma  volume. Within the dose range tested, non-linear 
PK was observed for free drug with an extended ha lf-life at higher doses (mean terminal half-life 
approximately 0.6 hours at 0.3 mg/kg compared to 0.3 hours at 0.03 mg/kg) suggesting saturation of MSLN-mediated clearance pathways. Clearance of total drug was consistently lower than that 
for free drug implying the presence of soluble bi nding partners such as soluble mesothelin and 
ADAs. Induction of anti-drug antibodies (ADA) res ponses was frequently detectable in all dose 
groups tested. Overall, given the limited predictive value of immunogenicity reactions in animals 
to human, a risk for immunogenicity in humans cannot be excluded. Toxicokinetics after repeated IV dosing in cynomolgus monkeys demonstrated an increase in total exposure in a dose proportional manner between 0.1 mg/kg and 3.0 mg /kg. No accumulation was observed over 5 
consecutive days of treatment or over two dosing cycles with 3 uper week dosing. Almost all 
monkeys developed ADAs upon treatment, while induction of high ADA levels impaired the 
exposure of free drug. In some cases, the induction of ADAs may have induced a slight increase in exposure 
The relationship between systemic drug exposure and anti-tumoral activity of LMB-100 was 
investigated on human lung cancer NCI-H596 xenograft growth in female SCID beige mice. Free and total drug profiles were similar in mice. Mo deling estimated a plasma concentration of 6800 
ng/mL (r36%) to trigger a half maximal rate of tumor regression. Concentrations of LMB-100 
above this level resulted in potent tumor regr ession after dosing. Normalized for exposure, SS1P 
was found to be ~3-fold more potent than LMB-100 in terms of tumor growth inhibition. 
1.2.4.1.4 Toxicology and Safety Pharmacology  
The toxicological profile of LMB-100 was assessed after repeated intravenous administration to 
cynomolgus monkeys, the only relevant species, f or a maximum of 5 daily doses for one week or 
2 cycles with QOD u3 dosing, separated by a 9 day dosing free period. Four daily doses of 3 
mg/kg exceeded the maximum tolerated dose with animals being found in moribund condition, indicated by clinical signs of hypoactivity, hunched posture, ataxia, and tremors. There were no histopathological changes to account specifically  for the deteriorating physical condition of these 
animals. 
Histopathological findings such as kidney tubu lar degeneration/regeneration and changes at 
serosal-lining tissues were observed at lower dos es as well. In general, administration of LMB-
100 resulted in both on- and off-target toxicities. 
On-target effects were observed on serosal-lining tissues, consistent with high expression of 
mesothelin. Mesothelium hypertrophy accompanied  by subpleural cellular hypertrophy and 
serosal fibrin exudate was observed in the lung at doses t1 mg/kg. Mesothelium hypertrophy also 
occurred in heart (epicardium), spleen, and st omach. Off-target or non-specific toxicity included 
degeneration/regeneration of kidney tubular  epithelium after repeated doses of t0.3 mg/kg. Local 
inflammatory findings at the injection sites were observed after administration of LMB-100 in 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
18 
 several studies. Clinically, reddening of the skin, swelling, and skin being warm to touch or flaky 
injection sites were reported. In the 2-cycle GL P study (3 intermittent doses over a 5-day period, 
9-days apart), impaired movement of animals from  all dose groups was likely related to injection 
site findings and an overall inflammatory profil e. One female at 1 mg/kg was sacrificed early on 
Day 4 after 2 doses due to severe clinical signs mo st likely attributed to inflammatory changes at 
injection sites resulting in moribundity of the an imal. Clinically observed inflammatory changes 
correlated with histopathological changes such as hemorrhages and/or acute inflammation at the 
injection sites and clinical pathology changes co nsistent with an overall inflammatory profile 
(increases in monocytes, neutrophils, CRP, and haptoglobin). Microscopic changes reversed 
completely after the 4-week recovery period in th e 2-cycle GLP study. The Highest Non Severely 
Toxic Dose in this study was 0.3 mg/kg, whic h resulted in a mean AUC for total drug of 16.0 
μg·h/mL (study day 1, preliminary data). In a subsequent 1 cycle GLP study (QOD u3 dosing), 
markedly reduced Injection site findings were observed after administration of a batch with 
reduced levels of product related modifications of LMB-100. In this study, the HNSTD was 1 
mg/kg, resulting in an AUC for total drug of 27.4 and 23.6 μg·h/mL after the first and third dose 
(preliminary data). 
The potential of LMB-100 to induce off-target vascular leak in lungs was assessed in female Wistar 
rats. Mild perivascular edema was reported microscopically, but did not correlate with 
macroscopic or serum chemistry findings consistent with VLS. Ultrasound evaluation in the NHP GLP study revealed minimal accumulation of pericardi al fluid with limited biological significance 
at the highest dose of 1 mg/kg. No appreciable  accumulation of pleural fluid was observed at 
necropsy. 
In vitro evaluation of LMB-100 in human whole bl ood assay indicated a low risk for cytokine-
mediated infusion related reaction (IRR)/cytokine release syndrome (CRS) upon first 
administrations. LMB-100 caused no hemolysis when added to human peripheral blood up to the highest concentrations of 0.5 mg/L. 
1.2.4.2 Previous Roche clinical study of LMB-100  
Initial clinical testing of LMB-100 was performed by Roche in a multi-center international first in 
human trial ([STUDY_ID_REMOVED]). The primary objective of th e Phase I study was to define the safety 
and tolerability (including the MTD) and pharmac okinetics of the drug in participants with MSLN-
expressing metastatic or locally advanced soli d tumors for whom no standard therapy was 
available. Secondary objectives included determin ation of the RP2D and schedule, exploration of 
preliminary anti-tumor activity by assessing obj ective response rate (ORR) and disease control 
rate (DCR), and assessment of pharmacodynamic effects.  
A total of 15 participants were enrolled onto the study before termination. Median age of 
participants was 60.8 years and 53.3% were female.  All participants had received prior anti-cancer 
therapy for their tumors. Enrolled participants had advanced mesothelioma (7), ovarian cancer (3), 
pancreatic cancer (3), and gastroesophageal cance r (2). Tumors from 13 of the 15 participants 
treated had moderately to strongly positive MSLN expression as measured by central IHC analysis.  
LMB-100 was administered intravenously on Days 1, 3 and 5 of a 21-day treatment cycle. No pre-
medications were given. Treatment was initiated at the MTD of SS1P, 45 mcg/ kg. Five different 
dose levels were tested (see Table 3 ). Dose limiting toxicity (DLT) was reached at 250 mcg/kg, 
with 2 of 4 participants treated at this dose level  experiencing vascular leak syndrome (grade 2 and 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
19 
 grade 4). Additional toxicities were associated with this toxic dose level. At this point, a sixth 
cohort receiving 200 mcg/kg of study drug was enrolled, however, the study was terminated by 
the company before the two accrued participants completed cycle 1 of therapy. Therefore, the 
single agent MTD was not determined.   
Table 3 . LMB-100 Dose escalation study- [STUDY_ID_REMOVED]  
Dose (mcg/kg) No. of patients Pts with DLT  
45 1 0 
65 1 0 
100 3 0 
170 4 0 
200 2 NE 
250 4 2 
DLTs were vascular leak syndrome and proteinuria 
NE, Study terminated before DLT assessment period was complete and 
patients only received single dose of RG7787 
1.2.4.2.1 LMB-100 Adverse Events 
Overall, 14 participants (93.3%) experienced at  least one AE.  The most common AEs were 
hypoalbuminemia (60.0%), fatigue (53.3%), periphe ral edema (53.3%), nausea (46.7%), pyrexia 
(40.0%), decreased appetite (33.3%), dyspnea (33.3%), and myalgia (33.3%). SAEs included vascular leak syndrome, pyrexia, atrial flutter, infusion related reaction, arthritis, glomerulonephritis minimal lesion and dyspnea.  No  participants experienced an AE that led to 
withdrawal of study treatment. Four participants experienced a total of 8 infusion-related reactions 
that were independent of drug dose level.  All of these AEs were non-serious and resolved within approximately 1 hour of onset. Pre-medication for infusion reaction was administered to these participants prior to subseque nt doses of LMB-100. Two suspected Type III hypersensitivity 
reactions were observed. These consisted of arthri tis (1) and rash with fever (1), both of which 
were fully reversible.  When other AEs attributed to the study drug are presented by dose level of 
drug, it becomes clear that toxicity was strongly associated with the 250 mcg/kg dose level at which DLT was reached (see Table 4  and Table 5  which are adapted from Roche Final Study 
Report, “Summary of Advers e Events Related to Stud y Medication, Safety-Evaluable Patients 
Protocol: BP29387”). Two of four patients treated at 250 mcg/kg experienced serious VLS which 
manifested with hypotension, respiratory compromise, serosal membrane reaction and hyponatremia as well as the hypoalbuminemia and ed ema that can be seen with mild VLS. Other 
symptoms associated with the DLT dose were fati gue, nausea, vomiting, decreased appetite and 
mild elevation of transaminases. In summary,  safety and tolerability of LMB-100 were as 
expected. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
20 
 Table 4: Grade 3 or 4 Adverse Events Attributed to LMB-1001 
Dose (mcg/kg) 45 65 100 170 250 ALL 
# of patients treated 1 1 3 4 4 13 
Vascular leak (gr 4) - - - - 1 1 
Hyponatremia (gr 3) - - - - 1 1 
Anemia (gr 3) - - - 1 - 1 
Decreased lymphocytes (gr 3) - - - - 1 1 
Dyspnea (gr 3) - - - - 1 1 
Infusion-related reaction (gr 3) - - 1 - - 1 
Arthritis (gr 3) - - 1 - - 1 
1 adapted from Clinical Study Report No 1066017 from Roche dated December 2015 , “Summary of Adverse Events 
Related to Study Medication, Safety- Evaluable Patients Protocol: BP29387”  See pages 175-193 of the report.  
Table 5: Adverse Events attributed to LMB-1001 
Dose (mcg/kg) 45 65 100 170 250 ALL 
# of patients treated 1 1 3 4 4 13 
Vascular Leak - - 1 1 2 4 
grade 3 or 4 vascular leak - - - - 1 1 
hypotension - - - - 2 2 
hypoalbuminemia - 1 3 2 3 9 
peripheral edema 1 1 3 2 4 11 
facial edema - 1 2 - 1 4 
weight gain - - 1 - 1 2 
hyponatremia - - - - 3 3 
hypophosphatemia - - - - 1 1 
dyspnea - 1 - - 2 3 
Infusion related reaction - - 2 - 2 4 
Constitutional              
fatigue - - - 1 4 5 
asthenia - - 3 - - 3 
fever 1 - 2 1 2 6 
Musculoskeletal             
myalgia - - 1 1 2 4 
arthralgia 1 - - - 1 2 
arthritis - - 1 - - 1 
muscle spasm - - - 1 - 1 
Cardiac             
pericardial effusion - - - - 1 1 
Atrial flutter - - - 1 - 1 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
21 
 Dose (mcg/kg) 45 65 100 170 250 ALL 
# of patients treated 1 1 3 4 4 13 
Renal Disorders       
glomerulonephritis minimal - - - 1 - 1 
proteinuria - - - 1 1 2 
Creatinine increase - - - - 2 2 
Gastrointestinal             
decreased appetite - 1 - 1 2 4 
nausea 1 - 1 1 4 7 
abdominal pain - 1 - 1 1 3 
diarrhea 1 - 1 - - 2 
vomiting - - - - 2 2 
abdominal distension - 1 - - - 1 
constipation - - - 1 - 1 
dyspepsia - - - 1 - 1 
AST increase - - - - 2 2 
Hematologic             
anemia - - - 1 - 1 
decreased lymphocytes - - - - 1 1 
Total Grade 3 or greater - - 2 1 2 5 
Orange highlighting indicates that one of the patients experienced a grade 3 or 4 toxicity in this category.  Please 
note that there was only 1 patient who exper ienced a high grade toxicity of each type.  
1 adapted from Clinical Study Report No 1066017 from  Roche dated December 2015, “Summary of Adverse 
Events Related to Study Medication, Safety- Evaluable Patients Protocol: BP29387” See pages 175 -193 of the 
report.”  
1.2.4.2.2 Anti-Drug Antibodies (ADAs) and LMB-100 Drug Levels 
Twelve participants were evaluable for efficacy.  The best confirmed overall response was stable 
disease in 3 participants.  A Roche-developed EL ISA test was used to retrospectively assess anti-
drug antibody (ADA) titers. 5 of 15 participants had detectable ADAs at study enrollment while 
the remaining participants did not, however, th e remaining participants developed detectable 
ADAs by the end of Cycle 2. Immunogenicity of LMB-100 did affect serum drug levels.  These 
data are summarized in  Figure 3. All evaluable participants achieved expected serum drug levels 
during the first cycle of treatment. Six of 7 pa rticipants without pre-existing ADAs achieved 
effective drug levels during the second cycle, while 0 of 2 participants with pre-existing ADAs did. One of 3 participants that received a third cy cle of treatment also achieved effective drug 
levels during this cycle.  A positive test for ADAs did not definitively predict poor blood levels in 
the subsequent cycle (see patient 1101 in Table 7  ). In summary these data show that the presence 
of ADAs is not predictive of ability to achieve me asurable LMB-100 concentration in the serum, 
which is the most important parameter for drug efficacy. 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
22 
 Figure 3: LMB-100 ADAs and Blood Levels 
 
Table 6: LMB-100 drug levels and ADAs in patients WITH pre-existing ADAs 
  Cycle 1 Cycle 2 
Patient  Dose 
(mcg/kg) ADA 
(Day1) Cmax 
(ng/ml) ADA 
(Day1) Cmax 
(ng/ml) dC1/dC2 
(%) 
1001 45 2700 620 196830 0 -100 
1201 100 8100 495 196830 0 -100 
1501* 250 2700 3730 196830 - - 
1003 250 900 2960 196830 - - 
* Patient’s treatment stopped due to study closure  
Table 7: LMB-100 drug levels and ADAs in  patients WITHOUT pre-existing ADAs 
  Cycle 1 Cycle 2 Cycle 3 
Patien
t  Dose 
(mcg/kg) ADA 
(Day1) Cmax 
(ng/ml) ADA 
(Day1) Cmax 
(ng/ml) dC1/dC 
(%) ADA 
(Day1) Cmax 
(ng/ml) dC1/dC 
(%) 
1002 65 0 1150 8100 711 -38 - - - 
1401* 100 0 1790 0 1610 -10 24300 267 -85 
1402 100 0 1650 0 1360 -18 8100 0 -100 
1101* 170 0 2760 300 3950 43 900 3490 26 
1202 170 0 3040 0 1940 -36 - - - 
1301 170 0 3430 72900 527 -85 - - - 
1403 170 0 1930 900 1550 -20 - - - 
1102* 250 0 5480 0 4770 -13 - - - 
1302 250 0 4340 - - - - - - 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
23 
 * Patient’s treatment stopped due to study closure  
ADA data are from Roche "Bioanalytical Report  (ADA) for Clinical Study BP29387“with ADA time 
point codes translated as specified in the BP29837 Lab Manual Version 1.0. Cmax data were taken from 
the Roche final study report.  
 
1.2.4.2.3 Comparison of toxicity and immunogenicity of LMB-100 to SS1P  
In the Roche Phase 1 trial, LMB-100 was safely administered to four patients at 170 mcg/kg 
without DLT.  This is nearly four times the maximum tolerated dose (MTD) of SS1P.  Most 
patients without pre-existing ADAs were able to  achieve effective drug levels of LMB-100 for 2 
cycles, unlike what has been seen previously with SS1P (see  Figure 4 ). These data demonstrate 
that LMB-100 is both less toxic and less immunogenic than SS1P.  
Figure 4: LMB-100 vs SS1P[31] Cycle 2 Blood Levels 
 
p>0.001 by two tailed Fisher’s exact test  
1.2.4.3 NCI Phase I study of LMB-100 in patients with malignant mesothelioma 
Clinical testing of LMB-100 in a second single agent study has recently been completed.  In this 
trial, LMB-100 given by short infusion dosing was assessed in 10 patients with malignant 
mesothelioma ([STUDY_ID_REMOVED]). Doses of 170 mcg/kg and 140 mcg/kg given as a 30-120 minute 
infusion every other day x3 doses were tested.  Reversible renal toxicity that prolonged 
hospitalization was observed at the 170 mcg/kg dose. Therefore, single agent short infusion MTD 
of 140 mcg/kg was established . Toxicities and peak drug levels have  thus far been similar to what 
was seen in the completed Roche study.  Low serum LMB-100 levels and a high rate of infusion-
related reactions were observed after cycle 2, presumably due to the development of anti-LMB-
100 antibodies. 
1.2.4.4 Results in current study (16C0128 as of 16 July 2018) 
Part A – short infusion 
As of 7/16/2018, 14 subjects have been enrolled to receive escalating doses of LMB-100 in 
combination with a fixed dose (125 mg/m2) of nab-paclitaxel. LMB-100 was administered on days 
1, 3 and 5 of a 21-day cycle, while nab-paclitaxel  was administered on days 1 and 8.  Six subjects 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
24 
 received LMB-100 at dose level 1 (100 mcg/kg), of whom  five were evaluable.  Of the five, two 
experienced DLTs of grade 3 myalgia. Therefore , per dose escalation rules, the next LMB-100 
dose level evaluated was 65 mcg/kg (dose level -1). Eight subjects have been enrolled, two of 
whom are deemed inevaluable. One of the six evaluable subjects experienced DLT of grade 3 
edema related to LMB-100 vascular leak.. This arm of the study (Arm A1) is now completed and 
closed to further accrual. Dose Level -1 is th e recommended Phase 2 dose. Arm A2 has opened to 
accrual of patients at this dose and schedule. 
Part B – continuous infusion 
Subjects are being evaluated on Arm B1, dose exploration for continuous infusion LMB-100 
monotherapy.  Dose level 1 was discarded after trea tment of 3 patients due to  erratic PK results. 1 
of 6 patients at dose level 2 experienced DLT (grade 3 proteinuria). However, a planned dose de-
escalation was initiated to try to determine a better tolerated schedule since 3 of 6 patients at dose 
level 2 experienced non-DLT VLS resulting in >5 kg weight gain. As of 7/16/18, 6 participants have been treated at dose level 3 and comp leted the DLT period. None of the participants 
experienced significant VLS. 3 of the 6 participants received on the Day 1 and not the Day 4 dose of LMB-100 due to complications from their dise ase unrelated to study drug (question of partial 
small bowel obstruction, fever and hypotension from cholangitis, dehydration from nausea and vomiting due to overeating), and were therefore inevaluable. 1 of the 3 evaluable participants did not receive the Day 4 dose of LMB-100 due to transient grade 2 creatinine elevation that was attributed at least partially to study drug. This was considered an investigator-determined DLT since the patient was unable to receive the fu ll course of treatment due to a study-drug related 
toxicity.   
1.2.5 Pharmacokinetics of LMB-100 and modeling of continuous infusion 
The initial Roche trial demonstrated that 
LMB-100 has an unexpectedly short drug 
half-life of 61 minutes as compared to 466 
minutes for the predecessor drug SS1P.[36] 
It is not known what factors contribute to 
the longer half-life in circulation of SS1P. 
Using these clinical pharmacokinetic data, 
estimations of individual pharmacokinetic 
parameters that would be achieved with a 
continuous infusion format can be 
calculated (see Table 8 ).  Using a one 
compartment population PK model, it is 
estimated through simulations that steady 
state maximum plasma concentration will 
be reached by 7 hours and that drug 
concentration will remain at this plateau 
level until the infusion is stopped ( Figure 5 ). Peak plasma drug concentration (C max) using the 
continuous infusion is expected to be 92% lowe r than those seen following short infusion of the 
same amount of drug. Following completion of the continuous infusion, drug levels are expected 
to fall to near zero within 5 hours from the end of  infusion. Results from patients enrolled onto the 
first Level of the Arm B1 Single Agent Lead-in have confirmed Cmax at or lower than that 
Figure 5 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
25 
 predicted by the model and also that drug levels fall to near zero in less than 4 hours from the end 
of infusion. 
Table 8. LMB-100 drug exposure comparison 
 
 
1.2.6 Rationale for treating pancreatic cancer  patients with LMB-100 and NAB-paclitaxel 
combination 
LMB-100 targets the cell surface antigen MSLN a nd is ineffective against tumor or normal cells 
that lack MSLN.  Expression of MSLN in pancreat ic adenocarcinoma has been examined in 
several published studies and ranges from 86 to 100%,[8-10] making this tumor type a good target 
for LMB-100.  There is clearly an unmet need to identify improved therapies for this patient 
population as patients with metastatic pancreatic can cer have a median OS of less than one year 
with the best currently available therapies.  Pre-clinical studies have demonstrated that 
combination of LMB-100 with nab-paclitaxel resu lts in synergistic anti-tumor efficacy.  NAB-
paclitaxel is part of an FDA approved regimen fo r patients with advanced pancreatic cancer and 
addition of LMB-100 to nab-paclitaxel may imp rove outcomes for these patients.  Given the 
overall poor prognosis of these patients, the potential  to directly benefit from treatment with the 
combination regimen outweighs the risks of participating in the study. 
1.2.7 Rationale for assessing continuous infusion of LMB-100 
Clinical trials have shown that LMB-100 has a short half-life in humans of only 1 hour. Drugs 
with short half-lives can be administered by continuous infusion in order to improve drug 
exposure. Short half-life standard of care chemot herapies such as 5-FU and cytarabine are 
preferentially administered in this format. In th e case of 5-FU the continuous infusion is preceded 
by a single bolus dose. Short half-life protein base d therapeutics also appear to benefit from 
continuous infusion.  For example, the dual spec ificity CD19/ CD3 bispecific T cell engaging 
(BiTE) antibody construct, blinatumomab, has a ha lf-life of just over 2 hours. In initial clinical 
trials using a 2-4 hour infusion given 2-3 times  per week, the drug performed poorly and these 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
26 
 trials were terminated early due  to poor risk to benefit ratio.[37] Subsequently, the drug was 
reintroduced in a continuous infusion format. Decreased toxicity and significant efficacy, 
including complete remissions in patients w ith chemotherapy-refractory disease, were 
observed.[38] Blinatumomab has since been approved by the FDA for administration in the 
continuous infusion format.  
We hypothesize that sustained infusion of LMB-100 will be 
safer and more effective than short infusion. We expect LMB-100 toxicity to decrease when given in the continuous infusion format because peak drug levels (Cmax) will be lower and this should reduce non-specific toxicity from the drug.  We expect greater efficacy because pre-clinical data suggest that duration of exposure to LMB-100 rather than peak dose may be more 
important for killing tumor cells. Specifically, we have found 
that sustained exposure of cultured cells to lower doses of LMB-100 can be more cytotoxic than treatments with higher doses given for shorter durations ( Figure 6 ). In addition, 
previously published studies in mouse models with another short half-life immunotoxin demonstrated that continuous infusion of immunotoxin administered by means of surgically inserted intraperitoneal osmotic pump is less toxic; continuous infusion of these immunotoxins at MTD resulted in at least 2.5 
times higher AUC than could be achieved safely with a short infusion at MTD. Because of this, better anti -tumor efficacy was achieved with the continuous 
infusion dosing.
[39]  
Instability of LMB-100 at 37°C precludes the ability to directly test its efficacy when administered 
continuously for several days in mouse pre-clinica l tumor models. This is because the drug must 
be administered in a pump kept within the per itoneal cavity at mouse body temperature throughout 
the experiment and the drug loses activity within 24 hours when stored at these temperatures. However, preliminary data from pre-clinical st udies performed by the LMB Immunotoxin group 
have shown increased efficacy and decreased to xicity when using 1) intraperitoneal continuous 
delivery of a related short half-life MSLN-targeted immunotoxin that is stable at 37°C and 2) bolus 
dosing of a long-half-life anti-MSLN immunotoxin that contains an albumin-binding domain that prolongs half-life. Both studies demonstrated in creased anti-tumor efficacy compared to bolus 
dosing of LMB-100 ( Figure 7 ).   
Figure 6 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
27 
 Figure 7 
 
Continuous infusion dosing of the LMB-100 predecessor drug, SS1P, has been examined in a 
Phase I clinical trial. Although the long half-life of SS1P is expected to lessen the clinical impact 
of switching from short to continuous infusion format,  these data also support our hypothesis. As 
predicted by the preclinical modeling, using a continuous infusion format allowed patients to 
achieve a higher total drug exposure. At MTD, continuous infusion resulted in an AUC of 1800 
mcg min/ mL[40] as compared to 590 mcg min/mL with the short infusion.[36] Unfortunately, 
comparative efficacy of the two formats could not be adequately assessed since the immunogenicity of SS1P prevented effective dosing over multiple cycles. Since multiple cycles of LMB-100 can be administered to most patients  prior to the development of anti-drug antibodies, 
this provides an ideal opportunity to determine  whether a continuous infusion format can improve 
therapeutic window in the clinic as predicted by pre-clinical models. 
Continuous LMB-100 will be delivered at a slow ra te, i.e. which may be less than one mL per hour 
in some cases.  The FDA has issued a warning regarding such low infusion rates particularly 
pertaining to high risk or life-sustaining therap ies.  However, LMB-100, is not considered to be a 
high risk (based on the fact that patients are currently tolerating infusions given over 30-60 
minutes) or life-sustaining therapy. 
1.2.8 Rationale for the initial dose and schedule and subsequent dose escalation of continuous 
infusion LMB-100 
Continuous infusion of 96 hours was deemed to be  the optimal duration for infusion after taking 
into consideration feasibility of administrati on and the potential risk to participants from 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
28 
 deconditioning while in hospital receiving continuous infusion of study drug, balanced against the 
possibility for increased efficacy with longer exposure times.  
As outlined in section 1.2.5  existing clinical PK data were used to generate a model that could 
simulate PK parameters during continuous infusion of LMB-100. This model predicts that 
continuous infusion of the same dose of LMB-100 ove r each 24 hours by continuous infusion as 
compared to daily bolus dosing would result in similar total LMB-100 exposure levels but much lower C
max. Lower C max should result in decreased off-target toxicity (such as VLS), and our pre-
clinical data suggest this should not adversel y affect efficacy. The effect of lower C max on on-target 
off-tumor toxicities (such as serosal membrane ir ritation) is not predictable, although increased 
on-target off-tumor toxicity was not apparent during clinical trial using a continuous infusion format of a predecessor mesothelin-targeted immunotoxin.
[40]  
Taking potential risk for increased on-target off-t umor toxicity into consideration, a reduction in 
starting dose compared to short-infusion MTD will be used.  A dose of 65 mcg/ kg was chosen as the initial dose for the escalation because it had b een a) previously tested in the short infusion 
format in the Roche study of single agent LMB-100, and b) would also result in participants receiving ~60% less drug per cycle compared to short infusion LMB-100 given at the MTD of 140 
mcg/kg every 48 hours for 3 doses (19.5 mg/ cycle versus 31.5 mg/cycle).  Based upon our simulations, we predict that participant drug exposure during a 96-hour continuous infusion of 65 mcg/ kg/ day of LMB-100 will be 80% of that compared to patients who receive short-infusion LMB-100 given at MTD (5528 versus 6927 hr*ng/ml/ cycle).  Subsequent dose levels administering 100, 140 and 200 mcg/kg/day ov er 96 hour continuous infusion were included 
although simulated drug exposures will exceed that of the short infusion MTD because the 
unacceptable toxicities seen with short-infusion LMB-100 at dosages higher than the established 
MTD for this format (VLS and reversible acute ki dney injury which prolonged hospitalization) are 
off-target toxicities, and likely to be minimized by the lower C
max that is predicted with continuous 
infusion. 
Although 96 hours is considered the optimal duration for continuous infusion, initial dose levels 
will test continuous infusions of 65 mcg/kg/day of drug for shorter durations since simulated drug exposure over each 48 hours of continuous infusion at  65 mcg/kg/day is 20% higher than for the 
short infusion MTD (2764 versus 2309 hr*ng/mL/48hr).  This is because just one dose of LMB-100 is given over 48 hours in the short infusion format.   
A loading dose of 40 mcg/kg LMB-100 given over 30 -180 minutes will be administered prior to 
initiation of the continuous infusion beginning af ter Level 1. The loading dose is expected to 
improve efficacy by reducing tumor site barrier effect. Such affect has been observed in pre-
clinical studies and may impair access of LMB-100 to the tumor during continuous infusion. 
1.2.9 Rationale for use of mesothelin testing (NSR device) 
In order to be eligible for the Arm B1 lead in portion of the study, participants are required to have 
positive mesothelin expression in archival tumor ti ssue, defined as at least 25% of tumor cells 
expressing mesothelin. Mesothelin expression te sting is not FDA approved for this purpose; 
however, it is being used as an in-vitro di agnostic device.  According to 21 CFR 812.3(m), a 
significant risk device presents a potential for seri ous risk to the health, safety and welfare of a 
subject and meets the significant risk criteria listed in the table below along with the sponsor’s 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
29 
 conclusions with regard to the applicability of th ese criteria to the current study. The device has 
been assessed by the sponsor as non-significant risk per the below. 
 
Significant Risk Criteria Applicable to 
current study Justification 
Is an implant  No The mesothelin test is not introduced into 
the subject  
Is used in supporting or 
sustaining human life  No The device is diagnostic  
Is of substantial importance in 
diagnosing mitigating or treating disease or preventing impairment of human health No While the device is diagnostic, we do not 
believe in presents a potential for serious risk to the health and welfare of the subject. The assessment of mesothelin positivity is only used in tumors that may not have a high rate of mesothelin expression, and is assessed to help to increase the possibility that all persons enrolling on the study might 
derive benefit from therapy.
  Persons that 
are deemed ineligible to enroll on the basis 
of this test  are eligible for studies within 
TGMB that are not reliant on this test.   
Otherwise poses a risk  No Testing will be performed on archival 
samples or on fresh tissue that is collected at screening for confirmation of diagnosis.  No additional collection of tissue will occur for purposes of mesothelin testing.
 
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  
2.1 ELIGIBILITY CRITERIA  
2.1.1 Inclusion Criteria 
2.1.1.1 For participants who will be receiving nab- paclitaxel (all arms except Arm B1 Single 
Agent Lead-in) 
2.1.1.1.1 Histologically confirmed recurrent, advanced or metastatic pancreatic ductal 
adenocarcinoma as determined by NCI Laboratory of Pathology. 
2.1.1.1.2 No treatment with paclitaxel or nab-paclitax el within 4 months prior to initiation of 
study therapy 
2.1.1.1.3 ECOG performance status (PS) 0 1 (Appendix A ). 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
30 
 2.1.1.1.4 Adequate hematological func tion: neutrophil count of t 1.0 u109 cells/L, platelet count 
of t95,000/PL, hemoglobin ≥9 g/dL 
2.1.1.1.5 Measurable disease as per the RECIST Criteria v 1.1 (see section 6.3) 
2.1.1.2 For participants who will NOT receive nab- paclitaxel (Arm B1 Single Agent Lead-in 
only) 
2.1.1.2.1 Histologically confirmed solid tumor malignancy for which no curative therapy exists 
with at least 25% of tumor cells expre ssing mesothelin as determined by NCI 
Laboratory of Pathology. Determination can be made using archival tumor tissue or fresh biopsy. Subjects with epithelioid mesothelioma and pancreatic adenocarcinoma 
are automatically eligible and are not required to have this test 
2.1.1.2.2 ECOG performance status (PS) 0 2 (Appendix A ). 
2.1.1.2.3 Adequate hematological func tion: neutrophil count of t 1.0 u109 cells/L, platelet count 
of t85,000/Pl, hemoglobin ≥8.5 g/dL 
2.1.1.2.4 Measurable and/or evaluable disease as per the RECIST Criteria v 1.1 (see section 6.3) 
2.1.1.3 For all arms of the protocol 
2.1.1.3.1 Participants must have received at least one prior chemotherapy regimen for their 
disease. 
2.1.1.3.2 Age ≥18 years. Because no dosing or adverse event data are currently available on the 
use of LMB-100 alone or in combination with nab-paclitaxel in persons <18 years of 
age, children are excluded from this study.  
2.1.1.3.3 Participants must be more than 14 days  removed from most recent minor surgical 
procedure (such as biliary stenting), 28 days from most recent major surgical procedure, 
14 days removed from most recent radiation therapy, chemotherapy or experimental 
drug treatment with published half-life known to be 72 hours or less and 28 days removed from last experimental drug treatment with unpublished or half-life greater than 72 hours. 
2.1.1.3.4 All acute toxic effects of any prior radiotherapy, chemotherapy, experimental drug 
treatment or surgical procedure must have resolved to Grade d1, except alopecia (any 
grade) and peripheral neuropathy. 
2.1.1.3.5 Serum albumin ≥ 2.5 mg/dL without intravenous supplementation 
2.1.1.3.6 Adequate liver function: Bilirubin, AST a nd ALT < 2.5 x ULN. AST and ALT up to 5x 
ULN is permitted for patients with liver metastases. 
2.1.1.3.7 Adequate renal function: creatinine clearance (by Cockcroft Gault formula Appendix B 
or measured) t 50 mL/min. 
2.1.1.3.8 Must have left ventricular ejection fraction ≥ 50% 
2.1.1.3.9 Must have an ambulatory oxygen saturation of > 88% on room air 
2.1.1.3.10 The effects of LMB-100 alone or in combination with nab-paclitaxel  on the developing 
human fetus are unknown.  For this reason, women of child-bearing potential and men 
must agree to use adequate contracepti on (hormonal or barrier method of birth control; 
abstinence) prior to study entry until 3 months the last dose of study therapy.  Should a 
woman become pregnant or suspect she is pregnant while she or her partner is 
participating in this study, she should inform her treating physician immediately. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
31 
 2.1.1.3.11 Ability of participant to understand and th e willingness to sign a written informed 
consent document. 
2.1.2 Exclusion Criteria 
2.1.2.1 Exclusion criteria for all study arms 
2.1.2.1.1 Known or clinically suspected CNS primary tumors or metastases including  
leptomeningeal metastases. History or clinical evidence of CNS metastases unless  they 
have been previously treated, are asymptomatic, and have had no requirement  for 
steroids or enzyme-inducing anticonvulsants in the last 14 days. 
2.1.2.1.2 Evidence of significant, uncontrolled concomitant diseases which could affect  
compliance with the protocol or interpretation of results, including significant  
pulmonary disease other than that related to the primary cancer, uncontrolled diabetes 
mellitus, and/or  significant cardiovascular disease (such as New York Heart Association 
Class III or  IV cardiac disease, myocardial infarction within the last 6 months, unstable  
arrhythmias, unstable angina, or clinically significant pericardial effusion)  
2.1.2.1.3 Any known diagnoses, metabolic dysfunction, physical examination finding, or clinical  
laboratory finding giving reasonable suspicion of a disease or condition (other than 
mesothelin [+] cancer diagnosis) that would  contraindicate the use of an investigational 
drug, interfere with tumor measurement or lead to an expected life expectancy of less than 6 months as judged by the investigator 
2.1.2.1.4  Active or uncontrolled infections. 
2.1.2.1.5 Live attenuated vaccinations within 14 days prior to treatment 
2.1.2.1.6 Dementia or altered mental status th at would prohibit informed consent 
2.1.2.1.7 Pregnant women are excluded from this study because the effects of LMB-100 on the developing fetus are unknown and may have the potential to cause teratogenic or abortifacient effects.  Because there is an unknown but potential risk for adverse events 
in nursing infants secondary to tr eatment of the mother with LMB-100 , breastfeeding 
should be discontinued if the mother is treated with LMB-100.  These potential risks may also apply to other agents used in this study. 
2.1.2.1.8 Known hypersensitivity to any of the components of LMB-100 
2.1.2.1.9 Baseline QTcF interval of > 470 ms, participan ts with baseline resting bradycardia < 45 
beats per minute, or baseline resting tachycardia !100 beats per minute. 
2.1.2.2  Exclusion criteria specific to patients who will be receiving nab-paclitaxel (all arms 
except Arm B1 Single Agent Lead-in) 
2.1.2.2.1 Participants with contra-indication and/or history of severe hypersensitivity reactions to  
nab-paclitaxel  
2.1.2.2.2 Participants with baseline periphera l neuropathy greater than grade 2. 
2.1.2.2.3 HIV or active HBV or HCV infection due to risk of progression while receiving immunosuppressive chemotherapy 
2.2 S
CREENING EVALUATION  
Assessments will be performed any time prior to study enrollment. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
32 
 x Archival tumor sample for NCI LP confirmation of diagnosis.  A block of primary tissue 
(or 10 unstained sections on charged slides) from the time of diagnosis will be required 
from each participant.  Tissue blocks from a known recurrence will be accepted if original 
tumor samples are unavailable.  Referring inst itutions will send the tumor block or 10 
unstained sections on charged slides to CCR/NCI for correlative studies and confirmation 
of diagnosis.  A fresh biopsy may be collected if tumor tissue is not available. 
x For patients on the Arm B1 Single Agent Lead-in who do not have a diagnosis of epithelioid mesothelioma or pancreatic adenocarcinoma
 ONLY: archival tissue or fresh 
biopsy samples sufficient to assess tumor MS LN expression by immunohistochemistry 
analysis. 
Assessments performed within 28 days prior to study enrollment 
x History and physical exam 
x Vital signs including ambulatory oxygen saturation by pulse oximetry 
x ECOG performance status 
x Pregnancy test in women of childbearing potential 
x ECG 
x Echocardiogram 
x CT scan of chest, abdomen and/or pelvis  and areas of known or suspected disease 
involvement; MRI may also be performed when appropriate 
x CBC with differential, Acute Care Panel (sodium, potassium, chloride, bicarbonate, 
creatinine, glucose, BUN), Hepatic Panel (alkaline phosphatase, AST, ALT, total bilirubin, 
direct bilirubin), Mineral Panel (albumi n, calcium, magnesium, phosphorus), creatine 
kinase, C-reactive protein, CK, vitamin D, 1,25-dihydroxy, Coagulation (PT, PTT), lactate 
dehydrogenase 
x CA 19-9 serum tumor marker for  pancreatic cancer patients  (or other appropriate tumor 
marker for patients enrolled in Arm B1 Sing le Agent Lead-in who do not have pancreatic 
cancer) 
x Testing for HIV, HCV, HBV: anti-HIV antibody, Anti-HCV Antibody, HBs Ag Screening (except for Arm B1 Single Agent Lead-in) 
x Urinalysis 
2.3 R
EGISTRATION PROCEDURES  
2.3.1 Arm B1, Single Agent Lead in Cohort Subjects  with Diseases other than Epithelioid 
Mesothelioma or Pancreat ic Adenocarcinoma Only 
Registration will be a two-part process as patients in this cohort that are not diagnosed with 
pancreatic adenocarcinoma or epithelioid mesotheli oma are screened on this protocol. Authorized 
staff must register an eligible candidate with NCI Central Registration Office (CRO) within 24 
hours of signing consent. To initially register a sub ject after the participant has signed the consent, 
complete the top portion the registration  Eligibility Checklist from the website 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) indicating that the patient is being 
registered for screening and send via encrypted email to: NCI Central Registration Office 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
33 
 ncicentralregistration-l@mail.nih.gov . Once eligibility is confirmed after completion of screening 
studies, complete the remainder of the form which is the eligibility checklist, indicating that the 
patient is being registered for tr eatment and email the completed re gistration checklist to the CRO 
at NCI Central Registration Office ncicentralregistration-l@mail.nih.gov . After confirmation of 
eligibility at Central Registration Office, CRO staff will call pharmacy to advise them of the 
acceptance of the patient on the protocol prio r to the release of any investigational 
agents.  Verification of Registration will be forwarded electronically via e-mail to the research team. A recorder is available during non-working hours.  
Subjects that do not meet screening criteria s hould be removed from the study following the 
procedure in section  3.5.2.1 . 
2.3.2 All other subjects 
Authorized staff must register an eligible ca ndidate with NCI Central Re gistration Office (CRO) 
within 24 hours of signing consent.  A registration Eligibility Checklist from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to:  NCI Ce ntral Registration Office ncicentralregistration-l@mail.nih.gov .  After 
confirmation of eligibility at Central Registration Of fice, CRO staff will call pharmacy to advise 
them of the acceptance of the participant on the protocol  prior to the release of any investigational 
agents.  Verification of Registration will be for warded electronically via e-mail to the research 
team. A recorder is available during non-working hours.  
2.3.3 Treatment Assignment  Procedures 
Cohorts 
Number Name  Description  
A1 Phase I Short I nfusion 
Cohort  The first 6 – 12 subjects with pancreatic cancer meeting nab-
paclitaxel eligibility criteria* to determine an MTD for part A. 
A2 Phase II Short I nfusion 
Cohort  The next 14 – 20 subjects with pancreatic cancer meeting nab-
paclitaxel eligibility criteria* (until at least 13 subjects have 
been evaluated at the Part A MTD  [stage 1] – a determination 
will then be made on whether to continue to 20 [stage 2]) 
B1 Continuous Infusion , 
Single Agent Lead-In 
Cohort  Up to 30 evaluable s ubjects with pancreatic cancer not meeting 
nab-paclitaxel eligibility criteria* or subjects with other 
mesothelin expressing tumors  for part B MTD determination. 
B2 Continuous Infusion , 
Combination Therapy  
Cohort  Up to 6 s ubjects with pancreatic cancer meeting nab- paclitaxel 
eligibility criteria, followed by an additional 4 subjects if 
safety is established.   
* criteria specific for nab-pacl itaxel are found in sections 2.1.1.1 and 2.1.2.2 ; criteria specific for 
subjects not receiving nab-paclitaxel are found in section 2.1.1.2 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
34 
 Arms 
Number Name  Description  
A1 Phase I , Short infusion  Subjects infused with escalating doses of LMB -100 on days 1, 
3 and 5 of each 21-day cycle.  Infusion length 30 – 180 
minutes.  Subjects will also receive nab -paclitaxel on day 1 of 
each cycle.  
A2 Phase II , Short infusion  Subjects infused at the LMB -100 dose determined in A1.  
Subjects will also receive nab -paclitaxel on day 1 of each 
cycle.  
B1 Continuous Infusion , 
Single Agent Lead-In  Subjects infused with LMB -100 monotherapy at escalating 
doses or escalating durations once per cycle – duration may 
range from 24 – 96 hours 
B2 Continuous Infusion, 
Combination Therapy  Subjects infused with LMB -100 at the dose level/dose 
duration determined after B1 is complete.  Subjects will also 
receive nab -paclitaxel on day 1 of each 14-day cycle. 
Arm Assignment 
Subjects will be directly assigned to each arm as follows: 
x Subjects in Cohort A1 will be directly assigned to Arm A1. 
x Subjects in Cohort A2 will be directly assigned to Arm A2 once an MTD has been 
determined in Arm A1.  Accrual to stage 2 of Arm A2 may commence after stage 1 is 
completed, but priority will be given to Arms  B1 and B2. Note: Cohort/Arm A2 will not 
be opened if dose level -1 is not deemed safe in part Cohort/Arm A1. 
x Subjects in Cohort B1 will be enrolled concur rently with subjects in Arm A1 & Arm A2 
(if this arm is opened) and will be directly a ssigned to Arm B1.  Priority will be given to 
Arm A1 followed by B1 then A2. 
x Subjects in Cohort B2 will be enrolled after Cohort/Arm B1.  These subjects are directly 
assigned to Arm B2. Enrollment to Arm B2 will be given priority over Arm A2 if these 
arms enroll concurrently.  
3 STUDY IMPLEMENTATION 
3.1 STUDY DESIGN  
This is a first-in-human, open-label, Phase I/II  study of LMB-100. It will be conducted in four 
parts. Three of the four parts accrue the same p opulation of patients with advanced pancreatic 
cancer (indicated by black outline around the arrows in the schema below): 
 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
35 
  
 
x Arm A1 (Phase I study): Dose escalation of short infusion LMB-100 with fixed dose nab-
paclitaxel in patients with advanced pancreatic cancer 
x Arm B1 Single Agent Lead-in: Dose es calation of continuous infusion LMB-100 as a 
single agent in patients with any solid tumo r malignancy expressing MSLN. This part will 
run concurrently with Arm A1 since it accrues a different patient population. 
x Arm B2: Single dose level of continuous infusi on LMB-100 with fixed dose nab-paclitaxel 
in patients with advanced pa ncreatic cancer. This part can  begin accrual after completion 
of Arm B1 Single Agent Lead-in. 
x Arm A2 (Phase II study): Investigates the clinical activity at MTD and/or RP2D for short 
infusion combination therapy with nab-paclitaxel in a 2-stage design.  The arm may not be 
explored if dose level -1 is deemed to be uns afe in Arm A1. If Arm A2 is opened, stage 2 
will only be accrued if pre-specified response cr iteria for Stage 1 are met.  Priority will be 
given to accrual of Arm B2 (which requires the same patient population) over either stage of Arm 2.  
* Eligibility requirements allow for accrual of pa tients with any solid tumor malignancy that 
expresses MSLN. Participants in this arm will NOT receive nab-paclitaxel 
3.1.1 Study Schema for short infusion LMB-100 with nab-paclitaxel (Arm A1 (Phase I)) 
 
 
 
Cycles 1 –2 
(21 days)  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
36 
 Participants will be treated with s hort infusion LMB-100 in combination with nab-paclitaxel for 2 
cycles or until unacceptable toxicities, disease pr ogression (per PI discretion), withdrawal from 
treatment for other reasons, or death, whichever occurs first.  During the phase I portion of the 
study, participants who withdraw prior to comp leting the DLT assessment period (for any reason 
other than toxicity) will be replaced.  
Arm A1 (Phase I) will utilize a dose escalation with LMB-100 administered in combination with 
a fixed dose of nab-paclitaxel (IV, 125 mg/m2). All cycles will be 21-days.  Nab-paclitaxel will be 
administered on days 1 and 8.  Participants w ill receive LMB-100 IV over 30 -180 minutes on 
Days 1, 3 and 5 (QOD x3).  
3.1.2 Study Schema for continuous infusion LMB-100 (Arm B1 [Single Agent Lead-in]) 
 
Participants will be treated with LMB-100 by  continuous infusion over 24 - 96 hours with or 
without a loading dose depending on dose level for 2 cycles or until unacceptable toxicities, disease 
progression (per PI discretion), withdrawal from trea tment for other reasons, or death, whichever 
occurs first.  During the phase I portion of the study, participants who withdraw prior to completing the DLT assessment period, for any reason other than toxicity, will be replaced. 
This arm will utilize a dose escalation of LMB-100.  All cycles will be 21-days.  Participants will 
receive continuous infusion of LMB-100 IV for the 1, 2, 3 or 4 days of each cycle depending on dose level. 
 
3.1.3 Study Schema for continuous infusion LMB-100 with nab-paclitaxel (Arm B2) 
 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
37 
 Up to 6 evaluable participants will be treated  with LMB-100 by continuous infusion over 24  hours 
with a loading dose in combination with nab-pacl itaxel for 3 cycles of 14 days duration or until 
unacceptable toxicities, disease progression (per PI discretion), withdrawal from treatment for 
other reasons, or death, whichever occurs first.  The DLT period will include the first 28 days 
following initial infusion of LMB-100 on C1D1. Par ticipants who withdraw prior to completing 
the DLT assessment period, for any reason other than toxicity, will be replaced. Participants may be enrolled concurrently. If no more than 2 of the 6 evaluable subjects experience unacceptable 
toxicity (as defined by DLT criteria in section 3.1.5 ), up to 4 additional participants may be accrued 
concurrently to better assess the safety and activity of this regimen. 
This arm will utilize a single dose of LMB-100 in combination with a fixed dose of nab-paclitaxel 
(IV, 125 mg/m2).  All cycles will be 14 days.  Nab-pa clitaxel will be administered on Day 1 . 
Participants will receive a 24-hour infusion of LM B-100 IV on Day 1 of each cycle for a total of 
3 cycles. 
3.1.4 Study Schema for Phase II 
Participants enrolled on the Phase II portion of the tr ial will be treated using the same schedule of 
short infusion LMB-100 and nab-paclitaxel  as given for Arm A1 (See Section 3.1.1), at the 65 
mcg/kg  dose of LMB-100, the RP2D in Part A. Th ey will be treated for 2 cycles or until 
unacceptable toxicities, disease progression (per PI discretion), withdrawal from treatment for 
other reasons, or death, whichever occurs first.  During the phase II portion of the study, 
participants who are not evaluable for response assessment will be replaced. 
The phase II study (Arm A2) will be conducted in a Simon Minimax two stage phase II design.  The first stage will enroll 13 evaluable participan ts, including the six participants treated at 65 
mcg/kg. If 1 or more has a response, then accrual  would continue until a total of 20 evaluable 
participants have been enrolled. 
3.1.5 Dose Limiting Toxicity 
The DLT period for Arm A1, A2 and B1 will cons ist of the 21 days following first administration 
of LMB-100 (1 cycle), while that for Arm B2 will include 28 days following first administration 
of LMB-100 (2 cycles). For the purpose of this study, a DLT will be defined as any of the following 
events attributed to LMB-100 (i.e. related to LMB-100) and occurring during the DLT period: 
Hematological toxicities: 
x Grade 4  neutropenia (i.e. absolute ne utrophil count (ANC) <0.5 x 109 cells/L) for a 
minimum duration of 7 days)  
x Grade 3 and 4 febrile neut ropenia (i.e. ANC < 1.0 x109 cells/L with a single 
temperature of >38.3°C or a sustained temperature of ≥38°C for more than one hour 
x Grade 4 thrombocytopenia ( ≤25.0 x109 cells/L) 
x Grade 3 thrombocytopenia associated with bleeding episodes 
Grade ≥3 non-hematological toxicity with the exception of: 
x Grade 3 nausea and vomiting without appropriate treatment 
x Grade 3 diarrhea lasting for ≤2 days with no fever or dehydration 
x Grade 3 infusion-related reactions are not considered to be DLTs since, based on 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
38 
 experience with monoclonal antibodies, IRRs  are idiosyncratic and not dose-related 
events.  
x Asymptomatic grade 3 elevation of ALT, AST, GGT, bilirubin or alkaline 
phosphatase attributable to study drug that persists for less than 7 days.  (Please 
note that all grade 4 elevations in these parameters should be considered a DLT) 
x Asymptomatic laboratory values (other than ALT, AST, GGT, bilirubin, 
alkaline phosphatase or creatinine) of Grade 3 that are judged not clinically 
significant by the investigator.  
x Isolated Grade 3 fever (without signs and/or symptoms of an infection) 
occurring within 48 hours of LMB-100 infusion and resolving within 48 hours to ≤ Grade 2 and fully resolved within 1 week 
Grade ≥ 4 non -hematological toxicity: 
x Infusion-related reactions 
Other toxicities: 
x Any other drug related toxicity considered significant enough to be qualified as a 
DLT in the opinion of the principal investigator. 
If a participant experiences a DLT of any grade, the investigator will have the option to either stop 
the LMB-100 treatment or to  resume the treatment at the next lowest dose level of LMB-100 based 
on best clinical judgment. This can be done to allow  participants, who could potentially benefit 
from LMB-100, to remain on the study  drug treatment, if considered the most beneficial therapeutic 
option for the participant  while managing and monitoring the participant ’s safety risks. 
3.1.6 Dose Escalation 
Dose escalation will proceed in cohorts of 3 –6 participants. The MTD is the dose level at which 
no more than 1 of up to 6 participants experience DLT during cycle 1, and the dose below that at which at least 2 (of ≤6) participants have DLT from the study drug. If a participant did not 
experience DLT and did not finish treatment, he or  she will not be evaluable for toxicity and will 
be replaced in the dose level to ensure that at least 3 participants in each cohort have been assessed 
for the full DLT period prior to moving to the next dose level. If 2 or more DLTs occur at dose level 1, dose level -1 will be evaluated. 
3.1.6.1 Dose escalation tables. 
3.1.6.1.1 Arm A1 (Phase 1 short infusion) 
Dose Escalation Schedule  Arm A1 (Phase I) 
Dose Level  Dose of  LMB-100 in μg/kg  
Level -1 65  
Level 1 100 
Level 2 140 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
39 
  
3.1.6.1.2 Arm B1 (Single Agent Lead-in Continuous Infusion) 
Table 9 
Dose/ Duration Escalation Scheme  
  LMB-100 
(mcg/kg/day) Schedule 
Level 1  65 48h 
Level 2  100 48h 
Level 3  100 24h, D1 & 4 
Level 3R 100 24 h, D1 only 
Level 4  140 24 h, D1 &4 
R(educed) - As the occurrence of more than 1 DLT will not 
automatically trigger a return to a previously attempted dose 
level, dose levels with an R designation will be identified for 
exploration as the study proceeds should more than 1 DLT 
occur in a previously named dose level 
Table 10 
Dose Steps LMB-100 
(mcg/kg/day) 
I 65 
II 100 
III 140 
IV 200 
Table 11 
Duration 
Steps Infusion Duration 
(hrs) 
A 24 
B 24, D1 & D4 
C 48 
D 72 
E 96 
 For Arm B1 (Single Agent Lead-in), the initia l dose for Level 1 was defined at 65 mcg/kg/day 
over 48 hours and was completed after accrual of 3 participants (2 of whom were evaluable for 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
40 
 DLT). No safety or efficacy signal was observed at this dose level. Based on these results, Dose 
Step I (65 mcg/kg/d) may no longer be used, such that the minimum Dose Step after Dose Level 
1 is Dose Step II (100 mcg/kg/d).  Beginning with Level 2, participants will receive short infusion 
of 40 mcg/kg LMB-100 over the first 30-180 minutes  followed by the continuous infusion defined 
in Table 9 .  DLT was observed in 1/6 patients at Le vel 2, and testing proceeded to Level 3, a 
planned dose de-escalation. After accruing 6 patien ts to dose level 3, 3 of which were evaluable 
for toxicity due to hold of day 4 dose for toxicity unrelated to study drug, it was determined by the investigator to close this arm of the and begin accrual to Arm B2. 
If a Level is determined to be  unsafe as defined in section 3.1.6.1.3, then: a) the preceding Level 
may be declared the MTD, or b) additional Levels may be tested so long as either the dose or the 
duration of infusion is stepped down) to a lower level that has not been previously tested as pre-defined in Table  10 and Table 11 .  Such doses carry the R designation for reduced in Table 9 . For 
this arm of the study, there is no pre-defined number of dose levels.  Dose tuning may continue until both the maximum drug dose and duration of infusion are defined or a maximum of 30 participants are treated on this arm. As dose tuni ng progresses, slots must be reserved in a manner 
that insures at least 6 participants can be treated at the RP2D. 
For Arm B2, a single dose of LMB-100 has been c hosen based upon safety and tolerability seen 
with single agent LMB-100 given in continuous infusion format in Arm B1 and taking into 
consideration safety and tolerability seen in Arm A1 with the combination. Given the low incidence of VLS causing weight gain greater than 5 kg with 24-hour continuous infusion given on Day 1 and that 48-hour continuous infusion give n on Day 1 is the MTD for long infusion, the 
following LMB-100 dose will be tested in comb ination with standard nab-paclitaxel (125 mg/m
2): 
x 40 mcg/kg IV loading dose of LMB-100 given over 30 minutes (to follow nab-paclitaxel 
administration by 30 minutes ±20 minutes) on Day 1 
x 100 mcg/kg LMB-100 IV given over 24 hours to immediately following loading dose 
These drugs will be given on a 14-day cycle to improve tolerability, rather than giving nab-
paclitaxel on Days 1 and 8 as in Part A. 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
41 
 3.1.6.1.3 Dose finding will follow the rules outlined in the Table below. 
Number of Participants 
with DLT 
at a Given Dose Level Escalation /De-Escalation Decision Rule 
0 out of 3 Enter up to 3 participants at the next (integer) dose 
level  OR may treat 1- 3 additional participants to better 
define safety signal. 
> 2 Per the discretion of the investigator, dose escalation 
may be stopped.  This dose level will be declared the 
maximally administered dose (highest dose 
administered).  Up to three (3) additional participants 
will be entered at the next  lowest previously explored 
dose level that resulted in fewer than 2 DLTs if only 3 
participan ts were treated previously at that dose. 
OR 
Enter up to 3 participants at the next dose level (R 
designation)  meeting criteria of not previously 
explored and at either lower dose or lower infusion 
duration  
1 out of 3 Enter up to 3 more participants at this dose level.  
x If 0 of these 3 participant s experience DLT, 
proceed to the next integer dose level. 
x If 1 or more of this group suffer DLT, then: 
o dose escalation may be stopped per PI 
discretion , and this dose is declared the 
maximally administered dose.  UP to t hree (3) 
additional participant s will be entered at the 
next lowest dose level that resulted in fewer 
than 2 DLTs if only 3 participant s were 
treated previously at that dose. 
OR 
o Enter up to 3 participants at the next dose level 
(R designation) meet ing criteria of not 
previously explored and at either lower dose 
or lower duration 
<1 out of 6 at highest dose 
level below the maximally 
administered dose This is the MTD .   
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
42 
 3.2 DRUG ADMINISTRATION  
Standard templates for a Chemotherapy Note for a patient on this study are available in Appendix 
C. 
3.2.1 LMB-100 
The qualified health care professional responsible for dispensing the study drug will prepare the 
correct dose according to the cohort or group allocation of each participant.  
Short infusion LMB-100 will be given as an IV solution on Days 1, 3 and 5 (QOD x3) of a 21-day 
cycle. Infusion duration should be 30-180 minutes. Continuous infusion LMB-100 will be given as an IV solution by syringe driver pump 1, 2, 3 or 4 days of a 21-day cycle depending on dose level. For continuous infusion Levels 2 and above, a loading dose of 40 mcg/kg LMB-100 given 
as an IV solution over 30-180 minutes will prece de the start of continuous infusion on Day 1 and 
if applicable, Day 4.   
LMB-100 must be administered in a hospital or clinic equipped for IV chemotherapy. Full 
emergency resuscitation facilities should be immed iately available and participants should be 
under close supervision of the investigator or delegate at all times.  The compatibility and stability of the active ingredient was tested under simulated 
preparation/administration conditions. 
3.2.1.1 General Instructions 
1. LMB-100 drug product should be inspected visually for particulates prior to 
administration. 
2. LMB-100 is to be handled following all hazardous precautions. 
3. Do not use the solution if there is particulate matter or if it is discolored. 
4. Do not shake or freeze the vial contents. 
5. Ensure the drug vial content is protected from  light during preparation and administration 
(ambient light conditions are acceptable but avoid exposure to direct sunlight). 
6. LMB-100 drug product does not contain any preservatives. Vials are for single use only 
and partially used vials must not be reused.   
7. Any unused product should be kept for drug reconciliation. 
8. No dilution of LMB-100 drug product into 0.9% saline bags should be performed. 
9. Do not administer as IV push or bolus. 
10. Other drugs that require parenteral co-administration (if applicable) should be delivered via separate infusion lines and at separate i nfusion sites and should not be mixed with the 
study drug. 
3.2.1.2 Specific Instructions  
LMB-100 is diluted with 0.9% NaCl in-line  immediately prior to administration (see  Figure 8  
below).  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
43 
 The undiluted LMB-100 drug product (DP), filled in a disposable syringe, is administered by 
intravenous syringe infusion using a syringe dri ver pump. So as not to compromise drug product 
physico-chemical stability , the dilution with 0.9% NaCl should be done in line , immediately prior 
to administration of the neat DP. 
In order to allow in-line dilution (1:10) immediately prior  to administration of neat drug product, 
a side flow with 0.9% NaCl must  be applied (as illustrated in Figure 8).  The side flow should be 
set-up at 1:10 in order to deliver 0.1 mg/mL DP. Du ring continuous infusion, the minimum rate 
for 0.9% NaCl infusion should be 20 mL/ hour (to prevent line occlusion), even if this results in a 
less concentrated infusion of study drug. An IV infusion pump and syringe driver should be used 
to control the infusion rate of isotonic 0.9% NaCl solution and LMB-100 respectively.   LMB-100 must be administered using a central venous catheter or an existing mediport for 
infusions lasting longer than 150 minutes. Centra l line access is neither required nor anticipated 
for patients in the short-infusion cohorts; however, a central line or use of an existing mediport 
may be permitted per PI discretion.  For contin uous infusion, syringes should be switched out 
every 12 hours (± 1 hour), which will require 2 sy ringes per 24 hour infusion, 4 syringes per 48 
hour infusion, 6 syringes per 72 hour infusion and 8 syringes per 96 hour infusion.  
 
 
 
Figure 8:  Schematic view of the administration set-up.  
The stopcock will be changed every 24 hours to prevent microbial ingress.  In line 
filters for the LMB-100 drug product as well as the saline will be used as depicted.   
1. The syringes for administration must be pre pared under appropriate aseptic conditions as 
LMB-100 drug product does not contain antimi crobial preservatives. All preparation 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
44 
 should be conducted under laminar flow hood w ith safety glasses, lab coat and arm 
protection and a work procedure to minimize particle contamination.  
2. An in-line filter will be used to filter the undiluted drug product (LMB-100) during syringe 
infusion before side-flow dilution. For this, an in-line filter (0.2 or 0.22 μm pore size) 
should be positioned between the syringe extension line and the injection/infusion valve 
(see Figure 8 ). The filtration must occur before in-line dilution with 0.9% saline. 
An in-line filter will be used during saline infusion as shown in Figure 8 .   
3. Withdraw up to 3 ml excess volume of LMB-100 to the intended dosing volume into the 
syringe for priming and purging the syringe ex tension lines before administration (see step 
9).   
4. The prepared syringe should be stored and transported with a closing cone/stopper. 
5. Since LMB-100 drug product does not contain antimicrobial preservatives and to comply 
with the chemical and physical in-use stabili ty, the prepared syringes for infusion should 
be used immediately. If not used immediately,  total storage times of prepared syringes 
should not exceed 12 hours to limit microbial growth in case of potential accidental 
contamination.  Storage conditions should generally be at 2°C to 8°C, but syringes may be 
held at room temperature for up to a maximum of 4 hours.  The temperature during syringe preparation, storage and drug administration must not exceed 25 °C. 
6. A freshly prepared syringe of drug product is required for every 12 hours of LMB-100 infusion and for the loading dose. To limit the potential for microbial growth, when preparing syringes for continuous infusion, drug vials may not be stored and reused to 
prepare syringes at later time points.  The syringe for the loading dose and that for the 
initial 12 hours of continuous infusion may be  prepared from the same vial.  All other 
syringes must be prepared from a fresh vial. Sa line bags must be changed at least every 24 
hours. 
7. Continuous infusion may be stopped for a total of up to 90 minutes within each 24 hour 
period for logistical purposed.  All stoppages  should be documented in CRIS (both actual 
or estimated stop time and actual restart time) 
8. Establish the saline flow first by flushing  the lines including the 4-way stopcock and 
extension lines with saline.  
9. Put the filled syringe in the pre-programmed syringe driver, remove the cap and attach the infusion set. Follow the syringe driver manua l/local instructions regarding how to set up 
and prime/purge the system before the line is attached to the closed 4-way stopcock before 
starting the administration. 
10. The end of infusion is defined as the time poi nt at which the syringe driver finishes 
administering the total volume of IMP to be infused.  
11. In case of any adverse events related to the infusion, please refer to the specific recommendation described in section 3.3.1 .  
12. The line for drawing blood for  PK samples should be placed in the opposite extremity from 
the one with the infusion line. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
45 
 3.2.1.3 Monitoring 
3.2.1.3.1 Short Infusion 
During short infusion, vital signs (including, if possible, supine diastolic and systolic blood  
pressure, pulse rate, and temperature) must be m onitored pre-infusion, every 15 minutes (± 5 
minutes) until the end of the infusion, and thereafter, every 30 minutes (±10 minutes) for 2 hours 
after the end of the first infusion. For subsequent infusions, if no IRR has been reported, monitoring 
will continue for 30 minutes af ter the end of the infusion. Vital signs during the infusion are not 
required to be captured  in the eCRF unless abnormalities are observed. 
3.2.1.3.2 Continuous Infusion 
During continuous infusion, vital signs including, if possible, supine diastolic and systolic blood  
pressure, pulse rate, and temperature) must be m onitored pre-infusion, every 15 minutes (± 5 
minutes) for the first two hours of the infusion, and thereafter, every 60 minutes (±10 minutes) for 
the next 4 hours of the infusion, and then every 6 hours until the  infusion is completed. Vital signs 
should also be recorded 2 hours (±10 minutes) after the end of infusion. 
3.2.1.4 Standard Pre-medication for Par ticipants Receiving LMB-100 
Due to the prevalence of infusion related reactions  (IRRs) seen in the previous study of LMB-100, 
all patients will be pre-medicated 30-60 minutes (+30 minutes) prior to each LMB-100 
administration with the following medications: 
o Diphenhydramine 25-50 mg PO or IV 
o Ranitidine 150 mg PO 
o Acetaminophen 650 mg PO 
Dexamethasone 8 mg IV should be physically available in the infusion unit in case of severe IRR 
during LMB-100 administration.   
3.2.1.4.1 Additional Precautions at subsequent Infusions of LMB-100 in patients with prior IRR 
during short infusion of LMB-100  
Participants receiving short infusion having experienced an IRR of Grade 2 to 4 on a previous infusion despite standard pre-mediation should also receive: 
o Dexamethasone 20 mg, PO, 6-12 hours prior to LMB-100 administration, OR 
o Dexamethasone 8 mg, IV, 30 – 60 minutes (+30 minutes) prior to LMB-100 
administration, OR 
o equivalent dose of another corticosteroid as clinically indicated 
(See section 3.3.1 for complete instructions on response to IRRs) 
Participants who experienced an IRR of Grade 3 or 4 on a previous infusion where dexamethasone or another steroid was pre-administered shoul d not receive further LMB-100 and will be 
discontinued from study therapy 
 3.2.1.4.2 Additional Precautions for administration of LMB-100 in patients with IRR during 
continuous infusion of LMB-10 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
46 
 Participants receiving continuous LMB-100 infusion having experienced an IRR of Grade 2 to 4 
earlier in the current infusion or during a previous infusion despite standard pre-mediation should receive for the remainder of the infusion and all subsequent infusions accompanied by: 
o Diphenhydramine 25-50 mg PO or IV, q6 hours 
o Ranitidine 150 mg PO, q12 hours 
o Acetaminophen 650 mg PO, q12 hours 
o Dexamethasone as described earlier in this section, q12 hours 
(See section 3.3.1 for complete instructions on response to IRRs) 
Participants who experienced an IRR of Grade 3 or 4 where dexamethasone or another steroid was pre-administered within the last 12 hours should  not receive further LMB-100 and will be 
discontinued from study therapy. 
Table 12 - Premedications for LMB-100 
Dose (mg) Route 
Acetaminophen  650 PO 
Diphenhydramine  25-50 PO or IV 
Ranitidine  150 PO 
Dexamethasone PRN  8 
OR IV 
Dexamethasone  PRN 20 PO 
3.2.2 Nab-Paclitaxel  
Nab- paclitaxel will be administered according to the  package inserts at a dose of 125 mg/m2, 
intravenously over 30 minutes ± 10 minutes on Days 1 and 8 of each 21-day cycle. Detailed 
information about the preparation of the infusion solution and administration of  nab-paclitaxel 
including information about compatible infusion bags,  administration sets, and in line filters can be 
found in the package insert. 
3.2.3 Co-administration of Nab-paclitaxel and LMB-100 
On days when both LMB-100 and nab-paclitaxel ar e both scheduled to be administered (Day 1 of 
each cycle), nab-paclitaxel will be administered first.  LMB-100  infusion will be initiated 30 
minutes ± 20 minutes after completion of the nab-paclitaxel.  
3.3 DOSE MODIFICATIONS  
Potential overlapping toxicities of LMB-100 and nab-paclitaxel must be  considered. In this 
context, peripheral edema (10%) and arthralgia (11-13%) have been seen with both drugs.  Nab-
paclitaxel has been shown to cause life-threatening pneumonitis in a small percentage of patients. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
47 
 Symptomatology of pneumonitis related to nab-paclitaxel could  overlap with pleuritis, which is an 
identified toxicity risk with LMB-100. Study partic ipants will be carefully monitored for adverse 
events associated with these organ systems. 
3.3.1 LMB-100 
Table 13  below provides a guideline on how to manage certain toxicities which are  expected with 
LMB-100 based on preclinical studies and previous clinical experience  with LMB-100 and 
molecules in the same class. Table 13 - Guidelines for Managing Specific LMB-100 Adverse Events 
Event  Action to Be Taken  
IRR/hypersensitivity  reaction during 
short infusion  of LMB-100 
(Arms A1 and A2 ) If an IRR/hypersensitivity develops, the infusion of LMB -100 
should  be temporarily interrupted. The participant should be 
monitored  until complete resolution of the symptoms and treated 
as clinically indicated. Treatment or concomitant medication 
may include IV saline, oxygen, bronchodilators, corticosteroids, 
and vasopressors depending on the symptoms. 
If the short infusion is interrupted (Arms A1 or A2): 
o In the event of IRR CTCAE Grade1, upon resolution of 
symptoms, the infusion will resume at the same rate (the 
rate being used at the time that the IRR occurred). 
o In the event of IRR Grade 2 or 3, upon resolution of 
symptoms, the infusion will resume at one- half the 
previous rate. The infusion can be re- escalated to initial rate 
if considered well tolerated after 1 hour of infusion. 
o In the event of IRR CTCAE Grade 3, or CTCA E Grade 4 
(which may include pulmonary or cardiac events) or an 
anaphylactic reaction: 
 The infusion must be stopped and the participant should 
receive aggressive treatment 
 Participants experiencing IRR CTCAE Grade 4 or 
anaphylaxis must be permanently discontinued from 
study treatment 
For participants receiving short infusion LMB-100 who 
previously experienced IRR CTCAE  tGrade 2, the infusion rate 
for subsequent LMB -100 infusion should be reduced to one -half 
of the previous rate and corticosteroids premedication should be 
given  30 minutes prior to infusion in addition to standard pre-
medications:  
o Dexamethasone (20 mg PO 6 - 12hrs before infusion or 8 
mg IV, 30 - 60 min [+ 30 minutes] before infusion) or 
equivalent dose of another corticosteroid as clinically 
indicated 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
48 
 Event  Action to Be Taken  
IRR/hypersensitivity  reaction during 
continuous  infusion of LMB-100  
(Arms B1 and B2 ) If an IRR/hypersensitivity develops , the infusion of LMB -100 
should  be temporarily interrupted. The participant should be 
monitored  until complete resolution of the symptoms and treated 
as clinically indicated. Treatment or concomitant medication 
may include IV saline, oxygen, bronchodilators, corticosteroids, 
and vasopres sors depending on the symptoms. 
In the event of IRR CT CAE Grade 4  (which may include 
pulmonary or cardiac events) or an anaphylactic reaction:  
 The participant should receive aggressive treatment  
 Participant s experiencing IRR CTCAE Grade 4 or 
anaphylaxis must be permanently discontinued from 
study treatment 
In the event of IRR CTCAE Grade 1, 2, 3 , upon resolution of 
symptoms,  
o If the loading dose is interrupted, the rema inder of the 
loading dose should be omitted and the patient should 
resume with the continuous infusion. 
o If the continuous infusion is interrupted:  
 Patients should be retreated with the standard pre-
medications if the infusion has already proceeded for 6 
hours or more 
 The infusion will resume at the same rate 
 Patients should receive repeated dosing of the standard 
pre-medications and dexamethasone at the intervals 
specified in Section 3.2.1.4.2  
Participants receiving continuous infusion LMB-100 who have 
experienced IRR CTCAE  tGrade 2  infusion, should receive: 
o Standard pre-medications 30- 60 minutes prior to start of 
infusion 
o Standard corticosteroids premedication should be given 30 
minutes prior to subsequent infusion in addition to standard 
pre-medications: 
 Dexamethasone (20 mg PO 6 - 12hrs before infusion or 8 
mg IV, 30 - 60 min [+ 30 minutes] before infusion) or 
equivalent dose of another corticosteroid as clinically 
indicated 
o Repeated dosing of standard pre-medications and 
dexamethasone at the following intervals: 
 Dexamethasone, q12 hours  
 Diphenhydramine, q6 hours 
 Acetaminophen, q12 hours 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
49 
 Event  Action to Be Taken  
 Ranitidine, q12 hours 
Vascular leak syndrome  In the event of Grade ≥2 CTCAE vascular leak syndrome 
(medical intervention indicated):  
o Vasopressor support (e.g., phenylephrine) if indicated to 
stabilize blood pressure 
o Administer colloidal solutions (e.g., albumin) if there is a 
clinically significant, symptomatic and persistent systolic 
blood pressure drop, urine output significantly dec lines or 
serum albumin falls to 2.5 mg/dL or lower 
o For pulmonary congestion provide diuretic and/or albumin 
treatment as appropriate 
o Progressive shortness of breath may require endotracheal 
intubation or drainage of a pleural effusion 
o For oliguria and /or rising serum creatinine level delay 
LMB-100 if Grade 3 urine output (<10 mL/hr) 
o Use dopamine if participant is unresponsive to or unable to 
tolerate fluids.  
o In the event of Grade ≥2 CTCAE pericardial effusion 
(asymptomatic effusion small to moderate size) , consider 
delaying LMB- 100 administration. In the event of Grade 
≥3 CTCAE pericardial effusion (effusion with physiologic 
consequences) stop LMB- 100 treatment until full 
resolution 
Inflammatory reactions to serosal 
membranes  o Hydrocortisone (200 mg IV) or equivalent dose of another 
corticosteroid as clinically indicated 
o In the event of Grade 2 CTCAE pericardial effusion 
(asymptomatic effusion small to moderate size), consider 
delaying LMB- 100 administration. In the event of Grade 
≥3 CTCAE pericardial effu sion (effusion with physiologic 
consequences) stop LMB- 100 treatment until full 
resolution 
o In the event of pleuritis resulting in mild to severe pleuritic 
pain, treat with analgesics or steroids as clinically indicated 
o For participant s who have previously experienced pleuritis 
consider administration of dexamethasone 4 mg, PO bid 
beginning with first LMB- 100 infusion and completing 24 
hours after the last LMB- 100 infusion of the cycle. (If 
participant is already receiving corticosteroi ds at dose and 
schedule at or above this amount as part of the pre-
medication regimen, do not give additional steroids for 
pleuritis) 
Dehydration  Encourage that participants maintain oral hydration (~ 1.5 L/ day) 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
50 
 Event  Action to Be Taken  
Nausea  Ondansetron or another anti -emetic should be available as needed 
during Days 1 -6 of each cycle 
Renal toxicity  In the event of Grade 1 or greater renal toxicity consider 
increasing oral or intravenous hydration, consider delaying 
LMB -100 administration by up to 48hrs. 
In the event of Grade 2 or great renal toxicity hold LMB -100 
administration until recovery to Grade 1 or better.  If this does 
not occur within 48hrs, no further LMB -100 should be given 
during the cycle.  
IRR = infusion related reaction; IV = intravenous; CTCAE = Common Terminology Criteria for Adverse 
Events  
3.3.2 Nab-paclitaxel 
If nab-paclitaxel  is withdrawn prior to completion of treat ment, LMB-100 may still be continued 
in the absence of progressive disease. 
3.3.2.1 Dose levels 
Dose modifications of nab-paclitaxel for myelosuppression and other chemotherapy related 
toxicities will be made as per package insert. 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
51 
 3.4 STUDY CALENDARS  
3.4.1 Calendar for patient receiving short infusion LMB-100 (Arms A1 and A2) 
1 cycle = 21-days,  
Unless otherwise indicated, screening assessments must occur wi thin 28 days prior to enrollment.  Cycle 1, day 1 assessments wi th the exception of 
imaging studies may occur up to 3 days prior to treatment initiation. Imaging studies must be completed ± 7 days from the indic ated time. If screening 
assessments are performed within the appropriate timeframe for Cycle 1 Day 1 assessments, they do not need to be repeated on th at day. 
Beyond cycle 1, performance status and standard laboratory assessments may be performed up to 1 day prior to the indicated time . 
Dosing cycles after cycle 1 may be delayed for up to one week to  accommodate schedule conflicts, Federal holidays and inclement  weather, etc. 
They may be delayed for up to two weeks due to toxicity. 
  Cycle 1 -2 Post Therapy 
Procedure Screening Day 1 Day 3 Day 5 Day 8 Withdrawal 
visit5 Safety Follow 
Up Visit6 Long Term 
Follow Up 
Nab-paclitaxel  X   X    
LMB-100  X X X     
History and PE X X    X X  
Weight  X X X X X X  
Height  X       
Vital signs1 X X X X X X X  
PS X X    X   
Labs2 X X X X X X X  
1,25-dihydroxy Vit D X     X   
Hepatitis and HIV screening panel X        
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
52 
   Cycle 1 -2 Post Therapy 
Procedure Screening Day 1 Day 3 Day 5 Day 8 Withdrawal 
visit5 Safety Follow 
Up Visit6 Long Term 
Follow Up 
Urinalysis X X X X X X X  
Pregnancy test3 X X     X  
Confirmation of Dx4 X        
CT CAP and/or MRI X     X X6 X7 
CA 19-9 X X    X   
ECG X X    X X  
Echocardiogram X        
Ambulatory Oxygen Saturation X        
Chest X-ray  X8       
NIH Advance Directives Form7  X9       
PKs  Please refer to section 5.2.1     
Correlative Studies  Please refer to section 5.2.1   
Annual phone call to monitor 
survival and additional CA therapy        X 
Adverse events  continuous X X  
Concomitant meds  continuous    
1 During the infusions of all study, vital signs (heart rate, blood pressure, oxygen saturation) have to be monitored pre-infusio n and 
every 15 minutes (± 5 minutes) during the infusion and then every 30 minutes (± 10 minutes) until 2 hours post-infusion.  
2 CBC with differential, Acute Care Panel, Hepa tic Panel, Mineral Panel, ,  C-reactive protein (CRP), creatine kinase (CK), PT, P TT, 
LDH 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
53 
   Cycle 1 -2 Post Therapy 
Procedure Screening Day 1 Day 3 Day 5 Day 8 Withdrawal 
visit5 Safety Follow 
Up Visit6 Long Term 
Follow Up 
3 Pregnancy test required in women of childbearin g potential; i.e. premenopausal women and women ≤ 2 years after menopause 
(menopause is defined as amenorrhea for > 2 years. 
4 Assessment may occur at any time prior to enrollment 
5 For participants who complete both cycles of therapy, the withdr awal visit should be scheduled for any time between Day 20 of a nd 
7 days following the end of Cycle 2. For participants who do not complete both cycles of therapy, the withdrawal visit should be 
scheduled 3-6 weeks from last treatment. Imaging studies do not need to be repeated if most recent were performed within the prior 
20 days.   
6 Safety follow up will occur 3 – 6 weeks after last dose of study therapy in patients that have progressed. The safety assessment will 
occur 6 weeks +/- 2 weeks after the previous scan in those that have stab le disease, partial response or complete response. The 
assessments lis ted refer to those that will be performed if the patient is seen in clinic. If withdrawal visit occurred within this 
timeframe, it can be used as the safety follow up visit. If the patient is unable to return to the clinic for the follow up vis it, an adverse 
event assessment will be performed by telephone. 
7 Scans, every 6 weeks, will only be performed until disease progre ssion. Note: for patients on long term follow up, scans may be  
performed outside of NIH. 
8 Chest x-ray to be done within 7 days prior to treatment on cycle 1 only. 
9 As indicated in section 9.3, all subjects will be offered the opportunity to comple te an NIH advanced directives form. This should be 
done preferably at baseline but can be done at any time during the study as long as the capacity to do so is retained. The completion 
of the form is strongly recommended, but is not required. 
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
54 
 3.4.2 Calendars subjects in Arm B1 (single agent continuous infusion LMB-100) 
3.4.2.1  24 HOUR INFUSION (on Day 1 OR Day 1 & 4) 
1 cycle = 21 days  
Unless otherwise indicated, screening assessments must occur wi thin 28 days prior to enrollment.  Cycle 1, day 1 assessments wi th the exception of 
imaging studies may occur up to 3 days prior to treatment initiation.  Imaging studies must be completed ± 7 days from the indi cated time. If 
screening assessments are performed within the appropriate timefra me for Cycle 1 Day 1 assessments, they do not need to be repe ated on that day. 
Beyond cycle 1, performance status and standard laboratory assessments may be performed up to 1 day prior to the indicated time . 
Dosing cycles after cycle 1 may be delayed for up to one week  to accommodate schedule conflicts , Federal holidays and inclement  
weather, etc. They may be delayed for up to two weeks due to toxicity. 
 
  Cycle 1 & 2 Post Therapy 
Procedure  Screening Day 1 Day 2 Day 3 Day 
4-5*  Day 6* Day 8 Withdrawal 
visit7 Safety 
Follow 
Up 
Visit8 Long 
Term 
Follow 
Up 
LMB-100  X X  X      
History and PE X X      X X  
Weight  X X X X X X X X  
Height  C1 only         
Vital signs1 X X X X X X X1 X X  
PS X X      X   
Labs2 X X X X X X X1 X X  
1,25-dihydroxy Vit D X       X   
Urinalysis X X X X X X X1 X X  
Pregnancy test3 X X    
   X  
Confirmation of Dx4 X                   
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
55 
   Cycle 1 & 2 Post Therapy 
Procedure  Screening Day 1 Day 2 Day 3 Day 
4-5*  Day 6* Day 8 Withdrawal 
visit7 Safety 
Follow 
Up 
Visit8 Long 
Term 
Follow 
Up 
Assessment of tumor 
MSLN expression4,  X                   
CT CAP and/or MRI X     
  X X9 X9 
CA 19-95  X X    
  X   
ECG X X X     X X  
Echocardiogram X          
Ambulatory Oxygen 
Saturation X 
    
     
Chest X-ray  X10    
     
NIH Advance 
Directives Form6  X6         
PKs                             Please refer to section  5.2.2.1      
Correlative Studies, 
including optional 
biopsy  Please refer to section 5.2.2.1  
Annual phone call to 
monitor survival and 
additional CA therapy          X 
Adverse events  continuous X X  
Concomitant meds  continuous  
 
 
 * For the D1&4 continuous infusion level only (and not for participants just getting 24 hr infusion on D1) 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
56 
 1 During continuous infusion, vital signs including,  if possible, supine diastolic and systolic blood  pressure, pulse rate, and oxygen saturation) 
must be monitored pre-infusion, every 30 minutes (± 5 minutes) for the first two hours of the infusion beginning with the start of loading 
dose, and thereafter, every 6 hours (±60 minutes)  until the  infusion finishes. Vital signs during the first 2 hours of infusion are not required 
to be captured  in the eCRF unless abnormalities are observed. 
2 CBC with differential, Acute Care Panel, He patic Panel, Mineral Panel, C-reactive protein (CRP), Creatine Kinase (CK), CK, PT, PTT, 
LDH 
3 Pregnancy test required in women of childbearing potential; i.e. premenopausal women and women ≤ 2 years after menopause (menopause 
is defined as amenorrhea for > 2 years 
4 Assessment may occur at any time prior to enrollment 
5 For patients with diagnosis pancreatic or biliary cancers (cholangiocarcinoma) only 
6 As indicated in section 9.3, all subjects will be offered the opportunity to complete an NIH advanced directives form.  This should be done 
preferably at baseline but can be done at any time during the st udy as long as the capacity to do so is retained.  The completion of the fo rm 
is strongly recommended, but is not required. 
7 For participants who complete both cycles of therapy, the wit hdrawal visit should be scheduled for any time between Day 20 of a nd 7 days 
following the end of Cycle 2.  For participants who do not complete  both cycles of therapy, the withdrawal visit should be sche duled 3- 6 
weeks from last treatment.  Imaging studies do not need to be repeated if most recent were performed within the prior 20 days.   
8 Safety follow up will occur 3 – 6 weeks after last dose of study therapy in patients that have progressed. The safety assessment will occur 6 
weeks +/-2 weeks after the previous scan in those that have stable disease, partial response or complete response. The assessments listed 
refer to those that will be performed if the patient is seen in clinic. If withdrawal visit occurred within this timeframe, it can be used as the 
safety follow up visit.  If the patient is unable to return to the clinic for the follow up visit, an adverse event assessmen t will be performed 
by telephone. 
9 Scans, every 6 weeks, will only be performed until disease progression. Note:  for patients on long term follow up, scans may b e performed 
outside of NIH. 
10 Chest x-ray to be done within 7 days prior to treatment on cycle 1 only 
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
57 
 3.4.2.2  48 HOUR INFUSION 
Unless otherwise indicated, screening assessments must occur wi thin 28 days prior to enrollment.  Cycle 1, day 1 assessments wi th the exception of 
imaging studies may occur up to 3 days prior to treatment initiation.  Imaging studies must be completed ± 7 days from the indi cated time. If 
screening assessments are performed within the appropriate timefra me for Cycle 1 Day 1 assessments, they do not need to be repe ated on that day. 
Beyond cycle 1, performance status and standard laboratory assessments may be performed up to 1 day prior to the indicated time . 
Dosing cycles after cycle 1 may be delayed for up to one week to  accommodate schedule conflicts, Federal holidays and inclement  weather, etc. 
They may be delayed for up to two weeks due to toxicity.  
   Cycle 1 & 2 Post Therapy 
Procedure Screening Day 1 Day 2-3 Day 4 Day 5 Day 8 Withdraw
al visit7 Safety 
Follow 
Up Visit8 Long 
Term 
Follow 
Up 
LMB-100  X X       
History and PE X X     X X  
Weight  X X X  X X X  
Height  C1 only        
Vital signs1 X X X X  X1 X X  
PS X X     X   
Labs2 X X X X  X1 X X  
1,25-dihydroxy Vit D X      X   
Urinalysis X X X X  X1 X X  
Pregnancy test3 X X      X  
Confirmation of Dx4 X         
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
58 
    Cycle 1 & 2 Post Therapy 
Procedure Screening Day 1 Day 2-3 Day 4 Day 5 Day 8 Withdraw
al visit7 Safety 
Follow 
Up Visit8 Long 
Term 
Follow 
Up 
Assessment of tumor MSLN 
expression4,  X         
CT CAP and/or MRI X      X X9 X9 
CA 19-95  X X     X   
ECG X X Day 3 
only    X X  
Echocardiogram X         
Ambulatory Oxygen 
Saturation X         
Chest X-ray  X10        
NIH Advance Directives 
Form6  X6        
PKs  Please refer to section 5.2.2.2    
Correlative Studies , 
including optional biopsy  Please refer to section 5.2.2.2  
Annual phone call to 
monitor survival and 
additional CA therapy         X 
Adverse events  continuous X X  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
59 
    Cycle 1 & 2 Post Therapy 
Procedure Screening Day 1 Day 2-3 Day 4 Day 5 Day 8 Withdraw
al visit7 Safety 
Follow 
Up Visit8 Long 
Term 
Follow 
Up 
Concomitant meds  continuous  
 
1 During continuous infusion, vital signs including, if possible,  supine diastolic and systolic bl ood pressure, pulse rate, and o xygen saturation) must be 
monitored pre-infusion, every 30 minutes (± 5 minutes) for the first two hours of the infusion begin ning with the start of loading dose, and thereafter, 
every 6 hours (±60 minutes)  until the infusion finishes. Vital si gns during the first 2 hours of infusion are not required t o be captured in the eCRF unless 
abnormalities are observed. 
2 CBC with differential, Acute Care Panel, Hepatic Panel, Mineral Pa nel, , C-reactive protein (CRP), Creatine Kinase (CK), PT, PT T, LDH 
3 Pregnancy test required in women of childbearing potential ; i.e. premenopausal women and women ≤ 2 years after menopause (menopaus e is defined as 
amenorrhea for > 2 years 
4 Assessment may occur at any time prior to enrollment 
5 For patients with diagnosis pancreatic or biliary cancers (cholangiocarcinoma) only 
6 As indicated in section 9.3, all subjects will be offered the opportunity to complete an NIH ad vanced directives form.  This should be done preferably at 
baseline but can be done at any time during the study as long as the capacity to do so is retained.  The comple tion of the form is strongly recommended, 
but is not required. 
7 For participants who complete both cycles of therapy, the withdraw al visit should be scheduled for any time between Day 20 of and 7 days following the 
end of Cycle 2.  For participan ts who do not complete both cycles of therapy, the withdrawal visit should be scheduled 3- 6 weeks from last treatment.  
Imaging studies do not need to be repeated if most recent were performed within the prior 20 days.   
8 Safety follow up will occur 3 – 6 weeks after last dose of study therapy in patients that have progressed. The safety assessment will occur 6 weeks +/-2 
weeks after the previous scan in those that have stable disease,  partial response or complete response. The assessments listed refer to those that will be 
performed if the patient is seen in clinic. If withdrawa l visit occurred within this timeframe, it can be used as the safety follow up visit.  If the patient is 
unable to return to the clinic for the follow up visit, an  adverse event assessment will be performed by telephone. 
9 Scans, every 6 weeks, will only be performed until disease progression. Note:  for patients on  long term follow up, scans may be performed outside of 
NIH. 
10 Chest x-ray to be done within 7 days prior to treatment on cycle 1 only 
 
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
60 
  
3.4.3  Calendar for Subjects in Arm B2 (LMB-100 24-hour continuous infusion combination therapy) 
1 cycle = 14 days  
Unless otherwise indicated, screening assessments must occur wi thin 28 days prior to enrollment.  Cycle 1, day 1 assessments wi th the exception of 
imaging studies may occur up to 3 days prior to treatment initiation.  Imaging studies must be completed ± 7 days from the indi cated time. If 
screening assessments are performed within the appropriate timefra me for Cycle 1 Day 1 assessments, they do not need to be repe ated on that day. 
Beyond cycle 1, performance status and standard laboratory assessments may be performed up to 1 day prior to the indicated time . 
Dosing cycles after cycle 1 may be delayed for up to one week  to accommodate schedule conflicts , Federal holidays and inclement  
weather, etc. They may be delayed for up to two weeks due to toxicity. 
 
    All cycles Post Therapy 
Procedure  Screening Day 1 Day 2 Day 3 Withdrawal 
visit7 Safety 
Follow Up 
Visit8 Long Term 
Follow Up 
Nab-paclitaxel  X      
LMB-100  X X     
History and PE X X   X X  
Weight  X X C1 only X X  
Height  C1 only      
Vital signs1 X X X C1 only X X  
PS X X   X   
Labs2 X X X C1 only X X  
1,25-dihydroxy Vit D X    X   
Hepatitis and HIV screening 
panel X 
      
Urinalysis X X X C1 only X X  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
61 
     All cycles Post Therapy 
Procedure  Screening Day 1 Day 2 Day 3 Withdrawal 
visit7 Safety 
Follow Up 
Visit8 Long Term 
Follow Up 
Pregnancy test3 X X    X  
Confirmation of Dx4 X            
CT CAP and/or MRI X    X X9 X9 
CA 19-95 X X   X   
ECG X X X  X X  
Echocardiogram X        
Ambulatory Oxygen Saturation X 
   
   
Chest X-ray  X10      
NIH Advance Directives Form6  X6      
PKs   Please refer to section  5.2.2.1     
Correlative Studies, including 
optional biopsy  Please refer to section  5.2.2.1   
Annual phone call to monitor 
survival and additional CA 
therapy       X 
Adverse events  continuous X X  
Concomitant meds  continuous  
 
 
1 During continuous infusion, vital signs including,  if possible, supine diastolic and systolic blood  pressure, pulse rate, and oxygen saturation) 
must be monitored pre-infusion, every 30 minutes (± 5 minutes) fo r the first two hours of the infusion beginning with the start  of loading 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
62 
 dose, and thereafter, every 6 hours (±60 minutes) until the  infusion finishes. Vital signs during the first 2 hours of infusion are not required 
to be captured  in the eCRF unless abnormalities are observed. 
2 CBC with differential, Acute Care Panel, He patic Panel, Mineral Panel, C-reactive protein (CRP), Creatine Kinase (CK), CK, PT, PTT, 
LDH 
3 Pregnancy test required in women of childbearing potential ; i.e. premenopausal women and women ≤ 2 years after menopause (menopause 
is defined as amenorrhea for > 2 years 
4 Assessment may occur at any time prior to enrollment 
5 For patients with diagnosis pancreatic or biliary cancers (cholangiocarcinoma) only 
6 As indicated in section 9.3, all subjects will be offered the opportunity to complete an NIH advanced directives form.  This should be done 
preferably at baseline but can be done at any time during the st udy as long as the capacity to do so is retained.  The completi on of the form 
is strongly recommended, but is not required. 
7 For participants who complete all cycles of therapy, the withdrawal visit should be scheduled for any time between Day 20 of an d 7 days 
following the end of Cycle 2.  For participants who do not complete  all cycles of therapy, the withdrawal visit should be sched uled 3-6 
weeks from last treatment.  Imaging studies do not need to be repeated if most recent were performed within the prior 20 days.   
8 Safety follow up will occur 3 – 6 weeks after last dose of study therapy in patients that have progressed. The safety assessment will occur 6 
weeks +/-2 weeks after the previous scan in those that have stable disease, partial response or complete response. The assessments listed 
refer to those that will be performed if the patient is seen  in clinic. If withdrawal visit occurred within this timefr ame, it can be used as the 
safety follow up visit.  If the patient is unable to return to the clinic for the follow up visit, an adverse event assessmen t will be performed 
by telephone. 
9 Scans, every 6 weeks, will only be performed until disease progression. Note:  for patients on long term follow up, scans may b e performed 
outside of NIH. 
10 Chest x-ray to be done within 7 days prior to treatment on cycle 1 only 
 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
63 
 3.5 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA  
Prior to removal from study, effort must be made to have all subjects complete a safety visit as 
indicated in the Study Calendar  following the last dose of study therapy. 
3.5.1 Criteria for removal from protocol therapy 
x Progressive disease 
x Participant has completed planned number of cycles of study therapy 
x Participant requests to be w ithdrawn from active therapy 
x Pregnancy 
x Unacceptable Toxicity as defined in sections  3.1.2  and 3.3 
x Investigator discretion 
3.5.2 Off-Study Criteria 
x Screen failure 
x Participant lost to follow-up 
x Participant requests to be  withdrawn from study 
x Death 
3.5.2.1 Off Protocol Therapy and Off-Study Procedure 
Authorized staff must notify Central Registrati on Office (CRO) when a subject is taken off 
protocol therapy and when a subject is taken off-study. A Participant Status Updates Form from 
the website (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted email to:  NCI Central Registration Office ncicentralregistration-l@mail.nih.gov . 
4 CONCOMITANT MEDICATIONS/MEASURES 
4.1.1 Permitted Therapy  
Concomitant therapy includes any medication (e.g., prescription drugs, over-the-counter  (OTC) 
drugs, approved dietary and herbal supplements, nutritional supplements) used  by a participant 
from the screening period until the follow-up visit. If any treatment is given  within 4 weeks prior 
to screening this should be reported to the investigator and  recorded in the eCRF.  
All therapy and/or medication administered to manage adverse events should be  recorded on the 
Adverse Event eCRF. 
4.1.2 Prohibited Therapy  
Participants should be treated for all concomit ant conditions and adverse events according to 
accepted standards of medical care at the discretion of the investigator. The following  treatments 
are not permitted during the study: 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
64 
 x Any other investigational therapy 
x Cytotoxic chemotherapy agents other than nab-paclitaxel 
x Radiotherapy. Note: palliative 8Gy radiotherapy is allowed. 
x Immunosuppressive therapy and chronically administered glucocorticoids (high  dose is 
considered as !20 mg of dexamethasone a day [or equivalent)] for !7 consecutive days)  
x Other systemic anti-neoplastic agents and targeted therapies 
If any anti-neoplastic or investigational therap ies listed above are needed, the participant will  be 
considered to have evidence of progressive ne oplastic disease and have experienced treatment 
failure with study treatment and should be withdrawn from study treatment. 
Caution should be exercised when drugs that are known to be substrates  (e.g., midazolam, 
buspirone, felodipine, lovastatin, eletriptan, sildenafil, simvastatin, and  triazolam), inhibitors (e.g., 
atazanavir, clarithromycin , indinavir, itraconazole,  ketoconazole, nefazodone, nelfinavir, ritonavir, 
saquinavir, and telithromycin), and  inducers (e.g., rifampin and carbamazepine) of CYP3A4 are to 
be co-administered with  paclitaxel. Caution should also be  exercised when paclitaxel is 
concomitantly  administered with known substrates (e.g., repaglinide and rosiglitazone), inhibitors 
(e.g.,  gemfibrozil), and inducers (e.g., rifampin) of CYP2C8. 
All concomitant treatments must  be documented in the eCRF. 
5 BIOSPECIMEN COLLECTION 
5.1 CORRELATIVE STUDIES FOR RESEARCH /PHARMACOKINETIC STUDIES  
5.1.1 LMB-100 Pharmacokinetic Assessments 
All blood samples for PK assessment w ill be collected from an IV li ne different to that receiving 
the infusion to measure free and total concentrations for LMB-100 for all patients. The date and 
time of each sample collection will be recorded. If multiple samples are drawn at a given time 
point, the PK sample should take precedence. 
Free and total plasma concentrations of LMB-100 will be measured using validated ligand-binding 
assays. 5.1.1.1 Sample collection: 
Blood will be collected in 2 mL K
2EDTA tubes (purple top) at the times defined in section 5.2. 
Samples should be inverted 8 to 10 times after co llection.  Store on wet ice or at 4°C.  Processing 
within 60 minutes of blood collection is highly preferred.   5.1.1.2 Sample processing 
Samples will be processed in the Clinical Pharmacology Program.  Please e-mail NCIBloodcore@mail.nih.gov  at least 24 hours before transporting samples (the 
Friday before is preferred). For sample pickup, page 102-11964. For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
65 
 For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov . 
Upon arrival in the CPP the following procedures should be followed: 
1. Store on wet ice until centrifugation.  
2. Centrifuge 1500xg for 10 minutes at 4°C within 60 minutes of blood collection.  
3. Transfer plasma specimen to 2mL cryovials and store at -70°C.   
The analyses will be performed retrospectively in batched samples or at the end of the trial. 
5.1.1.3 Sample Shipping 
Samples will be shipped by the CPP on dry ice to Ms. Yanyu Wang in Frederick for analysis. 
Leidos Biomedical, Inc. 
Attention: Ms. Yanyu Wang and Dr. Jon Inglefield. 
Building 469, Room 200 Miller Drive Frederick, MD 21702 Phone: 301-846-6905/301-846-6865 
5.1.1.4 Sample storage 
Samples will be stored in the CPP until shipment to the Leidos Biomedical Inc. Lab in Frederick.  
5.1.2 Nab-Paclitaxel Pharmacokinetic Assessments 
Blood samples for the determination of plasma levels of abraxane (nab-paclitaxel) will be obtained 
from each patient receiving nab-p aclitaxel as directed in section 5.2.   
Bioanalytical measurements will be conducted on an ultra HPLC-MSMS system using an assay 
developed and validated by the Clinical Pharmacology Program. 
This data will be used to monitor nab-paclitaxel  plasma concentrations both in the absence and 
presence of LMB-100 to assess any drug interactions  as well as correlate to pharmacodynamic 
endpoints, clinical response, toxicity,  and pharmacogenetic analyses.  
5.1.2.1 Sample Collection 
See section 5.2 for schedule, volumes and tube types. Bl ood samples will be inverted 4-5x then 
placed on wet ice until a member of the Blood Processing Core can pick them up and process into 
plasma for database entry, aliquoting and storage. P aclitaxel is stable in blood on wet ice overnight, 
if needed.  
5.1.2.2 Sample processing 
Samples will be processed in the Clinical Pharmacology Program.  
Please e-mail NCIBloodcore@mail.nih.gov at le ast 24 hours before transporting samples (the 
Friday before is preferred). For sample pickup, page 102-11964. For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
66 
 For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov. 
5.1.2.3 Sample storage 
Samples will be stored in the CPP. 
5.1.3 Pharmacogenetic Studies 
Pharmacogenetic studies will be performed to analyze the genomic DNA and assess the genotype 
of the most relevant drug metabolizing enzymes and transporters (DMET). DNA will be analyzed 
on a DMET Plus (Affymatrix) genotyping platfor m that tests for 1,936 genetic variations in 225 
drug disposition genes, including 47 CYP (phase I metabolism) genes, 13 non-CYP (phase I 
metabolism) genes, 78 phase II metabolizing gene s (including UGTs), 63 transporters, 4 genes 
involved in facilitation of drug transporters, 9 genes involved in global regulation of drug 
metabolizing/transporting proteins, 4 drug binding proteins, and 4 drug targets. 
Of specific interest to nab- paclitaxel are polymorphisms in CYP2C8, CYP3A4/5, and ABCB1, all 
of which are included in the DMET analysis.   Studies will be performed by the Clinical Pharmacology Program.  5.1.3.1 Sample Collection 
One blood sample will be collec ted per patient. See section 5.2 for timing, volume and tube type.  
5.1.3.2 Sample processing 
Samples will be processed in the Clinical Pharmacology Program.  Please e-mail NCIBloodcore@mail.nih.gov at le ast 24 hours before transporting samples (the 
Friday before is preferred). For sample pickup, page 102-11964. For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov. 5.1.3.3 Sample storage 
Samples will be stored in the CPP. 
5.1.4 Assessment of anti-drug antibodies (ADAs)  
5.1.4.1 Sample Collection   
Samples will be collected before the first dose of LMB-100 administration during each cycle. (See 
section 5.2)  
Draw 2mL into K 2EDTA tube (purple top).  Samples should be inverted 8 to 10 times after 
collection. Store on wet ice or at 4°C. Processing  within 60 minutes of blood collection is highly 
preferred. 
5.1.4.2 Sample Processing  
Samples will be processed in the Clinical Pharmacology Program.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
67 
 Please e-mail NCIBloodcore@mail.nih.gov at le ast 24 hours before transporting samples (the 
Friday before is preferred). 
For sample pickup, page 102-11964. For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). For questions regarding sample processing , contact NCIBloodcore@mail.nih.gov.    
Upon arrival in the CPP, each sample should be processed in the following manner:  
1. Store on wet ice until centrifugation.   
2. Centrifuge 1500xg for 10 minutes at 4°C within 60 minutes of blood collection.  
3. Transfer plasma specimen to 2mL cryovials and store at -70°C.   
Autoantibody levels will be retrospectively assessed. 5.1.4.3 Sample Shipping 
Samples will be shipped by the CPP on dry ice to Ms. Yanyu Wang in Frederick for analysis. 
Leidos Biomedical, Inc. 
Attention: Ms. Yanyu Wang and Dr. Jon Inglefield. Building 469, Room 200 Miller Drive Frederick, MD 21702 Phone: 301-846-6905/301-846-6865 
5.1.4.4 Sample Storage 
Samples will be stored in the CPP until shipment to the Leidos Biomedical Inc. Lab in Frederick.   
5.1.5 Retrospective Analysis of Mesoth elin Expression in tumor tissue 
IHC analysis will be performed by the Laborator y of Pathology at NCI to determine mesothelin 
expression within the tumor at any time after stud y enrollment.  Leftover tissue from archival 
specimens or tumor biopsies obtained at screening will be used for analysis. Specimens will be 
used to correlate treatment with response with mesothelin expression in an exploratory analysis.  5.1.6 Cytokines for identification of mechanism for PE-mediated capillary leak syndrome 
PE-based RITs cause dose-limiting CLS. At low dos es CLS manifests as mild and transient weight 
gain, hypoalbuminemia, and peripheral or facial ed ema.  At higher doses it can cause life-
threatening cardiopulmonary compromise. Previous studi es in rats have indicated that pathological 
changes indicative of CLS onset occur within just  two hours of toxin administration and even when 
the PE fragment lacks a targeting domain.
[41] In vitro studies with cultured endothelial cells have 
demonstrated that super-physiologic doses of  PE-based RITs cannot induce endothelial cell 
toxicity unless the cells express the RIT target.[42] Together these data suggest the hypothesis that 
PE-based RITs cause CLS by triggering release of vasoactive cytokines by specific immune 
cells rather than through direct damage to endothelial cells . To test this hypothesis, we will 
collect additional serum from participants during the first hours of standard PK measurements on 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
68 
 Cycle 1 Day 1 of treatment (see section 5.2 for specific time points).  Samples will be stored for 
later analysis.   
5.1.6.1 Specimen collection  
To test this hypothesis, we will collect additi onal serum from participants on the days and 
timepoints shown in sections 5.2.1 and 5.2.2 respectively for short infusion and continuous 
infusion cohorts. 
5.1.6.2 Sample processing 
Serum collected at some time points will also be  used for serum MPF measurements (see Section 
5.1.11) and must be aliquoted appropriately to complete both assays. 
Please e-mail NCIBloodcore@mail.nih.gov at le ast 24 hours before transporting samples (the 
Friday before is preferred). 
For sample pickup, page 102-11964. 
For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov. Cytokine levels will be retrospectively assessed. 
5.1.7 Circulating endothelial cells (CEP and CEC) for identification of mechanism for PE-
mediated capillary leak syndrome 
Circulating endothelial progenitor cells (CEP) and mature circulating endothelial cells (CEC) will 
be assessed by multiparameter flow cytometry. Cells will be analyzed  for forward and side scatter, 
and cells expressing hematopoietic markers will be  excluded.  Endothelial cells will be identified 
using co-expression of markers, such as CD 31 and CD146 for CEC, and CD31 and CD133 for 
CEP. The cell populations will also be analyzed for viability using scatter profiles and a vital stain, 
such as Hoechst 33258. Percentages of stained cel ls will be determined and compared with 
appropriate negative controls. Multiparameter flow cytometric analys is will be performed with a 
Miltenyi Quant equipped with FlowJo software , using a minimum of 100,000 events per analysis. 
5.1.7.1 Sample Collection 
Draw blood into one 8-cc CPT citrate (BD) tube at  (1) baseline, just prior to beginning therapy, 
(2) cycle 1 at 16 to 30 hours following end of last infusion as specified in sections 5.2.1 and 5.2.2, 
and (3) cycle 2 day 1, prior to therapy.   
5.1.7.2 Sample Processing 
Contact the Trepel Lab, Developmental Therap eutics Branch, NCI by email (Jane Trepel- 
trepel@helix.nih.gov ; and Sunmin Lee- lees@pop.nci.nih.gov ) when the patient is scheduled and 
by phone as soon as the blood is drawn at 240 760 6330and a lab member will pick up the sample.  
5.1.8 Immune subset analysis 
Peripheral blood mononuclear cells (PBMC) will be  assessed using multipar ameter flow cytometry 
for immune subsets including but not necessarily limited to CD8+ T-cells, CD4+Foxp3- T-cells, 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
69 
 Tregs, Th1, Th2 and Th17+ CD4+ T-cells, monocyte subsets, MDSC subsets. Assessment will 
include functional markers, i.e. PD-1, Tim -3, CTLA-4, PD-L1, HLA-DR and/or CD40.  
5.1.8.1 Sample Collection 
Draw blood into two 8-cc CPT citrate (BD) tubes at  (1) baseline, just prior to beginning therapy, 
(2) cycle 1 following end of last infusion as specified in sections 5.2.1  and 5.2.2 , and (3) cycle 2 
day 1, prior to therapy.   
5.1.8.2 Sample Processing 
Contact the Trepel Lab, Developmental Therap eutics Branch, NCI by email (Jane Trepel- 
trepel@helix.nih.gov ; Yusuke Tomita- yusuke.tomita@nih.gov  and Sunmin Lee- 
lees@pop.nci.nih.gov) when the patient is scheduled and by phone as soon as the blood is drawn 
at 240 760 6330. Please phone the lab as soon as it is  drawn and a lab member will come to pick 
up the blood.  Please keep bl ood at ambient temperature.  
Members of the lab will enter the samples in a se cure patient database, process the samples for 
viable cell storage, label each sample with a unique  2D barcode, and viab ly store the samples. 
They will prepare the samples for staining, s tain and run the samples by multiparametric flow 
cytometry (MACSQuant, Miltenyi Biotec, Bergisch Gladbach, DE), and analyze the data using 
FlowJo (FlowJo LLC, Ashland, OR) software.   
5.1.9 Peripheral blood immune  gene expression 
Peripheral blood immune gene expression will be evaluated by the Trepel Lab using the 
NanoString nCounter ® platform (NanoString Technologies, S eattle, WA). Collect peripheral 
blood in a PAXgene Blood RNA tube (PreAnalyt ix; 2.5 cc peripheral blood per tube) per the 
manufact urer’s instructions.  After the blood is draw n, the tube should be inverted several times 
and placed at room temperature.  RNA will be isolated using the PAXgene Blood RNA Kit 
according to the manufacturer’s instructions.  Peripheral immune gene expression will be 
evaluated using the PanCancer Immune Profil ing codeset of 730 immune  genes and 40 control 
genes at baseline and post-therapy by the Trepel  Lab to look for correlates of clinical response 
with innate or adaptive immunity. 
5.1.9.1 Sample Collection  
Draw blood into one 2.5 ml PAXgene RNA tube at (1)  baseline, just prior to beginning therapy, 
(2) cycle 1 following end of last infusion as specified in sections 5.2.1 and 5.2.2, and (3) cycle 2 
day 1, prior to therapy.   
5.1.9.2 Sample Processing 
Contact the Trepel Lab, Developmental Therap eutics Branch, NCI by email (Jane Trepel- 
trepel@helix.nih.gov ; Yusuke Tomita- yusuke.tomita@nih.gov  and Sunmin Lee- 
lees@pop.nci.nih.gov) when the patient is scheduled and by phone as soon as the blood is drawn 
at 240-760-6330. Please phone the lab as soon as it is  drawn and a lab member will come to pick 
up the blood.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
70 
 5.1.10 Circulating tumor cells 
Peripheral blood will be collected  to correlate changes in circ ulating tumor cells with clinical 
response as well as to assess immune-mediated cell death.  CTCs will be assessed using ferrofluidic 
enrichment and multi-parameter flow cytometric detection. CTCs are identified by positive expression of epithelial markers and a viability  marker and negative expression of hematopoietic 
markers.  
5.1.10.1 Sample Collection 
Draw blood into two 7.5 ml Veridex CellSave tubes at (1) baseline, just prior to beginning therapy, 
(2) cycle 1 following end of last infusion as specified in sections 5.2.1 and 5.2.2 and (3) cycle 2 
day 1, prior to therapy.   5.1.10.2 Sample Processing 
Contact the Trepel Lab, Developmental Therap eutics Branch, NCI by email (Jane Trepel- 
trepel@helix.nih.gov ; Yusuke Tomita- yusuke.tomita@nih.gov  and Sunmin Lee- 
lees@pop.nci.nih.gov) when the patient is scheduled and by phone as soon as the blood is drawn 
at 240-760-6330 and a lab member will come to pick  up the blood.  Please keep blood at ambient 
temperature. Members of the lab will enter the sa mples in a secure pati ent database, and process 
the samples for immediate CTC assessment. They w ill prepare the samples for staining, stain and 
run the samples by multiparametric flow cytometry (MACSQuant, Miltenyi Biotec, Bergisch 
Gladbach, DE), and analyze the data using FlowJo (FloJo LLC, Ashland, OR) software. 
5.1.11 Treatment Effect on Tumor Microenvironment 
An optional biopsy may be collected in Arm B1  on day 8 of cycle 2 and in arm B2on day 3 of 
cycle 2 in order to analyze any changes in the tumor microenvironment, pre and post.  The C2 D8 
samples will be collected in In terventional Radiology, using image guidance techniques, including 
CT guidance, as required.  Biopsies will be obtained from primary tumor sites and/or metastatic sites 
(if applicable). No more than 4 cores may be obtained per site. The biopsies collected post-treatment 
will be compared to those collected at the time of enrollment (section 5.1.5 ).  The samples will be 
assessed by immunohistochemistry in the NCI Laboratory of Pathology.  
5.1.12 Serum Megakaryocyte Potentiating Factor (MPF) level 
MPF is a second protein product produced by the MSLN  gene.  This product is secreted by the cell 
and can be detected in the circulation in some patients. We hypothesize that serum MPF level may 
be used as a marker of tumor response in patients  with MSLN-producing tumors like pancreatic 
cancer.  Also, because LMB-100 halts tumor cell protein synthesis, we hypothesize that during the 
time of treatment serum MPF levels may also decl ine due to LMB-100 effect on tumor cells. To 
test our first hypothesis, we will collect serum from participants pre-dose for C1 and C2 as well as 
at the conclusion of the study.  To address our second hypothesis, we  will collect serum at the end 
of infusion (see section 5.2 for specific time points).  Samples will be stored for later analysis in 
the Cao lab.   
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
71 
 5.1.12.1 Specimen collection  
To test this hypothesis, we will collect addition al serum from participants in 4 mL red SST tubes 
at the following time-points: Cycle 1 Day 1 pre- dose, Cycle 1 at end of infusion, Cycle 2 Day 1 
pre-dose, and at the time of progression or withdrawal from study.   
5.1.12.2 Sample processing 
Serum collected at some time points will also be used for serum cytokine analysis (see Section 
5.1.6).  For serum MPF analysis, aliquot 100 μL each into two cryovials with printed labels and a 
sample identifier and store at - 80°C. Coded, linked samples will be provided to the laboratory of 
Liang Cao upon request of the PI. 
Please e-mail NCIBloodcore@mail.nih.gov at le ast 24 hours before transporting samples (the 
Friday before is preferred). 
For sample pickup, page 102-11964. 
For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov.
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
72 
 5.2 SAMPLE COLLECTION SCHEDULE  
5.2.1 Sample Collection for Patients receiving short infusion LMB-100 (Arms A1 and A2) 
Timed samples should be collected within +/- 15 minutes of indicted time, except for nab- paclitaxel PKs collections dra wn at 5 or more hours after 
the end of infusion.  For these, samples should be collected with + / - 60 minutes of indicated time. 
Cycle Day  LMB -100 
PKs  
(5.1.1 ) Nab- paclitaxel 
PKs 
(5.1.2 ) Pharmacogenetic 
studies 
(5.1.3 ) ADA   
(5.1.2 ) PE mediated 
CLS 
(Cytokines) 
and serum 
MPF level 
(5.1.6 , 5.1.12 ) CECs, Immune 
Subsets,  
CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample 
(5.1.5 ) 
2 mL 
K2EDTA 
tube 4 mL in 6 mL 
sodium heparin 
tube 4-6 mL in p urple 
top tube 2 mL 
K2EDTA 
tube 4 mL red SST 
tube Two 7.5 mL 
Veridex 
CellSav e & t hree 
8 mL CPT citrate 
tubes 2.5 mL 
PAXgene 
RNA tube NA 
Screening Screening            Xa 
1 1 Pre-dose, 
EOI, 1, 2, 
and 4 
hours after 
EOI pre-infusion, half 
way through 
infusion (15 -min), 
2-5min prior to 
EOI (25- 28min), 
EOI, and 0.5, 1, 2, 
5, 8, 12, 24, 48 and 
72 hr post dose.   Xb Pre-dose Pre-dose, EOI, 
1, 2 and 4 hours 
after EOI Pre-dose  Pre-dose  
2         
3  Pre-dose, 
EOIc         
5     EOI    
6      Xd Xd  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
73 
 Cycle Day  LMB -100 
PKs  
(5.1.1 ) Nab- paclitaxel 
PKs 
(5.1.2 ) Pharmacogenetic 
studies 
(5.1.3 ) ADA   
(5.1.2 ) PE mediated 
CLS 
(Cytokines) 
and serum 
MPF level 
(5.1.6 , 5.1.12 ) CECs, Immune 
Subsets,  
CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample 
(5.1.5 ) 
2 mL 
K2EDTA 
tube 4 mL in 6 mL 
sodium heparin 
tube 4-6 mL in p urple 
top tube 2 mL 
K2EDTA 
tube 4 mL red SST 
tube Two 7.5 mL 
Veridex 
CellSav e & t hree 
8 mL CPT citrate 
tubes 2.5 mL 
PAXgene 
RNA tube NA 
2 1 Pre-dose, 
EOI   Pre- dose Pre-dose  Pre-dose  Pre-dose  
3  Pre-dose, 
EOIc         
At time of 
Progression     X  X    
Withdrawal Visit       X X    
Safety Follow -up 
Visit         X X    
ADA =anti-drug antibody; EOI =End of infusion; PK =pharmacokinetic; CTC=circulating tumor cell; CEC=circulating endothelial cel l 
a. Archival tissue collection or biopsy if no tissue available (mandatory).   
b. Collected preferably at baseline, but may be collected at any time during the study. 
c. Required only for patients on Arm A1.  May alternati vely be drawn on day 5 to avoid a weekend draw. 
d. May alternatively be drawn post treatment on C1D5 to avoid a weekend draw  
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
74 
 5.2.2 Sample Collection for Patients receiving continuous infusion of LMB-100 (Arms B1 and B2) 
5.2.2.1  24-hour continuous infusion 
Timed samples scheduled for within 4 hours after reference point (start of infusion or end of infusion) should be collected wit hin +/- 15 minutes of 
indicted time.  Those collected 4 or more  hours after reference point (start of infusion or end of infusion) may be collected w ithin +/- 60 minutes of 
indicated time.  
Cycle Day LMB -100 
PKs (5.1.1 )  Nab-paclitaxel 
PKsa (5.1.2) Pharmacogenetic 
studies ( 5.1.3 ) ADA 
(5.1.2 )  PE mediated 
CLS (Cytokines) 
and serum MPF 
level 
 (5.1.6 , 5.1.12 ) CECs, Immune 
Subsets, CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample  
(5.1.5 , 5.1.11 ) 
2 mL 
K2EDTA 
tube 4mL in 6 mL 
sodium heparin 
tube 4-6 mL in purple 
top tube 2 mL 
K2ED
TA 
tube 4 mL red SST 
tube Two 7.5 mL 
Veridex CellSave 
& three 8 mL CPT citrate tubes  2.5 mL 
PAXgene 
RNA tube  NA 
Screening  Screening                Xb 
1 1 Pre-dose, 
End of 
loading 
dose, 2, 
and 6 hours 
after start 
of 
continuous 
infusion Pre-infusion, 
half way 
through dose 
(~15- min), 2-5 
min prior to 
EOI(~25 -
28min), EOI, 
and 0.5, 1, 2, 5, 
8, 12 hours 
post-dose Xc Pre-
dose Pre-dose, 1, 2, 4 
and 6 hours after 
start of continuous 
infusion Pre-dose Pre- dose   
  2 EOI then 2 
hours after 
EOI 24 hr post -dose    EOI       
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
75 
 Cycle Day LMB -100 
PKs (5.1.1 )  Nab-paclitaxel 
PKsa (5.1.2) Pharmacogenetic 
studies ( 5.1.3 ) ADA 
(5.1.2 )  PE mediated 
CLS (Cytokines) 
and serum MPF 
level 
 (5.1.6 , 5.1.12 ) CECs, Immune 
Subsets, CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample  
(5.1.5 , 5.1.11 ) 
2 mL 
K2EDTA 
tube 4mL in 6 mL 
sodium heparin 
tube 4-6 mL in purple 
top tube 2 mL 
K2ED
TA 
tube 4 mL red SST 
tube Two 7.5 mL 
Veridex CellSave 
& three 8 mL CPT 
citrate tubes  2.5 mL 
PAXgene 
RNA tube  NA 
  3   48 hr post -dose       24 hrs after EOId 24 hrs after 
EOId   
  4   72 hr post -dose             
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
76 
 Cycle Day LMB -100 
PKs (5.1.1 )  Nab-paclitaxel 
PKsa (5.1.2) Pharmacogenetic 
studies ( 5.1.3 ) ADA 
(5.1.2 )  PE mediated 
CLS (Cytokines) 
and serum MPF 
level 
 (5.1.6 , 5.1.12 ) CECs, Immune 
Subsets, CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample  
(5.1.5 , 5.1.11 ) 
2 mL 
K2EDTA 
tube 4mL in 6 mL 
sodium heparin 
tube 4-6 mL in purple 
top tube 2 mL 
K2ED
TA 
tube 4 mL red SST 
tube Two 7.5 mL 
Veridex CellSave 
& three 8 mL CPT 
citrate tubes  2.5 mL 
PAXgene 
RNA tube  NA 
2 1 Pre-dose 
and end of 
loading 
dose      Pre-
dose Pre-dose Pre-dose Pre- dose   
2 EOI               
3  
(Arm B2 
only)        Xe 
8  
(Arms A1, 
A2, B1)               Xe 
3  
(Arm B2 
only) 1 
 Pre-dose 
and end of 
loading 
dose    Pre-
dose     
2 EOI        
At time of 
Progression 
         X X       
Withdrawal 
Visit         X X       
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
77 
 Cycle Day LMB -100 
PKs (5.1.1 )  Nab-paclitaxel 
PKsa (5.1.2) Pharmacogenetic 
studies ( 5.1.3 ) ADA 
(5.1.2 )  PE mediated 
CLS (Cytokines) 
and serum MPF 
level 
 (5.1.6 , 5.1.12 ) CECs, Immune 
Subsets, CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample  
(5.1.5 , 5.1.11 ) 
2 mL 
K2EDTA 
tube 4mL in 6 mL 
sodium heparin 
tube 4-6 mL in purple 
top tube 2 mL 
K2ED
TA 
tube 4 mL red SST 
tube Two 7.5 mL 
Veridex CellSave 
& three 8 mL CPT 
citrate tubes  2.5 mL 
PAXgene 
RNA tube  NA 
Safety 
Follow -up 
Visit           X X       
          
          
ADA =anti-drug antibody; EOI =End of infusion; PK =pharmacokinetic; CTC=circulating tumor cell; CEC=circulating endothelial cel l 
a. Performed only in subjects receiving nab-paclitaxel (i.e., not performed in single agent lead in) 
b. Archival tissue collection or biopsy if no tissue available (mandatory).   
c. Collected preferably at baseline, but may be collected at any time during the study.  
d. May alternatively be drawn on day prior (at least 2 hours post-EOI) to avoid a weekend draw 
e. Optional  
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
78 
  
5.2.2.2  48-hour continuous infusion 
Timed samples scheduled for within 4 hours after reference point (start of infusion or end of infusion) should be collected within +/- 15 minutes of 
indicted time.  Those collected 4 or more hours after referenc e point (start of infusion or end of infusion) may be collected w ithin +/- 60 minutes of 
indicated time.  
Cycle Day LMB -100 PKs  
(5.1.1 ) Nab- paclitaxel PKsa 
(5.1.2 ) Pharmacogenetic 
studies 
(5.1.3 ) ADA  
(5.1.2 ) PE mediated CLS 
(Cytokines) and 
serum MPF level 
(5.1.6, 5.1.12 ) CECs, Immune 
Subsets, 
CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample 
(5.1.5 , 
5.1.11 ) 
2 mL K 2EDTA 
tube 4mL in 6 mL sodium 
heparin tube 4-6 mL in purple 
top tube 2 mL 
K2EDTA 
tube 4 mL red SST  tube Two 7.5 mL 
Veridex CellSave 
& three 8 mL CPT 
citrate tubes 2.5 mL 
PAXgene 
RNA tube NA 
Screening Screening            Xb 
1 1  Pre-dose, End of 
loading dose, 2, 
and 6 hours after 
start of infusion pre-infusion, half way 
through loading dose 
(15-min), 2-5min prior 
to end of loading dose 
(25-28min), EOI , and 
0.5, 1, 2, 5, 8, 12, 24, 
48 and 72 hr post dose.   Xc Pre-dose Pre-dose, 1, 2 , 4 
and 6 hours after 
start of infusion Pre-dose Pre- dose  
 2 24 hours after 
start of infusion    24 hours after start 
of infusion    
 3 EOI then 2 hours 
after EOI     EOI    
 4       24 hrs after EOId 24 hrs after 
EOId  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
79 
 Cycle Day LMB -100 PKs  
(5.1.1 ) Nab- paclitaxel PKsa 
(5.1.2 ) Pharmacogenetic 
studies 
(5.1.3 ) ADA  
(5.1.2 ) PE mediated CLS 
(Cytokines) and 
serum MPF level 
(5.1.6, 5.1.12 ) CECs, Immune 
Subsets, 
CTCs 
(5.1.7 , 5.1.8 , 
5.1.10 ) Immune 
gene 
expression 
(5.1.9 ) Tumor 
Sample 
(5.1.5 , 
5.1.11 ) 
2 mL K 2EDTA 
tube 4mL in 6 mL sodium 
heparin tube 4-6 mL in purple 
top tube 2 mL 
K2EDTA 
tube 4 mL red SST  tube Two 7.5 mL 
Veridex CellSave 
& three 8 mL CPT 
citrate tubes 2.5 mL 
PAXgene 
RNA tube NA 
2 1 Pre-dose , end of 
loading dose and 
2 hours after 
start of infusion   Pre-dose Pre-dose Pre-dose Pre- dose  
2 24 hours after 
start of infusion        
3 EOI        
8        Xe 
At time of 
Progression     X  X    
Withdrawal 
Visit     X  X    
Safety 
Follow -up 
Visit       X  X    
ADA =anti-drug antibody; EOI =End of infusion; PK =pharmacokinetic; CTC=circulating tumor cell; CEC=circulating endothelial cel l 
a. Performed only in subjects receiving nab-paclitaxel (i.e., not performed in single agent lead in) 
b. Archival tissue collection or biopsy if no tissue available (mandatory).  
c. Collected preferably at baseline, but may be collected at any time during the study. 
d. May alternatively be drawn on day prior (at least 2 hours post-EOI) to avoid a weekend draw 
e. Optional 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
80 
  
5.3 SAMPLE STORAGE , TRACKING AND DISPOSITION  
Samples will be ordered in CRI S and tracked through a Clinical Trial Data Management system. 
Should a CRIS screen not be available, the CRIS  downtime procedures will be followed.  Samples 
will not be sent outside NIH without IR B notification and an executed MTA.  
5.3.1 Clinical Pharmacology Program 
Upon arrival in the Clinical Pharmacology Pr ogram (CPP), OCD, CCR, NCI, all samples are 
barcoded, with data entered and stored in Pati ent Sample Data Management System (PSDMS), 
also known as Labrador , the system utilized by the CPP. This is a secure program, with access to 
the PSDMS system limited to defined CPP personnel, who are issu ed individual user accounts. 
PSDMS creates a unique barcode ID for every sample and sample box, which cannot be traced 
back to patients without PSDMS access. The data recorded for each sample includes the patient 
ID, name, trial name/protocol number, time drawn, cy cle, time point, dose, material type, as well 
as box and freezer location. There are patient demogr aphics that can be obtained to correlate with 
the samples through PSDMS. For each sample, ther e are notes associated with processing method 
(delay in sample processing, storage conditions on the ward, etc.) 
Barcoded samples are stored in barcoded boxes in  a locked freezer at either -20°C or -80°C 
according to stability requirements. These freezers are located onsite in the CPP and offsite at NCI 
Frederick Central Repository Services in Frederic k, MD. Samples will be stored until requested 
by the researcher assigned to the protocol. All re quests are monitored and tracked in PSDMS. All 
researchers are required to sign a form stating that the samples are only to be used for research 
purposes associated with this tr ial (as per IRB approved protocol) and that any unused samples 
must be returned to the CPP. Following completion of this study, samples will  remain in storage as detailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the 
rights to use the material. 
5.3.2 Leidos Biomedical, Inc. Lab 
Blood and tissue collected during the course of this study will follow storage, handling and labeling 
procedures to ensure that security , confidentiality and sample inte grity are maintained. All samples 
(blood or tissue) are tracked by distinct identificat ion labels that include a unique patient identifier 
and date of specimen collection. Thus, samples will  be de-identified of personal data, with access 
to personal data restricted to the study investigators.   
All cryopreserved samples are tracked for freezer  location and storage criteria. All Samples are 
stored in a locked freezer at -70 qC according to stability requirements.  These freezers are located 
offsite at NCI-Frederick, at the Leidos Biomedical , Inc. lab in Frederick, MD.  Samples will be 
stored until requested by a researcher named on th e protocol.  All use and requests for use will be 
recorded by the Leidos Biomedical, Inc. Lab. Any unused samples must be returned. Some samples as indicated below may be stored in monitored freezers/refrigerators in the 
investigator’s laboratory at specified temperatures with alarm systems in place.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
81 
 At the termination of this protocol, samples will remain in storage as detailed above.  Access to 
these samples will only be granted following IRB approval of an additional protocol or an 
exemption from IRB approval, granting the rights to use the material.  If specimens are to be 
discarded at any point, they will be disposed  of in accordance with the environmental protection 
laws, regulations and guidelines of the Federal Government and the State of Maryland. 
If, at any time, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written  request. Following receipt of this request, the 
samples will be destroyed (or returned to the patien t, if so requested), and reported as such to the 
IRB.    
5.3.3 Laboratory of Jane Trepel 
Samples will be processed immediatel y by the Trepel laboratory.  Biospecimens will be collected 
and processed using validated SOPs that will ensure both specimen quality and patient 
confidentiality. Using a computerized inventor y system and a backup hardcopy process, all 
specimen collection and processing steps will be documented and the sp ecific location of each 
specimen will be tracked. Each  new specimen collected will be assigned a unique barcode 
identifier that can be linked to the original spec imen collected and other relevant information 
within the inventory system.  Specimen labels w ill indicate: protocol number, order in which the 
patient enrolled on the trial, ty pe of sample, collection time, and total volume collected, as 
appropriate.  The inventory process contains othe r security provisions sufficient to safeguard 
patient privacy and confi dentiality. Access to the inventory system and associated documents will 
be restricted to appropriate indi viduals. Requests to use specimens stored in the repository must 
be approved. SOPs ensure that any changes in infor med consent made by a patient and relayed to 
the PI will be reflected in the inventory system to ensure that specimens are destroyed as 
appropriate. All laboratory personnel will be trained to adhere to SOPs and will be monitored for 
high-quality performance. 
5.3.4 Protocol Completion/Sample Destruction 
All specimens obtained in the protocol are used  as defined in the protocol. Any specimens 
remaining at the completion of the protocol will be  stored in the conditions  described above. The 
study will remain open as long as sample or data  analysis continues. Samples from consenting 
subjects will be stored until they are no longer of scientific value or until a subject withdraws 
consent for their continued use, at which time th ey will be destroyed. Once primary research 
objectives for the protocol are achieved, intramur al researchers can request access to remaining 
samples, provided they have an IRB-approved prot ocol and participant consent or an exemption 
from OHSRP.  
The PI will report any loss or destruction of samples to the NIH Intramural IRB as soon as he/she 
is made aware of such loss. The PI will report de stroyed samples to the IRB if samples become 
unsalvageable because of environmental factors such as a broken freezer or lack of dry ice in a shipping container, or if a participant withdraws cons ent. Samples will also be reported as lost if 
they are lost in transit between facilities or misplaced by a researcher. Freezer problems, lost 
samples, or other problems associated with samples will also be reported to the IRB, the NCI Clinical Director, and the office of the CCR, NCI. 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
82 
 5.4 SAMPLES FOR GENETIC ANALYSIS  
Pharmacogenetic studies will be performed on this protocol as described in section 5.1.3 and 
samples will be stored and secured as described in section 5.3.1. Because the analysis is limited to 
genes that play a role in drug metabolism, none of which are currently associated with disease 
causing genes, incidental findings will not be returned on this study. 
6 DATA COLLECTION AND EVALUATION  
6.1 DATA COLLECTION  
Study data will be recorded and stored in th e C3D and Labmatrix databases. The PI will be 
responsible for overseeing entry of data into an in-house password protected electronic system and 
ensuring data accuracy, consistency and timeliness. The principal investigator, associate 
investigators/research nurses and/or a contract ed data manager will assist with the data 
management efforts. All data obtained during the conduc t of the protocol will be kept in secure 
network drives or in approve d alternative sites that comply with NIH security standards. Primary 
and final analyzed data will have identifiers so that research data can be attributed to an individual 
human subject participant. 
All adverse events, including clinically signif icant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return  to baseline or stabili zation of event. Patients 
will be followed for adverse events for 30 days after removal from study treatment or until off-
study, whichever comes first. Adverse events occ urring more than 30 days after the last dose of 
study therapy are only required to be recorded only if  they are considered to be serious and related 
to the investigational agent/intervention. 
An abnormal laboratory value will be recorded in the database as an AE only if the laboratory 
abnormality is characterized by any of the following: 
x Results in discontinuation from the study 
x Is associated with clinical signs or symptoms  
x Requires treatment or any othe r therapeutic intervention 
x Is associated with death or another serious adverse event, including hospitalization.  
x Is judged by the Investigator to be of significant clinical impact 
x If any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test drug and about the patient’s 
outcome. 
End of study procedures: Data will be stored according to HHS, FDA regulations and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or destruction of data: Should we become aware that a major breach in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
83 
 6.2 DATA SHARING PLANS  
6.2.1 Human Data Sharing Plan 
What data will be shared? 
I will share human data generated in this research for future research as follows: _X_ Coded, linked data in an NIH-funde d or approved public repository.   
_X_ Coded, linked data in BTRIS 
_X_ Identified or coded, linked data with ap proved outside collaborators under appropriate 
agreements.  
How and where will the data be shared?  
Data will be shared through: _X_ An NIH-funded or approved public repository.  Insert name or names:_clinicaltrials.gov__. 
_X_ BTRIS (automatic for activities in the Clinical Center) 
_X_ Approved outside collaborators unde r appropriate individual agreements. 
_X_ Publication and/or public presentations. 
 When will the data be shared? 
_X_ Before publication. 
_X_ At the time of publication or shortly thereafter.  
6.2.2 Genomic Data Sharing Plan 
The SNP arrays utilized on this study (DMET chip) cover approximately 2000 genes, which are 
not defined as large scale genomic data under the GDS policy. 
6.3 RESPONSE CRITERIA  
For the purposes of this study, participants should be re-evaluated following cycle 2, then every 6 
weeks (+/- 2 weeks) until disease progression.  In  addition to a baseline scan, confirmatory scans 
should also be obtained no less than 4 weeks following initial documentation of objective response. 
Response and progression will be assessed by the investigator on the  basis of physical 
examinations, computed tomography (CT) or Magnetic Resonance  (MR) scans, and potentially 
other modalities according to standard of care, using the international criteria proposed by the 
revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).[43]  
Changes in the largest diameter (unidimensiona l measurement) of the tumor lesions and the 
shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. For 
patients with pleural mesothelioma, modified RECI ST criteria will be used to assess response. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
84 
 ORR, DCR and PFS measured according to these criteria will be reported as exploratory 
objectives. 
6.3.1 Definitions 
Evaluable for toxicity:  All participants will be  evaluable for toxicity from the time of their first 
treatment with LMB-100. 
The dose determining population will consist of all participants evaluable for DLT. Participants  
are evaluable for DLT if they are evaluable for toxicity and discontinued earlier  due to DLT or 
completed the DLT observation period the first cycle during phase I and have undergone safety 
evaluations. Evaluable for pharmacokinetic analysis: All participants that are evaluable for toxicity will be 
included in the PK analysis population.  Participants will be excluded from the PK analysis 
population if they significantly violate the  inclusion or exclusion criteria, deviate from the protocol, 
or if data are unavailable or in complete which may influence the PK analysis. Excluded cases will 
be documented  with the reason for exclusion. 
Evaluable for objective response: Only those participants who have measurable disease present at 
baseline, have received at least one cycle of therapy, and have ha d their disease re-evaluated will 
be considered evaluable for response.  These pa rticipants will have their response classified 
according to the definitions stated below.  (No te:  Participants who exhibit objective disease 
progression prior to the end of cycle 1 will also be considered evaluable.) Evaluable Non-Target Disease Response:  Particip ants who have lesions present at baseline that 
are evaluable but do not meet the definitions of mea surable disease, have received at least one 
cycle of therapy, and have had their disease re-e valuated will be considered evaluable for non-
target disease.  The response assessment is ba sed on the presence, absence, or unequivocal 
progression of the lesions.  
6.3.2 All Diseases except pleural mesothelioma 
6.3.2.1 Disease Parameters 
Measurable disease:  Measurable lesions are defi ned as those that can be accurately measured in 
at least one dimension (longest diameter to be recorded) as: 
x By chest x-ray: >20 mm;  
x By CT scan:  
o Scan slice thickness 5 mm or under: as >10 mm 
o Scan slice thickness >5 mm: double the slice thickness  
x With calipers on clinical exam: >10 mm.   
All tumor measurements must be recorded in millimeters (or decimal fractions of centimeters). 
Malignant lymph nodes.  To be considered pat hologically enlarged and measurable, a lymph node 
must be >15 mm in short axis when assessed by  CT scan (CT scan slice thickness recommended 
to be no greater than 5 mm).  At  baseline and in follow-up, only th e short axis will be measured 
and followed. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
85 
 Non-measurable disease.  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), a re considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are considered as non-measurable. 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts. 
‘Cystic lesions’ thought to represent cystic metastas es can be considered as measurable lesions, if 
they meet the definition of measurability desc ribed above. However, if non-cystic lesions are 
present in the same participant, these are preferred for selection as target lesions. 
Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions  and recorded and 
measured at baseline.  Target lesions should be selec ted on the basis of their size (lesions with the 
longest diameter), be representative of all involved organs, but in addition should be those that 
lend themselves to reproducible repeated measure ments.  It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducibl e measurement in which circumstance the next 
largest lesion which can be measured reproducibl y should be selected.  A sum of the diameters 
(longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, then 
only the short axis is added into the sum.  The ba seline sum diameters will be used as reference to 
further characterize any objective tumor regressi on in the measurable dimension of the disease. 
Non-target lesions.  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline.  Measurements of these lesio ns are not required, but the presence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow-up.  
6.3.2.2 Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in  metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as clos ely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment. The same method of assessment and the same techni que should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be 
imaged but are assessable by clinical exam. 
Clinical lesions:   Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and t10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by color photography, including a 
ruler to estimate the size of the lesion, is recommended.  
Chest x-ray:   Lesions on chest x-ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by aerated lung.  However, CT is preferable.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
86 
 Conventional CT and MRI:  This guideline has de fined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less.  If CT scans have slice thickness greater 
than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is 
also acceptable in certain situations (e.g. for body scans).   
Use of MRI remains a complex issue.  MRI has excelle nt contrast, spatial, and temporal resolution; 
however, there are many image acquisition variables involved in MRI, which greatly impact image 
quality, lesion conspicuity, and measurement.  Furt hermore, the availability of MRI is variable 
globally.  As with CT, if an MRI is performed , the technical specifications of the scanning 
sequences used should be optimized for the evaluati on of the type and site of disease.  Furthermore, 
as with CT, the modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body 
parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition 
protocol should be followed as closely as possible to  prior scans.  Body scans should be performed 
with breath-hold scanning techniques, if possible. 
PET-CT:  At present, the low dose or attenuation correction CT portion of a combined PET-CT is 
not always of optimal diagnostic CT quality for us e with RECIST measurements.  However, if the 
site can document that the CT performed as part of  a PET-CT is of identical diagnostic quality to 
a diagnostic CT (with IV and oral contrast), then  the CT portion of the PET-CT can be used for 
RECIST measurements and can be used intercha ngeably with conventional CT in accurately 
measuring cancer lesions over time.  Note, how ever, that the PET portion of the CT introduces 
additional data which may bias an investigator if it is not routinely or serially performed.   Ultrasound:  Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to the next.  If new lesions are identified by ultrasound in the course of the study, confirmation by CT or 
MRI is advised.  If there is concern about rad iation exposure at CT, MRI may be used instead of 
CT in selected instances. 
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is not 
advised.  However, such techniques may be useful  to confirm complete pathological response 
when biopsies are obtained or to determine relapse in trials where recurrence following complete 
response (CR) or surgical resection is an endpoint. 
Tumor markers:  Tumor markers alone cannot be used  to assess response.  If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete 
clinical response.  Specific guidelines for both CA-125 response (in recurrent ovarian cancer) and 
PSA response (in recurrent prostate  cancer) have been published.[44-46 ]  In addition, the 
Gynecologic Cancer Intergroup has developed CA -125 progression criteria which are to be 
integrated with objective tumor assessment for use in first-line trials in ovarian cancer.[47] 
Cytology, Histology:  These techniques can be used to differentiate between partial responses (PR) 
and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain). 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
87 
 The cytological confirmation of the neoplastic orig in of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stab le disease (an effusion may be a side effect of 
the treatment) and progressive disease. 
FDG-PET:  While FDG-PET response assessments  need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanni ng to complement CT scanning in assessment 
of progression (particularly possible 'new' disease).  New lesions on the basis of FDG-PET imaging 
can be identified according to the following algorithm:  
a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based on a new lesion. 
b. No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive FDG-
PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD.  If 
the positive FDG-PET at follow-up is not confi rmed as a new site of disease on CT, 
additional follow-up CT  scans are needed to determine if there is truly progression 
occurring at that site (if so, the date of PD  will be the date of th e initial abnormal FDG-
PET scan).  If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the basis of the anatomic images, this is not 
PD. 
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG-PET in this ci rcumstance should be prospectively described 
in the protocol and supported by disease-spec ific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to false positive CR 
due to limitations of FDG-PET and biopsy resolution/sensitivity. 
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding ti ssue on the attenuation corrected image.  
6.3.2.3 RECIST 1.1 Criteria 
6.3.2.3.1 Evaluation of Target Lesions 
Complete Response (CR): Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm. 
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking 
as reference the baseline sum of diameters. Progressive Disease (PD): At least a 20% increase  in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this in cludes the baseline sum if that is the smallest 
on study).  In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also considered 
progressions). Stable Disease (SD): Neither sufficient shrinkage  to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of diameters while on study. 6.3.2.3.2 Evaluation of Non-Target Lesions 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
88 
 Complete Response (CR): Disappearance of all non -target lesions and normalization of tumor 
marker level.  All lymph nodes must be non-pathological in size (<10 mm short axis). 
Note:  If tumor markers are in itially above the upper normal limi t, they must normalize for a 
participant to be considered in complete clinical response. Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor 
marker level above the normal limits. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression  
of existing non-target lesions.  Unequivocal progression  should not normally trump target lesion 
status.  It must be representative of overall disease status change, not a single lesion increase. Although a clear progression of “non -target” lesions only is exceptional, the opinion of the treating 
physician should prevail in such circumstances, and the progression status should be confirmed at 
a later time by the review pane l (or Principal Investigator). 
6.3.2.3.3 Evaluation of Best Overall Response 
The best overall response is the best response reco rded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  The par ticipant's best response assignment will depend on 
the achievement of both measurement and confirmation criteria. 
For Participants with Measurable Disease (i.e., Target Disease) 
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Overall Response when 
Confirmation is Required* 
CR CR No CR >4 wks. Confirmation** 
CR Non-
CR/Non-PD No PR 
>4 wks. Confirmation** CR Not 
evaluated No PR 
PR Non-
CR/Non-
PD/not 
evaluated No PR 
SD Non-
CR/Non-
PD/not 
evaluated No SD 
Documented at least once >4 
wks. from baseline**  
PD Any Yes or 
No PD 
no prior SD, PR or CR  Any PD*** Yes or 
No PD 
Any Any Yes PD 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
89 
 Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Overall Response when 
Confirmation is Required* 
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion. 
** Only for non-randomized trials with response as primary endpoint. 
*** In exceptional circumstances, unequivocal progression in non- target lesions may be accepted as 
disease progression. 
Note : Participant s with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as “ symptomatic 
deterioration.”   Every effort should be made to document the obj ective progression even after 
discontinuation of treatment.  
For Participants with Non-Measurable Disease (i.e., Non-Target Disease)  
Non-Target Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No Non-CR/non-PD* 
Not all evaluated  No not evaluated 
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*  ‘Non -CR/non- PD’ is preferred over ‘stable disease’ for non -target disease since SD is  increasingly used as 
an endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be 
measured is not advised  
6.3.3 Pleural Mesothelioma 
Malignant pleural mesothelioma (MPM) lesions are difficult to measure reliably.[48] Therefore modified 
criteria were defined in 2004 adjusting target lesion measurements to the specific needs of this disease. 
6.3.3.1 Modified RECIST Criteria for MPM 
Target lesion:  
Measurable at baseline and defined as tumor th ickness measurements perpe ndicular to the chest 
wall or mediastinum in two positions at three sepa rate levels on transverse cuts of CT scan. The 
sum of those 6 measurements define a pleural un idimensional measure. For reproducibility of 
lesion identification in follow up scans, cuts were taken at least 1 cm apart and close to anatomical 
landmarks in the thorax. Reassessments should be  done at same position at the same level and by 
the same reader. Nodal, subcutaneous, and other measurable lesion were measured as per RECIST 
criteria. All unidimensional measurements we re added to obtain total tumor measurement. 
Evaluation of target lesions  
x Complete Response (CR): Disappearance of all target lesions with no evidence of tumor elsewhere.  
x Partial Response (PR): At least a 30% de crease in the total tumor measurement  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
90 
 x Confirmed response (PR and CR): require a repeat scan at least 4 weeks apart  
x Progressive Disease (PD): At least a 20% incr ease in the total tumor measurement, taking 
as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). (Note: the appearance of one  or more new lesions is also considered 
progression).  
x Stable Disease (SD): Neither sufficient shrinka ge to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum diameters while on study.  
6.3.3.2 Evaluation of Best Overall Response 
The best overall response is the best response reco rded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  The pati ent's best response assignment will depend on the 
achievement of both measurement and confirmation criteria.  
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Response for this 
Category Also Requires: 
CR CR No CR >4 wks. confirmation 
CR Non-CR/Non-
PD No PR  
>4 wks. confirmation 
PR Non-PD No PR 
SD Non-PD No SD documented at least once >4 
wks. from baseline 
PD Any Yes or No PD  
no prior SD, PR or CR  Any PD* Yes or No PD 
Any Any Yes PD 
* In exceptional circumstances, unequivocal progression in non- target lesions may be accepted 
as disease progression. 
 
Note : Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progre ssion at that time should be reported as 
“symptomatic deterioration” .  Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
 
               In some circumstances it may be difficult to distinguish residual disease from normal 
tissue. When the evaluation of complete response depends on this determination, it is 
recommended that the residual lesion be investig ated (fine needle aspirate/biopsy) to 
confirm the complete response status. 
 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
91 
 6.3.4 Duration of Response 
Duration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented. 
Duration of stable disease:  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements.  
6.3.5 Progression-Free Survival 
Progression free survival (PFS) is defined as th e duration of time from start of treatment to time 
of progression or death, whichever occurs first. 
6.3.6 Objective Response Rate 
Objective response rate (ORR) is defined as the proportion of participants with partial response or 
complete response. 
6.3.7 Disease Control Rate 
Disease control rate (DCR) is defined as the proportion of participants  with stable disease, partial 
response or complete response 
6.4 TOXICITY CRITERIA  
The following adverse event management guidelines  are intended to ensure the safety of each 
participant while on the study.  The descriptions  and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE 
reporting. All appropriate treatment areas should have access to a copy of the CTCAE version 4.0. 
A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site (http://ctep.cancer.gov/protocolDevelopmen t/electronic_applications/ctc.htm#ctc_40 ).  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN 
7.1 D
EFINITIONS  
7.1.1 Adverse Event 
Any untoward medical occurrence in a human sub ject, including any abnormal sign (for example, 
abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subject’s participation in research, whether or not considered related to the subject’s participation in the research.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
92 
 7.1.2 Suspected adverse reaction 
Suspected adverse reaction means any adverse even t for which there is a reasonable possibility 
that the drug caused the a dverse event. For the purposes of IND safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the 
adverse event. A suspected adverse reaction implie s a lesser degree of certainty about causality 
than adverse reaction, which means any adverse event caused by a drug. 
7.1.3 Unexpected adverse reaction 
An adverse event or suspected adverse reaction is c onsidered “unexpected” if it is not listed in the 
investigator brochure or is not listed at the specific ity or severity that has been observed; or, if an 
investigator brochure is not required or available,  is not consistent with the risk information 
described in the general investigational plan or elsewhere in the current application. "Unexpected” 
also refers to adverse events or suspected adverse reactions that are mentioned in the investigator 
brochure as occurring with a class of drugs or as  anticipated from the pharmacological properties 
of the drug, but are not specifically mentioned as occurring with the particular drug under 
investigation. 7.1.4 Serious  
An Unanticipated Problem or Protocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety, welfare or rights of subjects or others. 7.1.5 Serious Adverse Event 
An adverse event or suspected adverse reaction is  considered serious if in the view of the 
investigator, it results in any of the following: 
x Death, 
x A life-threatening adverse drug experience 
x Inpatient hospitalization or prolongation of existing hospitalizationPersistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions 
x A congenital anomaly/birth defect. 
x Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the participant or subject and may 
require medical or surgical intervention to prevent one of the outcomes listed in this 
definition. 
7.1.6 Disability 
 A substantial disruption of a person’s ability to conduct normal life functions.  
7.1.7 Life-threatening adverse drug experience 
Any adverse event or suspected adverse reaction that places the participant or subject, in the view 
of the investigator or sponsor, at immediate risk of death from the reaction as it occurred, i.e., it 
does not include a reaction that had it occurred in a more severe form, might have caused death. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
93 
 7.1.8 Protocol Deviation (NIH Definition) 
Any change, divergence, or departure from the IRB-approved research protocol.   
7.1.9 Non-compliance (NIH Definition) 
The failure to comply with applicable NIH Huma n Research Protections Program (HRPP) policies, 
IRB requirements, or regulatory requirements for the protection of human research subjects. 7.1.10 Unanticipated Problem 
Any incident, experience, or outcome that: 
x Is unexpected in terms of nature, se verity, or frequency in relation to  
(a) the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigator’s Brochure or other study documents, and  
(b) the characteristics of the subject population being studied; AND  
x Is related or possibly related to participation in the research; AND  
x Suggests that the research places subjects or others at a greater risk of harm  (including 
physical, psychological, economic, or soc ial harm) than was previously known or 
recognized. 
7.2 NIH
 INTRAMURAL IRB  AND CLINICAL DIRECTOR (CD)  REPORTING  
7.2.1 NIH Intramural IRB and NCI CD Expedited Reporting of Unanticipated Problems and 
Deaths 
The Protocol PI will report on the NIH Problem Fo rm to the NIH Intramural IRB and NCI Clinical 
Director: 
x All deaths, except deaths due to progressive disease  
x All Protocol Deviations 
x All Unanticipated Problems 
x All non-compliance 
Reports must be received within 7 days of PI awareness via iRIS. 
7.2.2 NIH Intramural IRB Requirements for PI Reporting at Continuing Review 
The protocol PI will report to the NIH Intramural IRB:  
1. A summary of all protocol deviations in a tabular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action. 
2. A summary of any instances of non-compliance 
3. A tabular summary of the following adverse events: 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
94 
 x All Grade 2 unexpected  events that are possibly, probably or definitely related to the 
research;  
x All Grade 3 and 4 events that are possibly, probably or definitely related to the research;  
x All Grade 5 events regardless of attribution;  
x All Serious Events regardless of attribution.  
NOTE : Grade 1 events are not required to be reported.  
7.2.3 NIH Intramural IRB Reporting of IND Safety Reports 
Only IND Safety Reports that meet the definition  of an unanticipated problem will need to be 
reported to the NIH Intramural IRB. 
7.3 IND  SPONSOR REPORTING CRITERIA  
Starting from the initiation of study therapy and continuing through  the first 30 days after the 
subject receives the last administration of the i nvestigational agent/intervention, the investigator 
must immediately report to the sponsor, using th e mandatory MedWatch form 3500a or equivalent, 
any serious adverse event, whether or not consid ered drug related, including those listed in the 
protocol or investigator brochure and must include  an assessment of whether there is a reasonable 
possibility that the drug caused the event. For events that occur more than 30 days after the last 
administration of investigational agent/interventi on, only report serious adverse events  that have 
an attribution of at least possibly related to the agent/intervention. 
Required timing for reporting per the above guideline: 
 
x Deaths (except death due to progressive disease) must be reported via email within 
24 hours.  A complete report must be submitted within one business day.  
x Other serious adverse events as well as deaths due to progressive disease must be reported within one business day 
Events will be submitted to the Ce nter for Cancer Research (CCR) at: CCRsafety@mail.nih.gov  
and to the CCR PI and study coordinator. 
7.3.1 Reporting Pregnancy  
7.3.1.1 Maternal exposure  
If a patient becomes pregnant during the course of the study, the study treatment should be 
discontinued immediately and the pregnancy reported to the Sponsor. The potential risk of 
exposure of the fetus to the investigational ag ent(s) or chemotherapy agents (s) should be 
documented in box B5 of the MedWatch form “Describe Event or Problem”.  
Pregnancy itself is not regarded as an SAE. However, as patients who become pregnant on study 
risk intrauterine exposure of the fetus to agents which may be teratogenic, the CCR is requesting that pregnancy should be reported in an expedited manner as Grade 3 “Pregnancy, puerperium 
and perinatal conditions - Other (pregnancy )” under the Pregnancy, puerperium and perinatal 
conditions SOC.  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
95 
 Congenital abnormalities or birth defects and sp ontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complications should not be handled as AEs. The 
outcome of all pregnancies (spontaneous miscarr iage, elective termination, ectopic pregnancy, 
normal birth, or congenital abnormality) should be followed up and documented. 
If any pregnancy occurs in the course of the study, then the investigator should inform the Sponsor 
within 1 day, i.e., immediately, but no later than 24 hours of when he or she becomes aware of 
it. 
The designated Sponsor representative will work with the investigator to ensure that all relevant 
information is provided to the Sponsor within 1 to 5 calendar days for SAEs and within 30 days 
for all other pregnancies. 
The same timelines apply when outcome information is available. 
7.3.1.2 Paternal exposure 
Male patients should refrain from fathering a ch ild or donating sperm during the study and for 3 
months after the last dose of LMB-100 or nab-paclitaxel. 
Pregnancy of the patient’s partner is not consid ered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or 
congenital abnormality) occurring from the date of the first dose until 3 months after the last dose 
should, if possible, be followed up and documented. 
7.4 DATA AND SAFETY MONITORING PLAN 
7.4.1 Principal Investigator/Research Team  
The clinical research team will meet on a regular basis when participants are being actively treated 
on the trial to discuss each participant. Decisi ons about dose level enrollment and dose escalation 
if applicable will be made based on the toxicity data from prior participants.  
All data will be collected in a timely manner and re viewed by the principal investigator or a lead 
associate investigator. Adverse events will be reported as required above. Any safety concerns, 
new information that might affect either the ethica l and or scientific conduct of the trial, or protocol 
deviations will be immediately reported to the IRB using iRIS.  
The principal investigator will review adverse event and response data on each participant to 
ensure safety and data accuracy. The principal inve stigator will personally conduct or supervise 
the investigation and provide appropriate delega tion of responsibilities to other members of the 
research staff.  
7.4.2 Sponsor Monitoring Plan 
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring 
program. The CCR’s program allows for confirmation of: study data, specifically data that could affect the interpretation of primary study endpoints; adherence to the protocol, regulations, and SOPs; and human subjects protection. This is done through independent verification of study data with source documentation focusing on: 
x Informed consent process 
x Eligibility confirmation 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
96 
 x Drug administration and accountability 
x Adverse events monitoring 
x Response assessment. 
The monitoring program also extends to mult i-site research when the CCR is the coordinating 
center. 
This trial will be monitored by personnel employ ed by an NCI contractor. Monitors are qualified 
by training and experience to monitor the progre ss of clinical trials. Personnel monitoring this 
study will not be affiliated in any way with the trial conduct. Safety Monitoring Committee (SMC) 
7.4.3 Safety Monitoring Committee 
This protocol will require oversight from the Safe ty Monitoring Committee (SMC).  Initial review 
will occur as soon as possible after the annual NIH Intramural IR B continuing review date.   
Subsequently, each protocol will be reviewed as close to annually as the quarterly meeting 
schedule permits or more frequently as may be re quired by the SMC. For initial and subsequent 
reviews, protocols will not be reviewed if ther e is no accrual within the review period. Written 
outcome letters will be generated in response to the monitoring activities and submitted to the 
Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI. 
8 STATISTICAL CONSIDERATIONS   
8.1 PRIMARY ENDPOINTS  
The primary objectives of this trial are to: 
1) determine the MTD of LMB-100 in combination with chemotherapy (NAB-paclitaxel) in 
participants with advanced pancreatic cancer both as a short infusion and as a continuous 
infusion 
2) determine the response rate of the combination as a short infusion 
8.1.1 Part A 
Arm A1 - Phase I . Part A begins with a two dose level escalation using a 3 + 3 design with LMB-
100 potentially evaluated at 100, and 140 mcg/kg in combination with chemotherapy. A lower dose of 65 mcg/kg may also be evaluated. If both intended dose levels are explored and each requires up to 6 participants, then up to 12 particip ants may be required for the phase I portion of 
the trial.  Note:  Subjects e nrolled prior to Amendment C (n=3) in which the maximum number of 
cycles was reduced, are included in the MTD evalua tion as they have received at least 1 cycle of 
LMB-100. 
After the enrollment of patients to the firs t 2 dose levels the pharmacokinetic and anti-drug 
antibody level (ADA) data will be analyzed before enrolling new pa tients.  Dr. William Figg, who 
has expertise in pharmacokinetics, will, in  conjunction with the NCI CCR leadership 
committee analyze the data.  Since the thresholds for ADA and its influence on pharmacokinetics 
are unclear, pre-specified criteria for making change s to the protocol cannot be established at this 
time.  The objective of the assessment will be to make recommendations as to whether a 
therapeutic threshold has been reached and what, if any adjustments should be made with regard 
to the eligibility criteria and/or study plan. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
97 
 Arm A2 -Phase II  portion of Part A. In Arm A2 we will evaluate the combination identified as 
being the MTD from Arm A1. As of 5/1/18, this is anti cipated to be at dose level -1.  If dose level 
-1 is not found to be same during Arm A1, we will not proceed to Arm A2.  
If Arm A2 does proceed, since the participants to be treated on the phase II portion will have the 
same eligibility criteria as those on phase I, the 6 participants treated at 65 mcg/kg (the anticipated 
RP2D from Arm A1) will be the 6 initial particip ants treated on the first stage of the phase II 
cohort. Based upon results from two small trials of NAB-paclitaxel treatment beyond the first-line 
setting, the response rate of participants with adva nced pancreatic cancer to NAB-paclitaxel is at 
most 5%.[49, 50]  It would be desirable if this were improved by 15-20% or more. As such, the goal 
would be to determine if using the combination w ould rule out a 5% response rate to target a rate 
of 25%. The trial will be conducted using a Si mon Minimax two-stage phase II trial design[51] in 
order to rule out an unacceptably low PR+CR rate of 5% (p0 = 0.05) in favor of an improved 
response rate of  25% (p1 = 0.25). With α  = 0.10 (probability of accepting a poor treatment = 0.10) 
and β = 0.10 (probability of rejecting a good treatment = 0.10). This first stage will enroll 13 
evaluable participants, and if 0 of the 13 have a cl inical response, then no further participants will 
be accrued. If 1or more of the first 13 participants  has a response, then accrual would continue 
until a total of 20 evaluable participants have been enrolled. As it may take up to several months 
to determine if a participant ha s experienced a response, a temporary pause in the accrual may be 
necessary to ensure that enrollment to the second stag e is warranted. If there are 1 to 2 participants 
with a response out of 20 participants, this would be an uninterestingly low response rate. If there 
were 3 or more of 20 (15%) who experienced a respons e, this would be sufficiently interesting to 
warrant further study in later trials. Under th e null hypothesis (5% response rate), the probability 
of early termination is 51%. 
8.1.2 Part B:  
Arm B1 -Phase I, Continuous Infusion Single Agent Lead-In.  While patients who are eligible 
for enrollment into Part A are being treated on Pa rt A, patients who have pancreatic cancer who 
do not meet eligibility criteria for nab-paclitaxel  and patients with other MSLN-expressing solid 
tumors will be enrolled onto Part B Single Agen t Lead-in. This portion of the trial has dose finding 
using a 3 + 3 design with LMB-100 alone as a continuous infusion, potentially evaluated at doses 
of 65, 100, 140 and 200 mcg/kg/day over 24, 24 *2, 48, 72 and 96 hours using a flexible escalation 
scheme. This will establish the single agent MTD for continuous infusion. Enrollment in this arm has been capped at a maximum of 30 participants be ing treated.  If each dose level requires all 6 
participants, then five dose levels may be examined.    
After the first 3 patients were enrolled, the phar macokinetic data were  analyzed before enrolling 
new patients.  Dr. William Figg, who has expert ise in pharmacokinetics, in conjunction with the 
NCI CCR leadership committee analyzed the data.  The objective of the assessment was to make 
recommendations as to whether drug levels near that projected by the simulation can be achieved 
(feasibility, safety) and what, if any adjustments should be made with regard to the dose escalation 
and/ or study plan. The first assessment completed  just prior to the implementation of Amendment 
F. leading to the new dose escalation plan a nd the addition of a bolus dose submitted in 
Amendment F. Similar assessments will continue at the completion of each dose level. 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
98 
 Arm B2 – Continuous Infusion, Combination therapy:  After the Part B Single Agent Lead-in 
is completed, assessment of continuous infusion of  LMB-100 in combination with chemotherapy 
will be tested in the same populati on of pancreatic cancer patients enrolling in Part A. A single 
dose level of LMB-100 will be assessed in combination with chemotherapy in Phase I Part B.  This 
will require a maximum of 6 additional evaluable patients. If safety and tolerability of this 
combination is established in these 6 patients, then an additional 4 pa tients will be enrolled (total 
of 10 patients) to complete a small pilot investig ation of the response rate of the combination of 
continuous infusion LMB-100 and Nab-paclitaxel. Th is is being kept deliberately small to permit 
more rapid assessment of any evidence of efficacy. These 10 patients’ clinical responses will be 
reported along with an appropriate confidence inter val, and will be used to characterize the 
potential clinical efficacy of the combination. Theref ore, 10 total participants with pancreatic 
cancer will be required to complete Phase I and pilot investigation of response rate. 
At the conclusion of the trial, the response infor mation from the phase II portion of Part A and the 
pilot in Part B will be used to identify paramete rs which may merit further exploration in a more 
definitive subsequent trial. 
8.2 DETERMINATION OF SAMPLE SIZE 
Part A: the phase I portion of the trial may require up to 12 participants, and the phase II portion, 
if explored, may require up to 20 evaluable partic ipants. However, with 6 participants from phase 
I potentially being included in phase II, up to 12+20-6=26 individual participants may be required.  
Part B: The lead-in with single agent continuous LMB-100 may require up to 30 patients. 
Evaluation of the combination with nab-paclitaxel will require 10 patients if the combination is 
deemed safe and feasible.  Therefore, up to 40 patients may be required. 
Candidates for the phase 1 lead in portion of the stud y will be screened on the current protocol.  
With an anticipated screen failure rate of 50%, up  to 30/0.5 = 60 subjects may need to enroll to 
this portion of the study.  With an additional 26 subj ects required in part A (phase I and II) and 10 
subjects in the combination therapy portion of Part B,  the overall accrual ceil ing will be set at 100 
(26+60+10 +4 = 100 in order to allow for a smal l number of inevaluable participants).  If 1-2 
eligible pancreatic cancer patients enroll per m onth and 2-3 patients with other MSLN-expressing 
tumor types enroll on this trial, accrual would be expected to be completed in approximately 3 to 
5 years if the second stage of Phase II Part A is reached.  
9 HUMAN SUBJECTS PROTECTIONS  
9.1 RATIONALE FOR SUBJECT SELECTION  
LMB-100 is a mesothelin-targeted cFP and has shown preclinical dose-dependent activity in 
monotherapy and/or combination in xenografts representing MSLN-positive indications (NSCLC, mesothelioma, triple negative breast cancer, gastric cancer, pancreas, ovarian, potentially other 
tumor indications). The rationale to include MSLN - positive tumors of epithelial cell origin is 
based on preclinical models demonstrating promis ing anti-tumor efficacy. In addition, molecular 
pathology data demonstrated a high prevalence  of mesothelin protein in these tumors. The 
rationale to evaluate LMB-100 in advanced/m etastatic PDA and in mesothelin expressing solid 
tumors is to preliminarily assess the safety of LMB-100 alone or in combination with the standard 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
99 
 of care (SoC) chemotherapy nab-paclitaxel and We will also a ssess the preliminary anti-tumor 
activity of LMB-100 in PDA. 
9.2 PARTICIPATION OF CHILDREN  
As this is a first in human study, there are no dosing or adverse event data are currently available 
on the use of LMB-100 in combination with nab-p aclitaxel in participants <18 years of age; 
therefore, children are excluded from this study. 
9.3 PARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT  
Adults unable to give consent are excluded from  enrolling in the protocol.  However re-consent 
may be necessary and there is a possibility , though unlikely, that subjects could become 
decisionally impaired. For this reason and beca use there is a prospect of direct benefit from 
research participation (section 9.5), all subjects will be offered the opportunity to fill in their wishes 
for research and care, and assign a substitute decision maker on the “NI H Advance Directive for 
Health Care and Medical Research Participation” form so that another person can make decisions 
about their medical care in the event that they b ecome incapacitated or cognitively impaired during 
the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment 
Team (ACAT) for evaluation as needed for the following: an independent assessment of whether 
an individual has the capacity to provide consent;  assistance in identifying and assessing an 
appropriate surrogate when indicated; and/or an as sessment of the capacity to appoint a surrogate.  
For those subjects that become incapacitated and do not have pre-determined substitute decision 
maker, the procedures described in MAS Policy 87-4 and NIH HRPP SOP 14E for appointing a 
surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) who do not 
have a legal guardian or durable power  of attorney, will be followed. 
9.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
9.4.1 Risks from Study Drugs 
Participant safety will be managed by careful proactive participant selection prior to study to 
exclude participants at risk from study treatme nt due to their pre-existing conditions. During the 
study, safety of participants will be proactively managed by protocol-mandated physical 
examinations, vital signs assessments, chest X-rays, ECGs, clinical laboratory assessments, and collection of adverse events and their assessment.  
The risks of the study include those associated with study agents as discussed in section 10. 
Additional risks may also be encountered from th e use of the agents in combination as discussed 
below. 9.4.1.1 Potential Toxicities of Combining LMB-100 with Nab- paclitaxel  
The most common clinically significant adve rse reactions associated with the use of nab-paclitaxel 
have been neutropenia, peripheral neuropathy, art hralgia/myalgia, and gastrointestinal disorders. 
In the nab-paclitaxel treated population, the most frequently ( t40% of participants) reported 
treatment emergent adverse events  (TEAEs) were fatigue, nausea, peripheral neuropathy, alopecia, 
peripheral edema, diarrhea, anemia , neutropenia, and pyrexia. The most frequently reported Grade 
3 or higher TEAEs in the nab-paclitaxel arm were neutropenia, fatigue, peripheral neuropathy, 
thrombocytopenia, and anemia. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
100 
 9.4.2 Risks of study procedures 
Study procedures such as research blood collection a nd ECGs are of minimal risk to the subject.  
Higher risk procedures performed include: 
9.4.2.1 CT Guided Research Biopsy 
The risks of the optional research biopsy collected in cycle 2 include pain, bleeding and infection 
at the biopsy site.  In addition, as the biopsy may be collected under CT guidance, subjects in this 
study may be exposed to approximately 0.77 rem.   This amount is below the guideline of 5 rem 
per year allowed for adult research subjects by the NIH Radiation Safety Committee.  
9.4.2.2 Central Line Insertion 
All subjects in Arms B1 and B2 are required to re ceive study therapy through  a central line or an 
existing mediport. In addition, per PI discreti on, some subjects in Arms A1 and A2 may also 
require central line insertion. The risks of  this procedure include catheter contamination, 
pneumothorax, arrhythmia and air embolus.  All care  will be taken to minimize complications of 
central insertion during the procedure. 
9.5 RISKS/BENEFITS ANALYSIS  
Patients with advanced and/or metastatic cance r are in continuous need of improved therapy 
options. This is especially true for patients where no standard therapy exists such as the population 
that will be eligible for this trial. Preclinica l data has demonstrated promising anti-tumor efficacy 
of LMB-100 in xenograft models in monotherapy and even more so when LMB-100 has been combined with chemotherapy. Therefore, LM B-100 may improve clinical outcome of patients 
with pancreatic ductal adenocar cinoma in combination with nab-paclitaxel, an approved agent in 
advanced/metastatic PDA as well as the outcome of patients with mesothelin positive solid tumors 
receiving LMB-100 monotherapy. A num ber of clinically appropriate st rategies to minimize risk 
to participants have been built into the protocol  through the means of inclusion/exclusion criteria, 
monitoring strategies, and management guidelines.  
Overall, the potential benefits of LMB-100 for cancer participants, those able to consent and those 
who lose the capacity to do so during the course of the trial, outweigh the risks associated with the 
proposed entry-into-human trial with LMB-100. 
9.6 C
ONSENT AND ASSENT PROCESS AND DOCUMENTATION  
All participants will be thoroughly screened by the physician and the research nurse prior to 
completing the consent. During the initial consultation, the participant and family or friends, if 
present, will be presented with a forthright a nd detailed overview of the treatment option available 
to them at the NIH. The experimental nature of  the treatment, its objectives, its theoretical 
advantages and disadvantages will be presented. The Informed Consent document is given to the 
participant and they are asked to review it, mak e notes and ask questions prior to agreeing to 
participate in this protocol. The participant is re assured that participation on this trial is entirely 
voluntary and that he/she can withdraw or decide against treatment at any time without adverse 
consequences. The physician assures the participant that if alternative therapy or no therapy at all is preferred, we will do all that we can to fa cilitate consultation with the appropriate referral 
organizations. Consent for optional biopsy will be  obtained at the time of the procedure. If the 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
101 
 patient refuses the optional biopsy at that time, the refusal will be documented in the medical 
record and in the research record. 
The Informed Consent document may be obtained  from the participant by the principal 
investigator, associate investigators, or the med ical staff fellow under the supervision of the 
principal investigator. 
9.6.1 Consent procedure for non-English speaking patients 
If there is an unexpected enrollment of a research participant for whom there is no translated extant 
IRB approved consent document, the principal investigator and/or those authorized to obtain 
informed consent will use the Short Form Oral Consent Process as described in MAS Policy M77-
2, OHSRP SOP 12, 45 CFR 46.117 (b) (2), and 21 CFR 50.27 (b) (2).  The summary that will be used is the English version of the extant IRB approved consent document.  Signed copies of both 
the English version of the consent and the translated  short form will be given to the subject or their 
legally authorized representative and the signed original will be filed in the medical record. 
Unless the PI is fluent in the prospective subject’ s language, an interpreter will be present to 
facilitate the conversation. Preferably someone who is independent of the subject (i.e., not a family 
member) will assist in presenting information and obtaining consent. Whenever possible, 
interpreters will be provi ded copies of the relevant consent documents well before the consent 
conversation with the subject (24 to 48 hours if possible).  
We request prospective IRB approval of the use of the short form process and will notify the IRB 
at the time of continuing review of th e frequency of the use of the Short Form. 
9.6.2 Telephone consent procedure 
Consent for screening and re-consent on this study may be obtained via telephone according to the following procedure: the informed consent document will  be sent to the subject.  An explanation 
of the study will be provided over the telephone afte r the subject has had the opportunity to read 
the consent form.  The subject will sign and date the informed consent. A witness to the subject’s 
signature will sign and date the consent.  The original informed consent document will be sent 
back to the consenting investigator who will si gn and date the consent form with the date the 
consent was obtained via telephone.  A fully execu ted copy will be returned via mail for the 
subject’s records.  The informed consent process will be documented on a progress note by the consenting investigator. 
10 PHARMACEUTICAL INFORMATION   
Nab-paclitaxel is approved for use as a first line agent in metastatic pancreat ic cancer.  It is not 
approved for use as a second line agent, the use in  the current protocol.  The investigation is not 
intended to support a new indication for use or any other significant changes to labeling or 
advertising in any of the commercial agents used on the study.  The investigation does not involve 
a route of administration or dosage level in use in a patient population or other factor that 
significantly increases the risks (or decreases the acceptability of the risks) associated with the use 
of the drug products. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
102 
 10.1 LMB-100  (IND  # 123332) 
10.1.1 Source  
LMB-100 was transferred to the NIH CC Pharmacy by Roche, the drug manufacturer.  For this 
trial, the drug will be supplied by the NIH CC Pharmacy.  
10.1.2 Toxicity  
Information in this section is based on preclinical studies with LMB-100, and clinical  studies of the 
cytolytic fusion protein SS1-P. Participants should receive a full dose of  LMB-100 unless a DLT 
and/or a treatment limiting toxicity is observed. In case  of DLT and/or treatment limiting toxicities, 
treatment with LMB-100 will be  stopped until resolution of toxicity to NCI CTCAE Grade d2 
hematological  toxicities or Grade d1 non-hematological toxicities. A delay of LMB-100 
administration for up to two weeks of the planned schedule will be acceptable to  allow for 
resolution of toxicity to NCI CTCAE Grade d2 hematological toxicities or  Grade d1 non-
hematological toxicities. If toxicity does not resolve to NCI CTCAE  Grade d2 hematological 
toxicities or Grade d1 non-hematological toxicities and the participant is unable to resume 
treatment with LMB-100 after this time, no ad ditional doses will be administered and the 
participant will be withdrawn from study treatment. 
10.1.2.1 Infusion-Related Reactions and Hypersensitivity Including Anaphylaxis 
LMB-100 administration may cause infusion-associated symptoms such as fever,  chills, 
hypotension, shortness of breath, skin ra sh, headache, nausea, and/or vomiting.  Such reactions 
typically occur during or shortly after an infus ion. Participants may also develop IgE-mediated 
hypersensitivity reactions to  LMB-100. IRRs may be indistinguishable from an anaphylactic 
reaction. Participants  should receive full supportive care to treat IRRs or anaphylaxis according to 
institutional  practice. If infusion-associated signs or sy mptoms occur, participants should be 
monitored  until complete resolution. 
In vitro data and previous clinical experience with LMB-100 suggest that the risk for the release of 
pro-inflammatory cytokines upon first  administration of LMB-100 to humans is low (human whole 
blood assay, see section 1.2.4.1.4).  Past experience with monoclonal antibodies that demonstrated 
a risk in the whole blood  assay has shown that this risk could be effectively managed in the clinic 
with appropriate  risk-minimization measures. The release of pro-inflammatory cytokines is 
believed to be  partially responsible for the occurrence of IRRs. 
10.1.2.2 Risk of Immunogenicity and Potential Safety Impact 
LMB-100 may cause the formation of ADAs. These may trigger hypersensitivity  reactions or 
immune complex-mediated responses. The development of ADAs to  LMB-100, an improved 
cytolytic fusion protein with a humanized targeting moiety  directed against mesothelin and a de-
humanized, truncated Pseudomonas exotoxin A is  expected to be less likely than SS1P. Clinical 
trials with SS1P have led to the development of neutralizing ADAs in 75% and 88% of participants after 1 cycle of therapy, in
 the IV bolus and continuous infusion trials respectively.[31]  
Participants will be monitored at regular intervals for the development of ADAs and  cytokines. In 
particular, any clinical signs and symptoms suggestive of a hypersensitivity  reaction and/or an 
immune complex-mediated reaction possibly due to ADA formation  will be carefully investigated. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
103 
 10.1.2.3 Risk of Inflammatory Reactions to Serosal Membranes  
LMB-100 administration may cause inflammatory reactions to serosal membranes  including 
pleuritis, characterized by pleuritic chest pain, dyspnea, and hypoxia and  pericarditis, characterized 
by precordial chest pain, congestive heart failure,  hypotension, and uremia. Clinical trials with 
SS1P monotherapy have led to reversible  pleuritis and pericarditis. Participants who develop 
symptoms of serosal inflammation  should be closely monitored and receive standard treatments 
which may include  corticosteroids. 
10.1.2.4 Risk of Vascular Leak Syndrome  
LMB-100 administration may cause VLS characterized by hypotension,  hypoalbuminemia, edema, 
weight gain, and hemoconcentration. Clinical trials with  SS1P monotherapy have led to the 
development of reversible VLS. Participants will be  monitored with frequent assessments of chest 
x-rays, weight, edema, blood pressure,  and serum albumin levels prior to and during treatment. 
Participants who develop  symptoms of VLS should be closely monitored and receive standard 
symptomatic  treatments. 
10.1.2.5 Risk of Renal Toxicity  
LMB-100 administration may cause renal toxicity characterized by increased  creatinine, BUN, and 
proteinuria. In preclinical cynomolgus monkey studies,  LMB-100 has shown increases in 
creatinine and histological changes including  regenerative and degenerative changes to the tubular 
epithelium. Hemolytic uremic  syndrome has been reported for other cytolytic fusion antibodies in 
development. 
Participants should be monitored with renal laboratory assessments including creatinine,  BUN, and 
urinalysis. 10.1.2.6 Injection Site Reactions  
LMB-100 administration may cause adve rse reactions at the infusion site
 characterized by pain, 
swelling, induration, and nodules. In preclinical NHP studies for both SS1P and LMB-100 
reddening and swelling of the infusion site were noted.  Participants who develop symptoms of 
infusion site reactions can be administered pain  relieving medication (analgesic) as required, and 
rotation of infusion sites is  recommended. 
10.1.2.7 Pregnancy  
No studies assessing the reproductive and developmental toxicity of LMB-100 have  been 
conducted to date. It is not known whether LMB-100 can cross the placenta or  cause harm to the 
fetus when administered to pregnant women or whether it affects  reproductive capacity. LMB-100 
should not be administered to pregnant women. 
10.1.3 Formulation and preparation  
LMB-100 drug product (20 mg/20 mL) is provided for syringe infusion as a sterile,  colorless to 
brownish, preservative-free liquid in single-use, 20 mL vials. The nominal fill  volume is 20 mL 
and the approximate concentration of LMB-100 recombinant fusion  protein in the vials is 1 mg/mL. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
104 
 10.1.4 Stability and Storage  
Chemical and physical in-use  stability for undiluted LMB-
100 drug product in  syringes has been demonstrated for 24 
hours at 2-8 °C and 24 hours at ambient  temperature. 
Storage conditions should generally be at 2-8 qC, but  
syringes may be held at room temperature for up to a 
maximum of 4 hours. 
Roche has extensively studied the stability of LMB-100.  
Vials of LMB-100 can be stored at 4°C for at least 24 months without loss of activity or degradation of the drug product. At 25°C, no loss of activity is observed over a 4-
week period, and 94% of potency is retained even after 3 
months of exposure to this temperature ( Figure 9). 
However, when vials of LMB-100 are exposed to temperatures of 37°C, the drug begins to lose activity within 12 hours.  
10.1.5 Administration procedures 
Please refer to section 3.2.1  
10.1.6 Incompatibilities   
Pharmacodynamic drug interaction studies have not been conducted. LMB-100 is contraindicated 
in subjects with a history of severe allergic an aphylactic reactions to humanized, chimeric or 
mouse peptides/antibodies or to any components of the product. 
10.1.6.1 Mechanism of action 
LMB-100 is a novel recombinant an ti-mesothelin targeted cytolytic fusion protein (cFP) 
developed for the treatment of participants with solid tumors that express the mesothelin protein.  
Mesothelin is a suitable candidate for targeted therapy due to its very limited expression in normal/non-malignant tissue and its high expre ssion in several tumor entities including 
mesothelioma, ovarian cancer, pancreatic cancer , gastric cancer, breast cancer, and lung cancer. 
To target mesothelin, a humanized Fab fragment of the anti-mesothelin antibody SS1 is linked to a truncated and de-immunized recombinant 24 kD fragment of Pseudomonas exotoxin (PE24).  After binding to mesothelin, the complex is interna lized by endocytosis and kills cells by inhibition 
of eukaryotic elongation factor 2 (eEF2), leading to arrest of protein synthesis and secondarily triggering cell death by apoptosis or necrosis. 
Figure 9 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
105 
 10.1.6.2 Molecular Weight: approximately 73 kDa 
10.1.6.3 Chemical Structure 
 
H1L1 polypeptide structure consisting of one variable heavy chain containing the Pseudomonas 
Exotoxin A moiety and one variable light change held together by a disulfide bond. 
10.2 NAB-PACLITAXEL  
Please refer to package insert for additional information. 
10.2.1 Source  
Nab-paclitaxel will be purchased from commercial sources by the NIH CC Pharmacy. 10.2.2 Toxicity  
The most common clinically signific ant adverse reactions reported with nab-paclitaxel in patients 
with pancreatic cancer include:
 neutropenia, anemia, thrombocytope nia, pancytopenia peripheral 
neuropathy, cardiac  failure, tachycardia, dyspnea, pneum onitis, nausea, vomiting, diarrhea 
abdominal pain,  intestinal obstruction, colitisarthralgia/myalgia, renal failure, increased alanine  
aminotransferase, increased aspartate amin otransferase, increased bilirubin, and  increased 
creatinine. 
Hypersensitivity reactions including fatal anaphylactic reactions have rarely been  reported with 
nab-paclitaxel. If a hypersensitivity reaction occurs, nab-paclitaxel should  be discontinued 
immediately, symptomatic treatment shoul d be initiated, and the participant  should not be 
rechallenged with paclitaxel. 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
106 
 Bone marrow suppression (primarily ne utropenia) occurs frequently with nab-paclitaxel.  Frequent 
monitoring of blood cell counts should be performed. Participants should not be  retreated with 
subsequent cycles of nab-paclitaxel until neutrophils recover to !1500 cells/mm2 and platelets to 
!100,000 cells. 
Sensory neuropathy occurs frequently with nab-paclitaxel, though generally not severe.  The 
occurrence of Grade 1 or 2 sensory ne uropathy does not generally require dose  reduction.  
Sepsis was reported in 5% of participants  with or without neutropenia who received nab- 
paclitaxel.[52] Complications due to underlying  pancreatic cancer, especially biliary obstruction or 
presence of biliary stent, were  identified as significant contributing factors. 
Pneumonitis occurred in 4% of participants using nab-paclitaxel. Closely monitor all participants 
for signs and symptoms of pneumonitis.  After ruling out infectious etiology and upon making a 
diagnosis of pneumonitis,  permanently discontinue treatment with nab-paclitaxel and promptly  
initiate appropriate treatment with supportive measures. 
Hepatic impairment may increase the toxicity of nab-paclitaxel, particularly  myelosuppression. 
Administration of nab-paclitaxel in participants with hepatic impairment  should be performed with 
caution. Congestive heart failure and left ventricular dysfunction ha ve rarely been observed in
 participants 
receiving nab-paclitaxel. Most of these participants were previously exposed to  cardiotoxic 
medicinal products such as anthracyclin es or had underlying cardiac history.  Participants receiving 
nab-paclitaxel should be vigilantly monitored for the occurrence of  cardiac events. 
Nausea, vomiting, and diarrhea following administration of nab-paclitaxel may be treated  with 
commonly used anti-emetics and constipating agents. 
In the very elderly ( ≥75 years) who received nab-paclitaxel, there was  a higher incidence of serious 
adverse reactions and adverse reactions that led to  discontinuation including hematologic toxicities, 
peripheral neuropathy, decreased  appetite, and dehydration. Participants 75 years or older should 
be carefully assessed for  their ability to tolerate nab-paclitaxel with special  consideration to 
performance status, co-morbidities, and increased risk of infections. 
10.2.3 Formulation and preparation  
Formulation 
ABRAXANE is supplied as a lyophilized powder containing 100 mg of paclitaxel formulated as 
albumin-bound particles in single-use vial for reconstitution. 
Preparation 
1. Aseptically, reconstitute each vial by injectin g 20 mL of 0.9% Sodium Chloride Injection, 
USP. 
2. Slowly inject the 20 mL of 0.9% Sodium Ch loride Injection, USP, over a minimum of 1 
minute, using the sterile syringe to direct the solution flow onto the INSIDE WALL OF 
THE VIAL. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
107 
  
3. DO NOT INJECT the 0.9% Sodium Chloride Injection, USP, directly onto the lyophilized 
cake as this will result in foaming. 
4. Once the injection is complete, allow the vial to sit for a minimum of 5 minutes to ensure proper wetting of the lyophilized cake/powder. 
5. Gently swirl and/or invert the vial slowly for at least 2 minutes until complete dissolution of any cake/powder occurs. Avoid generation of foam. 
6. If foaming or clumping occurs, stand solution for at least 15 minutes until foam subsides . 
Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel. 
Calculate the exact total dosing volume of 5 mg/mL suspension required for the participant: 
Dosing volume (mL) = Total dose (mg)/5 (mg/mL) 
The reconstituted suspension should be milky an d homogenous without visible particulates. If 
particulates or settling are visible, the vial should be gently inverted again to ensure complete 
resuspension prior to use. Discard the reconsti tuted suspension if precipitates are observed. 
Discard any unused portion. Inject the appropriate amount of reconstituted ABRAXANE® into an empty, sterile IV bag 
(plasticized polyvinyl chloride (PVC) container s, PVC or non-PVC type IV bag). The use of 
specialized DEHP-free solution containers or admini stration sets is not n ecessary to prepare or 
administer ABRAXANE infusions. The use of an in-line filter is not recommended. 
Parenteral drug products should be inspected visual ly for particulate matter and discoloration prior 
to administration whenever solution and container permit. 
10.2.4 Stability and Storage  
Unopened vials of ABRAXANE are stable until the date indicated on the package when stored 
between 20°C to 25°C (68°F to 77°F), in the origi nal package. Neither freezing nor refrigeration 
adversely affects the stability of the product.  Produc t should be retained in the original packaging 
to protect from bright light. 
Stability of Reconstituted Suspension in the Vial 
Reconstituted ABRAXANE should be used immediately, but may be refrigerated at 2°C to 8°C 
(36°F to 46°F) for a maximum of 24 hours if necessary. If not used immediately, each vial of reconstituted suspension should be replaced in th e original carton to protect it from bright light. 
Discard any unused portion. 
Stability of Reconstituted Suspension in the Infusion Bag 
The suspension for infusion when prepared as recommended in an infusion bag should be used immediately, but may be refrigerated a
t 2°C to 8°C (36°F to 46°F) and protected from bright light 
for a maximum of 24 hours. .. 

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
108 
 10.2.5 Administration procedures 
Please see section 3.2.2.  
10.2.6 Incompatibilities   
Please refer to the package insert.   
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
109 
  
11 REFERENCES  
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012 . CA: a cancer journal for 
clinicians 2012, 62(1):10-29. 
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul 
JL, Gourgou-Bourgade S, de la Fouchardiere C  et al : FOLFIRINOX versus gemcitabine 
for metastatic pancreatic cancer . The New England journal of medicine 2011, 
364(19):1817-1825. 
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin 
SA, Ma WW, Saleh MN  et al : Increased survival in pancreatic cancer with nab-
paclitaxel plus gemcitabine . The New England journal of medicine 2013, 369(18):1691-
1703. 
4. Zhang Y, Hochster H, Stein S, Lacy J: Gemcitabine plus nab-paclitaxel for advanced 
pancreatic cancer after first-line FOLFI RINOX: single institution retrospective 
review of efficacy and toxicity . Experimental hematology & oncology 2015, 4:29. 
5. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, Hammel P, 
Lecomte T, Dreanic J, Coriat R  et al : Nab-paclitaxel plus gemcitabine for metastatic 
pancreatic adenocarcinoma after Folfirin ox failure: an AGEO prospective 
multicentre cohort . British journal of cancer 2015, 113(7):989-995. 
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, 
Walde D, Wolff RA  et al : Erlotinib plus gemcitabine comp ared with gemcitabine alone 
in patients with advanced pa ncreatic cancer: a phase III trial of the National Cancer 
Institute of Canada Clinical Trials Group . Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology 2007, 25(15):1960-1966. 
7. Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF: Second-line treatment in 
advanced pancreatic cancer: a comprehensive analysis of published clinical trials . 
Annals of oncology : official journal of th e European Society for Medical Oncology / 
ESMO 2013, 24 (8):1972-1979. 
8. Einama T, Kamachi H, Nishihara H, Homma S, Kanno H, Takahashi K, Sasaki A, Tahara 
M, Okada K, Muraoka S  et al : Co-expression of mesothelin  and CA125 correlates with 
unfavorable patient outcome in pa ncreatic ductal adenocarcinoma . Pancreas 2011, 
40(8):1276-1282. 
9. 
Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D: Mesothelin is 
overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas 
and chronic pancreatitis . American journal of clinical pathology 2005, 124(6):838-845. 
10. Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-
Hamilton V, Luis E, Chuh J  et al : An antimesothelin-monomethyl auristatin e conjugate 
with potent antitumor activity in ovaria n, pancreatic, and mesothelioma models . 
Molecular cancer therapeutics 2014, 13(11):2630-2640. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
110 
 11. Stromnes IM, Schmitt TM, Hulbert A, Brockenbrough JS, Nguyen HN, Cuevas C, Dotson 
AM, Tan X, Hotes JL, Greenberg PD  et al : T Cells Engineered against a Native Antigen 
Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal 
Adenocarcinoma . Cancer cell 2015, 28(5):638-652. 
12. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, 
Hruban RH: Multicomponent analysis of the pancreatic adenocarcinoma progression 
model using a pancreatic intraepith elial neoplasia tissue microarray . Modern 
pathology : an official journal of the United  States and Canadian Academy of Pathology, 
Inc 2003, 16(9):902-912. 
13. Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, 
D'Angelica MI, DeMatteo RP  et al : A novel survival-based tissue microarray of 
pancreatic cancer validates MUC1 and mesothelin as biomarkers . PloS one 2012, 
7(7):e40157. 
14. Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, Hsieh CY, Chen CA: 
High mesothelin correlates with chemoresis tance and poor survi val in epithelial 
ovarian carcinoma . British journal of cancer 2009, 100(7):1144-1153. 
15. Wang L, Niu Z, Zhang L, Liu X, Wang X, Li F, Wang Y: Clinicopathological significance 
of mesothelin expression in invasive breast cancer . The Journal of international medical 
research 2012, 40(3):909-916. 
16. Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, Abdullaev Z, Alewine C, 
Rajan A, Giaccone G  et al : High mesothelin expression in advanced lung 
adenocarcinoma is associated with KRAS mutations and a poor prognosis . Oncotarget 
2015, 6(13):11694-11703. 
17. Nomura R, Fujii H, Abe M, Sugo H, Ishizaki Y, Kawasaki S, Hino O: Mesothelin 
expression is a prognostic factor  in cholangiocellular carcinoma . International surgery 
2013, 98(2):164-169. 
18. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, Brunicardi FC, Chen C, Yao 
Q: Mesothelin is a malignant factor and th erapeutic vaccine tar get for pancreatic 
cancer. Molecular cancer therapeutics 2008, 7(2):286-296. 
19. Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I: Mesothelin 
Immunotherapy for Cancer: Ready for Prime Time?  Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 2016, 34(34):4171-4179. 
20. Weldon JE, Pastan I: A guid e to taming a toxin--recombinant immunotoxins 
constructed from Pseudomonas exotoxin A for the treatment of cancer . The FEBS 
journal 2011, 278 (23):4683-4700. 
21. Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, 
Pastan I: Identification and elimination of an  immunodominant T-cell epitope in 
recombinant immunotoxins based on Pseudomonas exotoxin A . Proceedings of the 
National Academy of Sciences of the United States of America 2012, 109(51):E3597-3603. 
22. Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I: A 
recombinant immunotoxin against the tumor-associated antigen mesothelin 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
111 
 reengineered for high activity, low off- target toxicity, and reduced antigenicity . 
Molecular cancer therapeutics 2013, 12(1):48-57. 
23. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I: 
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant 
antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro . Clinical cancer research : an official journal of the 
American Association for Cancer Research 2002, 8(11):3520-3526. 
24. Li Q, Verschraegen CF, Mendoza J, Hassan R: Cytotoxic activity of the recombinant 
anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established 
from ascites of patients with peritoneal mesotheliomas . Anticancer research 2004, 
24(3a):1327-1335. 
25. Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R: Loss 
of mesothelin expression by mesothelioma cel ls grown in vitro determines sensitivity 
to anti-mesothelin immunotoxin SS1P . Anticancer research 2012, 32(12):5151-5158. 
26. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel 
E, Herbst RS, Onn A  et al : Targeted therapy against human lung cancer in nude mice 
by high-affinity recombinant antimesothelin single-chain Fv immunotoxin . Molecular 
cancer therapeutics 2002, 1(8):595-600. 
27. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, Le N, Ho M, Pastan I: 
Synergistic antitumor activity of taxol a nd immunotoxin SS1P in tumor-bearing mice . 
Clinical cancer research : an official journa l of the American Association for Cancer 
Research 2006, 12(15):4695-4701. 
28. Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I: A flow 
cytometry method to quantitate inte rnalized immunotoxins shows that taxol 
synergistically increases cellular immunotoxins uptake . Cancer research 2010, 
70(3):1082-1089. 
29. Zhang Y, Xiang L, Hassan R, Pastan I: Immunotoxin and Taxol synergy results from a 
decrease in shed mesothelin levels in the extracellular space of tumors . Proceedings of 
the National Academy of Sciences of  the United States of America 2007, 104(43):17099-
17104. 
30. Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang QC, Ho M, 
Beers R  et al : Releasable PEGylation of mesothelin targeted immunotoxin SS1P 
achieves single dosage complete regression of a human carcinoma in mice . 
Bioconjugate chemistry 2007, 18(3):773-784. 
31. Hassan R, Bullock S, Premkumar A, Kreitman  RJ, Kindler H, Willingham MC, Pastan I: 
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesoth elin-expressing mesothelioma, ovarian, and 
pancreatic cancers . Clinical cancer research : an official journal of the American 
Association for Cancer Research 2007, 13 (17):5144-5149. 
32. Pastan 
I: Personal communication. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
112 
 33. Hassan R, Sharon E, Thomas A, Zhang J, Li ng A, Miettinen M, Kreitman RJ, Steinberg 
SM, Hollevoet K, Pastan I: Phase 1 study of the antimesothelin immunotoxin SS1P in 
combination with pemetrexed and cispl atin for front-line therapy of pleural 
mesothelioma and correlation of tumor response with serum mesothelin, 
megakaryocyte potentiating fa ctor, and cancer antigen 125 . Cancer 2014, 
120(21):3311-3319. 
34. Hollevoet K, Mason-Osann E, Liu XF, Imhof-Jung S, Niederfellner G, Pastan I: In vitro 
and in vivo activity of the low-immunoge nic antimesothelin immunotoxin RG7787 in 
pancreatic cancer . Molecular cancer therapeutics 2014, 13(8):2040-2049. 
35. Alewine C, Xiang L, Yamori T, Nied erfellner G, Bosslet K, Pastan I: Efficacy of RG7787, 
a next-generation mesothelin-targeted im munotoxin, against triple-negative breast 
and gastric cancers . Molecular cancer therapeutics 2014, 13(11):2653-2661. 
36. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I: Mesothelin 
expression in human lung cancer . Clinical cancer research : an official journal of the 
American Association for Cancer Research 2007, 13(5):1571-1575. 
37. Nagorsen D, Kufer P, Baeuerle PA, Bargou R: Blinatumomab: a historical perspective . 
Pharmacol Ther 2012, 136(3):334-342. 
38. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, 
Hess G, Schuler M  et al : Tumor regression in cancer patients by very low doses of a T 
cell-engaging antibody . Science 2008, 321 (5891):974-977. 
39. Benhar I, Reiter Y, Pai LH, Pastan I: Administration of disulfide-stabilized Fv-
immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing larg e tumor xenografts in nude mice . International journal of 
cancer Journal international du cancer 1995, 62(3):351-355. 
40. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I: Phase I trial of continuous infusion anti-
mesothelin recombinant immunotoxin SS1P . Clinical cancer research : an official 
journal of the American Association for Cancer Research 2009, 15 (16):5274-5279. 
41. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M: 
Characterization of vascular leak syndro me induced by the toxin component of 
Pseudomonas exotoxin-based immunotoxins and its potential inhibition with 
nonsteroidal anti-inflammatory drugs . Clinical cancer research : an official journal of 
the American Association for Cancer Research 1997, 3(3):339-345. 
42. Kuan CT, Pai LH, Pastan I: Immunotoxins containing Pseudomonas exotoxin that 
target LeY damage human endothelial cells in  an antibody-speci fic mode: relevance 
to vascular leak syndrome . Clinical cancer res
 earch : an official journal of the American 
Association for Cancer Research 1995, 1 (12):1589-1594. 
43. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M  et al : New response evaluation  criteria in solid 
tumours: revised RECIST guideline (version 1.1) . European journal of cancer 2009, 
45(2):228-247. 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
113 
 44. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, 
Higano C, Bubley GJ, Dreicer R  et al : Design and end points of clinical trials for patients 
with progressive prostate cancer and castrate levels of testosterone: 
recommendations of the Prostate Cancer Clinical Trials Working Group . Journal of 
clinical oncology : official journal of th e American Society of Clinical Oncology 2008, 
26(7):1148-1159. 
45. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer 
E, Sagae S, Greven K, Vergote I  et al : Re: New guidelines to evaluate the response to 
treatment in solid tumors (ovarian cancer) . Journal of the National Cancer Institute 
2004, 96(6):487-488. 
46. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, 
Freidlin B, Halabi S, Hudes G  et al : Eligibility and response guidelines for phase II 
clinical trials in androgen-independent prostate cancer: recommendations from the 
Prostate-Specific Antigen Working Group . Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 1999, 17(11):3461-3467. 
47. Vergote I, Rustin GJ, Eisenhauer EA, Kris tensen GB, Pujade-Lauraine E, Parmar MK, 
Friedlander M, Jakobsen A, Vermorken JB: Re: new guidelines to evaluate the response 
to treatment in solid tumors [ovarian ca ncer]. Gynecologic Cancer Intergroup . 
Journal of the National Cancer Institute 2000, 92(18):1534-1535. 
48. Byrne MJ, Nowak AK: Modified RECIST criteria for assessment of response in 
malignant pleural mesothelioma . Annals of oncology : official journal of the European 
Society for Medical Oncology / ESMO 2004, 15(2):257-260. 
49. Peddi PF, Cho M, Wang J, Gao F, Wang-Gillam A: Nab-paclitaxel monotherapy in 
refractory pancreatic adenocarcinoma . Journal of gastrointestinal oncology 2013, 
4(4):370-373. 
50. Hosein PJ, de Lima Lopes G, Jr., Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, 
Montero AJ, Merchan JR, Rocha Lima CM: A phase II trial of nab-Paclitaxel as second-
line therapy in patients with advanced pa ncreatic cancer . American journal of clinical 
oncology 2013, 36(2):151-156. 
51. Simon R: Optimal two-stage designs for phase II clinical trials . Control Clin Trials 
1989, 10(1):1-10. 
52. European Medicines Agency, Committee for Medicinal Products for Human Use 
(CHMP). Summary of opinion – ABRAXANE (available online at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/11/W  
C500155476.pdf ) . 
 
 
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
114 
 12 APPENDICES 
12.1 APPENDIX A – PERFORMANCE STATUS CRITERIA  
ECOG Performance Status Scale 
 Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity.  Fully active, able 
to carry on all pre -disease 
performance without restriction. 100 Normal, no complaints, no 
evidence of disease. 
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease. 
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).
 80 Normal activity with effort; some 
signs or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work. 
2 In bed <50% of the time.  
Ambulatory and capable of all self
-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours. 60 Requires occasional assistance, 
but is able to care for most of his/her needs. 
50 Requires considerable assistance 
and frequent medical care. 
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care 
and assistance. 
30 Severely disabled, hospitalization 
indicated.  Death not imminent. 
4 100% bedridden.   Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair.  20 Very sick, hospitalization 
indicated. Death not imminent. 
10 Moribund, fatal processes 
progressing rapidly. 
5 Dead. 0 Dead. 
 
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
115 
 12.2 APPENDIX B – COCKCROFT -GAULT FORMULA FOR CALCULATION OF CREATININE 
CLEARANCE  
 
 
  

Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
116 
 12.3 APPENDIX C: SAMPLE CHEMOTHERAPY NOTES  
12.3.1 For Part A 
 
(1) Nab-paclitaxel, 125 mg/m2, IV over 30 minutes ± 10 minutes on Days 1 and 8  (2) LMB-100, <dose as per escalation scheme> mcg/kg, IV on Days 1, 3 and 5 
On Day 1, administer 30 minutes ± 20 minutes following completion of Nab-paclitaxel infusion 
 Pre-medications: 
o Diphenhydramine 25-50 mg PO or IV 
o Ranitidine 150 mg PO 
o Acetaminophen 650 mg PO 
 Additional medications: -Dexamethasone 8 mg IV, PRN severe infusion related reaction (should be available on unit) 
-Ondansetron 8 mg PO q8h, PRN nausea 
 
Please encourage oral hydration of 1.5 to 2L daily while receiving LMB-100. 
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
117 
 12.3.2 For Arm B1 
 
(1)  
Loading dose of LMB-100 
LMB-100, 40 mcg/kg, IV on Day 1 and if applicable, Day 4  
Continuous infusion LMB-100 to immediately following loading dose on Day 1 and if applicable, 
Day 4 
LMB-100, <dose as per escalation scheme> mcg/kg/day IV, for # hrs  
Syringes of drug must be changed q12hrs. In-line filtration required.   
Dose per 12 hours = <dose as per escalation scheme> / 2 = # mcg/kg Infusion rate = <Dose per 12 hours> / 12 = # ml/hr Run with Normal Saline at 20cc/hour IV for in-line dilution.  Pre-medications on Day 1: 
o Diphenhydramine 25-50 mg PO or IV 
o Ranitidine 150 mg PO 
o Acetaminophen 650 mg PO 
 
Additional medications: 
-Dexamethasone 8 mg IV, PRN severe infusion related reaction (should be available on unit) 
-Ondansetron 8 mg PO q8h, PRN nausea  Please encourage oral hydration daily of  1.5 to 2L daily while receiving LMB-100. 
  
Abbreviated Title : LMB-100 + Abrx in PDA 
Version Date: 12/11/2018 
 
118 
 12.3.3  For Arm B2  
 
(1) Nab-paclitaxel, 125 mg/m2, IV over 30 minutes ± 10 minutes on Days 1   (2) Loading dose of LMB-100 
LMB-100, 40 mcg/kg, IV on Day 1  
 
Continuous infusion LMB-100 to immediately following loading dose on Day 1  
LMB-100, 100 mcg/kg/day IV, for 24 hrs  
Syringes of drug must be changed q12hrs. In-line filtration required.   
Dose per 12 hours = 50 mcg/kg * <patient weight> = # mg Infusion rate = <Dose per 12 hours (mg)> / 1 mg/mL / 12 hrs = # ml/hr Run with Normal Saline at 20cc/hour IV for in-line dilution. On Day 1, administer 30 minutes ± 20 minutes fol lowing completion of Nab-paclitaxel infusion 
 
Pre-medications: 
o Diphenhydramine 25-50 mg PO or IV 
o Ranitidine 150 mg PO 
o Acetaminophen 650 mg PO 
 
Additional medications: -Dexamethasone 8 mg IV, PRN severe infusion related reaction (should be available on unit) 
-Ondansetron 8 mg PO q8h, PRN nausea  
Please encourage oral hydration of 1.5 to 2L daily while receiving LMB-100. 
 